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ABSTRACT 
 
Mental disorders are associated with a range of neurobiological abnormalities, 
including hormonal disturbances and brain changes. However, most of the research has 
been conducted in established and even chronic mental health conditions. Recently, clinical 
staging models have emerged, aiming to guide treatment selection relevant to stage and 
progression of illness. Whereas clinical staging has established itself for the psychosis 
continuum, less is known about staging in other disorders such as depression, mania, 
anxiety, substance use, and eating disorders. This thesis looked at the early stages of 
mental disorders in general, and specifically at the ultra-high risk state for psychosis. 73 
help-seeking youths aged 16-26 years were interviewed for clinical symptomatology and 
social and role functioning, and followed up after 3 and 6 months. Neurobiological 
assessments were additionally undertaken in a subset of those clinical participants (n = 35), 
and healthy controls (HC, n = 35), involving hair cortisol analyses, and brain imaging during 
working memory processes and rest. Significantly increased hair cortisol levels, and brain 
hypo-activation during working memory processes and subtly decreased resting-state brain 
connectivity were discovered in clinical participants as compared to HC. Early mental health 
problems appear to have some neurobiological manifestations, however, larger cohort 
studies with multiple follow-up assessments over an extended time period are needed to 
replicate findings and to draw firm conclusions addressing clinical practice. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
Mental illnesses, such as schizophrenia and depression are constituting 13% of the 
global burden of disease, outreaching cancer and cardiovascular disease (Collins et al., 
2011). With 75% of mental illnesses starting before the age of 24 (Kessler et al., 2005), 
health systems, researchers and clinicians aspire to understand and improve especially 
youth mental health (Shah, 2015), questioning parameters by which mental health is defined 
at the moment. Stepping away from conventional Diagnostic and Statistical Manual of 
Psychiatric Disorders (DSM) and the International Classification of Diseases (ICD) 
diagnoses, by utilising a dimensional approach and clinical staging in mental disorders 
(McGorry et al., 2007), is thought to more efficiently detect and treat mental health problems. 
The idea of risk syndromes for mental disorders (especially in the field of psychosis and 
bipolar disorder) has emerged, for an early detection and intervention to delay, ameliorate or 
prevent threshold disorders (McGorry et al., 2007). Even though being a promising approach 
with good evidence for its utility, new challenges have emerged, e.g. whether this risk 
syndrome was to be included as diagnostic category in the DSM (Yung, Nelson, Thompson, 
& Wood, 2010), how important psychosocial functioning actually is as predictor and outcome 
variable, and how clinical staging can be implemented for disorders other than psychosis 
and bipolar disorder.  
This thesis looks at youth mental health and therefore the early stages of mental 
health problems in help-seeking adolescents and young adults. Even though there have 
been some recent attempts to look at the role of neurobiological variables in the 
development of mental health problems (e.g., Lagopoulos, Hermens, Naismith, Scott, & 
Hickie, 2012; Lagopoulos et al., 2013), generally only little research has been conducted in 
this field to look at underlying biological mechanisms. This thesis therefore included working 
CHAPTER ONE: LITERATURE REVIEW                        
	  
	  2	  
memory as a key executive function and functional intrinsic brain connectivity, and cortisol 
levels as stress marker. The aims are to explore: 
• how depressive, psychotic and anxiety symptoms are related to each other 
and social and occupational functioning, observed over a period of six months,  
• how longer-term stress links in with mental health symptoms as measured by 
means of hair cortisol analyses, 
• if brain activity during working memory processes is altered in individuals with 
early mental health problems,  
• if connectivity of brain networks during rest is altered in individuals with early 
mental health problems, 
• and whether there is an association between brain function and longer-term 
cortisol levels, 
focusing on depressive, psychotic and anxiety symptoms due to the comparatively high 
prevalence in the current sample.    
 
This literature review gives an overview about youth mental health and the importance of 
the period of adolescence and early adulthood for the development of psychiatric disorders, 
also by looking at underlying neurobiological mechanisms (Section 1.1). Epidemiological, 
clinical and neurobiological findings for most common mental disorders (affective, psychotic, 
anxiety, eating, and substance use disorders) and their risk syndromes and risk factors, and 
how mental health symptoms interact with each other, are described in Section 1.2. Section 
1.3 describes different approaches to mental health and issues that are associated with 
these approaches respectively, and Section 1.4 how clinical and functional outcomes can be 
improved, followed by Section 1.5 which gives an outlook of the thesis. 
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1.1 Youth mental health and development of psychiatric disorders  
Adolescence is defined as the “gradual period of transition from childhood to adulthood” 
(Spear, 2000), which includes puberty – the period where sexual maturity takes place 
(Sinclair, Purves-Tyson, Allen, & Weickert, 2014). The foundations of future patterns of adult 
health are laid during adolescence; health in adolescence is in turn the product of 
interactions between the development during prenatal development and childhood, and 
changes in biology and social and role demands that come along with puberty (Sawyer et 
al., 2012). This period of adolescence and young adulthood is furthermore characterised by 
a greatly increased vulnerability for the development of mental disorders, with half of the 
lifetime cases of mental disorders starting by age 14 and three quarters by age 24 (Kessler 
et al., 2005).  
Although puberty can be seen as a biological marker for the onset of adolescence, 
adolescence constitutes a vague concept, considering its differential definition across 
cultures worldwide (Patel, Flisher, Hetrick, & McGorry, 2007). Patel et al. (2007) questioned 
the validity of the notion of adolescence, and alternatively suggested to separately consider 
the developmental and health needs of children (<12 years) and young people (12-24 years) 
instead. This differentiation may be more useful in terms of looking at youth mental health 
and its underlying neurobiological mechanisms, however, for the purpose of this literature 
review such a distinction cannot be made, because existing - for this thesis relevant - 
literature mainly focuses on and defines very heterogeneous age groups. Relevant studies, 
comprising older aged children up to early adulthood will be reported.  
Overall prevalence rates for mental disorders in children and youths are an estimated 
15% (for review, see Waddell & Shepherd, 2002), with lifetime prevalence estimates being 
3% for psychotic disorders (Peraala et al., 2007), 29% for anxiety disorders, 21% for mood 
disorders, and 15% for substance use disorders (Kessler et al., 2005). Median age of onset 
for schizophrenia was 23 years (Kessler et al., 2007), for anxiety at age 11, for substance 
use at age 20 and for mood disorders at age 30 (Kessler et al., 2005). McGorry, Goldstone, 
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Parker, Rickwood, and Hickie (2014) summarise that prevalence rates of mental disorders in 
youths are further documented to be the highest of all age groups. 
 Patel et al. (2007) describe mixed evidence for whether prevalence of mental 
disorders in youths have increased in recent decades. Evidence, e.g. for depressive disorder 
is mixed, with some studies indicating increases, however, those studies are based on recall 
data, and older people have the tendency to forget episodes from their younger years. A 
meta-analysis that addressed this issue, showed no evidence to support the claim of an 
increase (Patel et al., 2007). Multifactorial causes for the development of mental disorders in 
young people have been well supported in the literature; risk and protective factors are 
illustrated in Table 1.1 by domain. Various risk factors have been proposed (e.g. growing up 
in environments with parents with mental disorders, parental conflict or separation, violence, 
child abuse, substance use), often suggesting complex pathways of their association with 
mental health outcomes. It should, however, be emphasised that a considerable proportion 
of those individuals facing severe adversities and multiple risk factors, do not develop mental 
disorders, since protective factors can modify and eliminate the effect of risk factors. 
Amongst others, appear social support and adequate psychosocial stimulation during early 
childhood, to be important in promoting mental health (Patel et al., 2007). 
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Table 1.1 
Risk and protective factors of mental health in youths (in Patel et al., 2007) 
 Risk factors Protective factors  
Biological Exposure to toxins (e.g., tobacco, alcohol) in 
pregnancy 
Genetic tendency to psychiatric disorder 
Head trauma 
Hypoxia at birth and other birth complications 
HIV infection 
Malnutrition 
Substance abuse 
Other illnesses 
Age-appropriate physical 
development 
Good physical health 
Good intellectual functioning 
   
Psychological Learning disorders 
Maladaptive personality traits 
Sexual, physical, emotional abuse and 
neglect 
Difficult temperament 
Ability to learn from experiences 
Good self-esteem 
High level of problem-solving 
ability 
Social skills 
   
Social 
 
   Family      
 
 
 
Inconsistent care-giving 
Family conflict 
Poor family discipline 
Poor family management 
Death of a family member 
 
 
 
Family attachment 
Opportunities for positive 
involvement in family 
Rewards for involvement in family 
   
   School 
  
 
 
 
 
 
 
Community 
 
 
 
 
 
Academic failure 
Failure of schools to provide appropriate 
environment to support attendance and 
learning  
Inadequate or inappropriate provision of 
education 
Bullying 
 
Transitions (e.g., urbanisation) 
Community disorganisation 
Discrimination and marginalisation 
Exposure to violence 
 
Opportunities for involvement in 
school life 
Positive reinforcement from 
academic achievement 
Identity with school or need for 
educational attainment 
 
 
Connectedness to community 
Opportunities for leisure 
Positive cultural experiences 
Positive role models 
Rewards for community 
involvement 
Connection with community 
Organisations 
      
 
Risk factors play an important role for understanding the psychopathology of mental 
disorders; when connecting certain risk characteristics, so-called “risk syndromes” emerge. 
Individuals with these risk syndromes or sub-threshold disorders are at increased risk for 
transitioning to similar or different threshold disorders (Shah, 2015). Early intervention and 
staged treatment (see Section 1.4.2) might help reduce disability and morbidity, however, 
this requires identification of risk syndromes (Ratheesh et al., 2015). Risk syndromes for 
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psychosis have been extensively studied in the past decades (see Section 1.2.2), and 
literature on other risk syndromes, e.g. for bipolar disorder, and on sub-threshold depression 
(see Section 1.2.1), anxiety (see Section 1.2.3), and eating disorders (see Section 1.2.4) 
have started to arise and will be discussed under the respective chapters. 
Another concept, which is very useful in understanding youth mental health, is that of 
developmental epidemiology - which aims to integrate developmental psychopathology into 
epidemiology. The overall goal is to understand how developmental processes affect the risk 
for mental disorders, to ultimately propose preventive and early intervention strategies 
according to the stage of risk (Patel et al., 2007). This is of high importance because youth is 
the period where social, psychological, academic, and occupational pathways are laid down, 
and even mild and brief episodes can seriously disable and block young people’s potential, 
possibly even leading to circles of dysfunction and disadvantage which can be difficult to 
reverse. Psychopathology in young people plays an important role in limiting social and 
economic participation, extending into adult life, however, improving youth mental health can 
significantly reduce unemployment and dependency from state benefits (McGorry, Purcell, 
Hickie, & Jorm, 2007; Patel et al., 2007). 
Young people present with comparatively high rates of suicide and self-harm, and a 
strong association exists between poor mental health and other health and developmental 
concerns such as academic achievements, use and misuse of substances, violence and 
sexual health (Patel et al., 2007). In particular, depressed adolescents were found to show 
more adverse behaviours such as cigarette smoking, substance use, conduct disorders, and 
problems at school (including drop-out) (Keyes, 2006). Keyes (2006) argues that depressed 
youths are not mentally healthy, however, the reverse is not true by implying that youths 
without depression and other mental illness are healthy, and that health can be defined as 
the absence of illness and malfunctioning. There is no standard for how to measure the 
presence of mental health. In the past decades, science has portrayed it by default as the 
absence of psychopathology. This position has been rested on the assumption that mental 
illness and health are dichotomous, forming a single bipolar dimension. This simplification 
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comes with certain issues, e.g. individuals who are free of mental disorder, may not feel 
healthy or function well (Keyes, 2005). 
The assessment of positive mental health, that is, positive feelings towards one’s self, 
and functioning well in life, has therefore been translated into markers of developmental 
success in youth, with main findings being that depressive symptoms and conduct problems 
(e.g. arrest, school absence, substance use) decreased, and psychosocial functioning 
improved (more positive self-concept, being closer to others, better school integration) as 
mental health increased (Keyes, 2006). 
  The importance of considering subjective wellbeing in the context of adolescent 
mental health has been supported by evaluating a dual-factor model in early adolescence, 
which proposes to assess positive indicators of wellbeing, additionally to traditional negative 
indicators such as psychopathology (Suldo & Shaffer, 2008). Subjective wellbeing consists 
of 3 components: life satisfaction, positive and negative affect. This includes the appraisal of 
one’s happiness with global and domain-specific aspects of life (e.g. family, school), a 
positive judgement of one’s quality of life and a more frequent experience of positive relative 
to negative affect. The identification of four groups supported the existence of this dual-factor 
model: 57% of youths were considered to have “complete mental health” (high wellbeing, 
low psychopathology), 13% were “vulnerable” (low wellbeing, low psychopathology), 13% 
“symptomatic but content” (high wellbeing, high psychopathology), and 17% “troubled” (low 
wellbeing, high psychopathology), with means for academic outcome, physical health, and 
social functioning significantly differing between the four groups. The importance of high 
wellbeing was emphasised as only adolescents in the “complete mental health” group 
demonstrated optimal functioning (Suldo & Shaffer, 2008). This also emphasises the 
importance of looking at youth mental health not only from the viewpoint of classifying into 
psychopathological categories (see Section 1.3.1), but by looking at other relevant factors 
such as wellbeing and contentment, despite experiencing mental health problems. 
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1.1.1 Development of the brain and endocrine system during adolescence 
Adolescence and early adulthood are often associated with the onset of mental 
disorders due to the occurrence of biological, psychological and sociological reasons. In 
addition to ordinary risk factors (such as family history and temperament) that apply across 
the life span, occur risk factors that are specific for this time period of adolescence (e.g. 
challenges that are associated with gaining independence from parents and being self-
sufficient, and with academic success and establishing social relationships outside of the 
family), as well as biological changes in the adolescent brain and endocrine system. Typical 
developmental processes of the healthy maturing brain during adolescence and early 
adulthood shall be described in this section, to understand the neurobiology of 
psychopathological processes of mental disorders in youth, which will be provided 
consequently (see Section 1.1.2). 
Amongst those biological reasons are dynamic changes in brain structure and 
function, resulting in a refinement of neural circuits (McGorry et al., 2014). Keshavan, Giedd, 
Lau, Lewis, and Paus (2014) reviewed brain changes during adolescence, and stated that 
whereas continuing myelination is leading to white matter volume increases from childhood 
to early adulthood, cortical thickness, e.g. in the dorsal medial prefrontal cortex (PFC) and 
temporo-parietal junction has been found to decrease - that is, in regions which are 
important for the development of social cognition (Van Overwalle, 2009). Adolescence is not 
only a period that is associated with volumetric brain changes: adequate functional 
connectivity is further important for social-emotional processing (Keshavan et al., 2014). 
Increases in functional connectivity between those regions during adolescence give further 
insight into enhanced social and emotional understanding and responses in youth with 
increasing age. This is an important development because social relationships are especially 
relevant in the period of adolescence for developing and consolidating one’s (social) identity, 
and to take one another’s perspective to successfully communicate (Choudhury, Blakemore, 
& Charman, 2006).  
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Refinement of neurochemical pathways happens via a synaptic reorganisation during 
adolescence (e.g. in the dorsolateral PFC), increasing the efficiency of cognitive systems 
(Choudhury et al., 2006). Efficiency has various specific definitions when considering the 
connectivity of the brain (e.g. global and local efficiency, see Bullmore & Sporns, 2009); 
however, high efficiency generally means that closely adjacent brain areas form local 
clusters which are specialised in certain brain functions but also that brain areas which are 
segregated by greater distance are well connected to communicate effectively (van den 
Heuvel, Stam, Kahn, & Hulshof Pol, 2009). For example, higher cognitive functions such as 
working memory, activate local clusters in various regions of the prefrontal cortex, but are 
also connected to parietal regions in functional magnetic resonance imaging (fMRI) studies 
(e.g. Owen et al., 2005, see Chapter 5).  
This elimination of specific synapses (= pruning) is possibly associated with the 
neurons’ experience-related plasticity. Selective attention, for example, may improve due to 
pruning of glutamatergic synapses by reducing the number of distractors from childhood to 
early adolescence (Keshavan et al., 2014). This means, older children and adolescents will 
be better able to focus and attend to few, but relevant stimuli, whereas younger children may 
be overwhelmed by attempting to simultaneously process a large number of stimuli, due to 
their brain’s inability to filter relevant information from the wealth of internal and external 
stimuli. Changes in limbo-cortical dopamine balance, that further occur during this period, 
might in part be responsible for risk taking behaviour, mood, substance use and psychotic 
disorders (Keshavan et al., 2014). 
Due to age-dependent volume increases of the pituitary gland as key structure of the 
hypothalamus-pituitary-gonadal (HPG) and hypothalamus-pituitary-adrenal (HPA) axis, a 
rise of gonadal and stress hormones takes place during adolescence. This pituitary volume 
increase is probably the result of stimulating effects of gonadotropin- (and corticotropin-) 
releasing hormones synthesised in the hypothalamus, and feedback effects from circulating 
gonadal (and adrenal) hormones on the pituitary (Keshavan et al., 2014). Increasing levels 
of testosterone (in men) and fluctuating female gonadal hormones (during the menstrual 
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cycle and as found in contraceptive hormones) were thought to affect brain structure and 
function during adolescence, e.g. contributing to decreases of cortical grey matter 
(Keshavan et al., 2014). Whilst adolescence is a time of high stress reactivity and the stress 
response of the HPA axis is maturing, gonadal hormones and glucocorticoids have been 
shown to affect dopaminergic neurotransmission in specific brain areas (e.g. striatum, PFC), 
and are therefore proposed to be implicated in cognitive and affective processes during 
adolescence (Keshavan et al., 2014). Further, the maturing brain is well fitted with hormone 
receptors and conversion enzymes to respond to sex and stress hormones, and therefore 
adolescence can be characterised by an increasing responsiveness for gonadal and adrenal 
hormones in cortical brain regions (e.g. especially in the temporal lobe for sex hormones, 
and PFC for stress hormones) (Sinclair et al., 2014).  
 
1.1.2 Adolescence and Psychopathology 
 Keshavan et al. (2014) state that imbalances or deviations in the developmental 
processes of the brain and endocrine system increase the risk for mental illnesses in youth. 
Those biological peri-adolescent risk factors were found - together with psychosocial factors 
(e.g. school, relationships) (Paus, Keshavan, & Giedd, 2008), genetic and environmental risk 
factors - to be involved in the pathogenesis of psychotic and mood disorders (Keshavan et 
al., 2014). A dysmaturation of neural connectivity during adolescence, is an important part of 
the pathophysiology of psychotic disorders, which leads to an imbalance of excitatory and 
inhibitory systems and to constraint of neuronal plasticity. This involves dopaminergic and 
glutamatergic synapses of neural circuits that are associated with executive, affective, and 
social functions. Similarly, adolescents with bipolar disorder and those at risk, display 
dysfunction of emotion regulation (PFC, amygdala, hippocampus) and reward (PFC, 
striatum) circuits (Keshavan et al., 2014).  
Advanced pubertal status has repeatedly been linked to psychopathology. E. g., 
larger pituitary volumes (as key component of the HPA and HPG axis, see Section 1.1.1), 
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and higher depressive symptoms cross-sectionally were predicted by early pubertal timing, 
and mediated longitudinally the association between early pubertal timing and higher 
depressive symptoms (Whittle et al., 2012). These findings support the idea of 
neurobiological mechanisms being responsible for linking pubertal timing and depressive 
symptoms (Simmons et al., 2014). The evidence for the association between advanced 
pubertal status and anxiety symptoms is, however, mixed: A review concluded that whereas 
there is only limited and very little evidence for girls, more consistent associations were 
observed for boys (e.g. for testosterone) (Reardon, Leen-Feldner, & Hayward, 2009). 
Findings for cortisol and anxiety symptoms were similarly inconsistent, e.g. positive 
correlations amongst girls but not boys, but no association of pubertal status and cortisol 
levels after biological challenge (carbon-dioxide inhalation) in youths with anxiety or mood 
disorder, were found (Reardon et al., 2009). Further, pubertal status and tempo at age 12 
significantly predicted substance use problems in mid to late adolescence, partially mediated 
by high sensation seeking and low impulse control (Castellanos-Ryan, Parent, Vitaro, 
Tremblay, & Seguin, 2013).  
Nelson, Leibenluft, McClure, and Pine (2005) speculated that the dysregulation of the 
social information processing network (SIPN) might be involved in the development of mood 
and anxiety disorders during adolescence. A network is a system of interconnected sets of 
brain regions (nodes) that serve specific functions. The SIPN, for example, is a large 
network that consists of three nodes that each consist of multiple regions. It serves as the 
name indicates, the processing of socially relevant information. The first node, the detection 
node, e.g. consists of the inferior occipital cortex, and fusiform gyrus, and is important for 
perceptual functions and categorising a stimulus as social. The second node, the affective 
node is composed of areas primarily involved in reward and punishment, such as the ventral 
striatum and the amygdala, and thirdly, the cognitive-regulatory node is involved in 
perceiving mental states of others and goal-directed behaviour, and is anchored in e.g. 
paracingulate areas, and dorsal, dorso-medial, and ventral prefrontal cortices. With 
adolescence being a period of increased emotional responsiveness to social stimuli, and 
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social cognition playing an important role during adolescence (see Section 1.1.1), 
development-related changes to this network might be particularly relevant for emergent 
psychopathology during adolescence: Rapid and drastic changes occur to the affective node 
with the onset of puberty (e.g. regarding sexual behaviour and the formation of social 
bonds), whereas the maturation of the cognitive node lags behind by several years. This 
theory of dysregulation of the SIPN is supported by volumetric alterations of the superior 
temporal gyrus (STG, which is generally involved in social cognition), ventral PFC (as part of 
the cognitive-regulatory node) and amygdala (as part of the affective node), alterations of 
frontal white matter, and of orbitofrontal choline levels in adolescents with mood and anxiety 
disorders (Nelson et al., 2005). 
 
1.2 Description of major psychological disorders relevant for clinical staging 
(epidemiology, clinical and neurobiological findings) 
Depression, mania, psychotic, anxiety, eating and substance use disorders will be 
described in the following, concerning their epidemiology, and clinical and neurobiological 
findings relevant to the outlook of this thesis (e.g. cortisol levels, and neuroimaging findings). 
The focus is on the period of adolescence and early adulthood due to the ages 16-25 years 
of the currently investigated sample, however, due to a shortage of relevant literature in this 
age range, the following description also covers earlier periods such as childhood, or later 
periods in adulthood. The ultra-high risk (UHR) state of psychosis and bipolar disorder will 
receive special attention due to their similarity with early mental health problems in general. 
Even though the aim of this thesis is to look at youth mental health without diagnosing or 
specifically referring to diagnostic categories, findings are described on the basis of 
symptom categories in the following. This is due to the vast majority of studies being based 
on classification systems such as the DSM, and studies using alternative approaches to 
mental health having only recently emerged (see Section 1.3). Results from the empirical 
chapters of this thesis will be linked to these reported findings from previous literature by 
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classifying individuals into a dichotomy of high versus low depressive, psychotic and anxiety 
symptoms, respectively.      
	  
1.2.1 Affective disorders 
Depression and mania are common mental disorders in the adolescent general 
population. Kessler, Avenevoli, and Merikangas (2001) reviewed retrospective reports, 
demonstrating that 50% of depressive and 90% of mania cases that have their onset during 
or before adolescence, persist into adulthood. The course of depression is often 
characterised by high continuity and recurrences when disorder onset takes place in 
childhood or adolescence, whereas the course of mania is typically characterised by 
chronicity (Kessler et al., 2001). Recurrence rates in depression are as high as at least 50% 
for those who have recovered from a first episode, and 80% for those who have recovered 
from a second episode (American Psychiatric Association, 2000).  An early onset of 
depression was further shown to increase the risk of subsequent substance abuse (Kessler 
et al., 2001). Thapar, Collishaw, Pine, and Thapar (2012) identified genetic disposition and 
psychosocial stress as the major risk factors for depression, and sex hormones and early 
adversity are further increasing the risk for the disorder in adolescents. Depression, in turn, 
constitutes a strong risk factor for suicide, with half of the suicide cases coinciding with 
depression at time of the death. Interestingly, a British national survey revealed that risk 
factors such as biological and economic deprivation early in life (e.g. low birth weight, 
overcrowding in childhood) were only indirectly associated with depression in adulthood: low 
birth weight was found to be associated with the intermediate risk factor of developmental 
delay in infancy, and overcrowding in childhood with the intermediate risk factor of economic 
deprivation in adulthood. Both intermediate risk factors subsequently showed an association 
with depression in adulthood (Colman et al., 2014).  
Adolescents with bipolar disorder presented with functional impairment, high rates of 
comorbidity, and suicide attempts (Lewinsohn, Klein, & Seeley, 1995). About 27% of 
individuals with sub-syndromal depression went on to develop major depression (Fergusson, 
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Horwood, Ridder, & Beautrais, 2005) within 2 years and 45% of individuals with sub-
syndromal bipolar disorder transitioned to threshold disorder within one year (Axelson et al., 
2011). A population-based study of 12,000 adolescents reported 29% sub-threshold (and 
10% threshold) depression – sub-threshold disorders, likewise to threshold disorders, 
presenting with high rates of comorbidity, functional impairment and suicidality (Balazs et al., 
2013). However, not all young individuals who are presenting with risk factors, develop the 
disorder: High intelligence, emotion-regulation capacities, coping and thinking styles, and 
good quality interpersonal relationships have been identified as markers of resilience 
(Thapar et al., 2012).  
Alterations of two interrelated neuronal circuits have been linked with the risk for 
depression and the disorder itself. A circuit being crucial for the response to danger, that 
connects the amygdala, hippocampus, PFC and the HPA axis, displayed hyperactivity in 
adolescents at risk for or diagnosed with major depression (MD) (Thapar et al., 2012). A 
second circuit, comprising the striatum, PFC and ventral dopamine-based systems, which 
plays an important role in learning of reward, demonstrates reduced activity in at-risk and 
depressed individuals (Thapar et al., 2012). Likewise, abnormalities of the PFC, striatum, 
and amygdala were discovered early in the course of bipolar disorder, and proposed to 
potentially precede illness onset (Strakowski, DelBello, & Adler, 2005). These changes in 
brain circuits may provide neurobiological explanations for diverse symptoms and 
observations in mood disorders such as the reduced ability to think, memory problems, and 
indecisiveness that might be related to prefrontal abnormalities, high comorbidity with 
anxiety due to the involvement of the amygdala, and diminished interest and motivation due 
to reduced involvement of the striatum. 
 
Bipolar at-risk (BAR) state 
Due to the highly disabling nature and the likewise high economic burden of bipolar 
disorder (Bechdolf et al., 2012), early detection and intervention of the BAR state has 
become a well researched risk syndrome for mental disorders as well, after the at-risk state 
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for psychosis (Section 1.2.2). BAR criteria are the ages between 15-25 years, and 
experiencing (1) sub-threshold mania symptoms, (2) minor depression plus hypo-manic 
features (that is, episodes of depression and mania that do not reach the threshold for major 
depression and mania), or (3) minor depression plus genetic risk (Bechdolf et al., 2012). 
There is preliminary evidence for the predictive validity for BAR criteria predicting the onset 
of mania and hypomania: 14% of individuals meeting BAR criteria transitioned to 
mania/hypomania within 12 months, as opposed to no one in the non-BAR group (Bechdolf 
et al., 2014). In a sample of help-seeking youths for depression, anxiety and substance use 
disorders, alcohol use disorders and a family history of substance use disorders were 
significantly associated with developing bipolar disorder, and depressive symptoms and 
cannabis use had further high effect sizes, despite not reaching statistical significance 
(Ratheesh et al., 2015).  
The relevance of unspecific mental health symptoms has been demonstrated in a 
review of prospective cohort studies, investigating risk factors for the development of bipolar 
disorder: More than 50% of the individuals who developed bipolar disorder, experienced 
unspecific prodromal symptoms - even before the age of 14 years – similar to those 
preceding the onset of psychosis and depression (Geoffroy, Leboyer, & Scott, 2015). This 
finding supports the stage description of the clinical staging model, with early stages 
consisting of undifferentiated general symptoms and syndromes (Lin, Reniers, & Wood, 
2013, see Section 1.3.2).  
 Brain imaging revealed significant volume reductions in the amygdala and insula in 
UHR for psychosis individuals who subsequently developed bipolar disorder, as compared to 
UHR for psychosis individuals who did not develop any psychiatric disorder at least 12 
months after the scan, and healthy controls (HC) (Bechdolf et al., 2012). This gives 
preliminary evidence that imaging studies might help to predict who is subsequently going to 
transition to bipolar disorder (at least in symptomatically enriched clinical samples) (Bechdolf 
et al., 2012). 
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1.2.2 Psychosis 
Schizophrenia is one of the most common psychotic disorders and debilitating in its 
nature, therefore extensive research has focused on its aetiology. Schizophrenia has a 
strong genetic component, is more prevalent in males and individuals with migration history, 
and further associated with urbanicity, cannabis use, prenatal infections, and perinatal 
complications (Tandon, Keshavan, & Nasrallah, 2008). Even though a number of genes and 
chromosomal abnormalities have been linked to an increased risk for developing 
schizophrenia, no single gene variation could be consistently identified (Tandon et al., 2008). 
Neurodevelopmental abnormalities were proposed to be the result of errors in synaptic 
pruning during adolescence and early adulthood (Shenton, Dickey, Frumin, & McCarley, 
2001). Amongst brain abnormalities, such as ventricular enlargement, and involvement of 
the frontal and parietal lobe, and diverse subcortical structures, the temporal lobe has been 
viewed as the key to understanding the pathogenesis of schizophrenia due to its importance 
in language and memory processes (Shenton et al., 2001). The observation of insular 
activation during hallucinations suggests that the insula is creating heightened salience 
during otherwise normal activity, supporting the notion of an insular dysfunction model of 
psychosis (Palaniyappan & Liddle, 2012). The psychopathology of schizophrenia has further 
been attempted to be explained by anatomical and functional dysconnectivity (Stephan, 
Baldeweg, & Friston, 2006), and hypo-frontality (Pettersson-Yeo, Allen, Benetti, McGuire, & 
Mechelli, 2011). Concepts of hypo-frontality and dysconnectivity in individuals with (sub-) 
threshold psychotic symptoms will be discussed in more detail in Section 5 and 6.  
 
Ultra-high risk for psychosis 
The period preceding the onset of schizophrenia and other psychotic disorders is 
characterised by non-specific symptoms such as anxiety and depressed mood, attenuated 
psychotic symptoms (e.g. delusions or hallucinations) and a decline in social and role 
functioning. To detect young people in the prodromal phase of psychotic illness, these 
characteristics have been operationalised and are known as UHR for psychosis (or clinical 
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high risk or the at-risk mental state). One way of defining these UHR criteria is by using the 
Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005), and 
classifying into attenuated psychotic symptoms (APS), brief limited intermittent psychotic 
symptoms (BLIPS), and/or trait vulnerability.  
For the APS criterion, symptoms must be present for at least once a week, with a 
frequency of at least several times per week. The BLIPS criterion refers to psychotic 
symptoms at the severity and frequency of a psychotic episode but which spontaneously 
resolve within 7 days. Trait vulnerability refers to young people with a first degree relative 
with psychotic illness, or schizotypal personality disorder in the individual, accompanied by a 
substantial deterioration in functioning, maintained for at least a month within the past year, 
or by chronic low functioning (Yung et al., 2005). Rates of transition to a first episode of 
psychosis (FEP) in individuals presenting with these features are estimated to be 
approximately 22% over twelve months, increasing to 29% after two years and 36% after 
three years according to a recent meta-analysis (Fusar-Poli et al., 2012), highlighting the 
importance of early intervention (McGorry et al., 2002) to reduce the risk of pronounced and 
possibly non-reversible structural brain alterations associated with progression to a first 
episode of psychosis (Wood, Yung, McGorry, & Pantelis, 2011). Special attention may need 
to be paid to the BLIPS group with highest rates of transition over the short term, followed by 
the APS group, and least risk of transition in the trait group (Nelson, Yuen, & Yung, 2011). 
Neurobiological abnormalities in such individuals appear to be qualitatively similar but 
less severe than in schizophrenia (Jung, Borgwardt, Fusar-Poli, & Kwon, 2012). Region of 
interest (ROI) studies have identified smaller frontal (Mechelli et al., 2011), insular 
(Takahashi et al., 2009), parahippocampal (Mechelli et al., 2011; Tognin et al., 2014) and 
superior temporal gyri (Takahashi et al., 2010) volumes, characterising UHR individuals 
and/or predating the onset of psychosis, which has generally been replicated by whole-brain, 
voxel-wise brain morphometric studies (Fusar-Poli, Radua, McGuire, & Borgwardt, 2011). 
Progressively declining insular volumes were detected in UHR patients who subsequently 
transitioned to psychosis, when compared to those who did not transition and HC 
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(Takahashi et al., 2009), confirming the idea of an insular dysfunction model of psychosis 
(Palaniyappan & Liddle, 2012) even before the onset of psychosis. Such changes, which are 
also associated with the pathogenesis of schizophrenia, are assumed to be distributed, 
involving inter-connected brain networks rather than focal regions (Chen et al., 2014). This 
view is in accordance with the manifestation of abnormalities of brain networks in individuals 
at familial risk and UHR for psychosis: fMRI studies showed altered resting-state connectivity 
within the default-mode network (see Section 6.1) between the posterior cingulate cortex 
(PCC), precuneus, and prefrontal areas in individuals with a familial risk (Jang et al., 2011; 
Jukuri et al., 2013; van Buuren, Vink, & Kahn, 2012) and between diverse frontal and 
subcortical regions in UHR subjects (Dandash et al., 2014).  
 
1.2.3 Anxiety disorders 
Age of onset varies across anxiety disorders with separation anxiety disorder and 
some specific phobias having their onset before age 12, social phobia from later childhood to 
adolescence, panic disorder, agoraphobia, and generalised anxiety disorder (GAD) from 
adolescence to early adulthood (Beesdo, Knappe, & Pine, 2009). Estimates for lifetime 
prevalence for anxiety disorders in childhood and adolescence ranges from 15-20% (Beesdo 
et al., 2009). 12-months prevalence rates for social anxiety disorder, in particular, were 
about 2% and for sub-threshold social anxiety with one DSM criterion missing, 3%, and with 
two or more missing, 7.5% - all three groups being associated with greater impairment as 
seen in controls (Fehm, Beesdo, Jacobi, & Fiedler, 2008) and greater suicide risk (Balázs et 
al., 2013).  Anxiety disorders are highly comorbid among each other and with other 
psychiatric disorders, and have a modest genetic predisposition in the range of 30-40% 
(Hettema, Neale, & Kendler, 2001). Amongst others are childhood adversities and life 
events, behavioural inhibition, and parental overprotection risk factors for developing anxiety 
disorders (Beesdo et al., 2009). Paediatric structural imaging reports inconsistent findings, 
e.g. some reporting increases and other decreases in amygdala volume (Pine, 2007). 
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Functional imaging studies discovered amygdala hypersensitivity - that is, increased 
amygdala activation, e.g. when viewing emotional stimuli (Beesdo et al., 2009).  
 
1.2.4 Eating disorders 
Results from an adolescent national comorbidity survey revealed lifetime prevalence 
of anorexia and bulimia nervosa, and binge-eating disorder being settled below 2%, 
respectively; however, sub-threshold conditions of disordered eating are estimated to be 
considerably higher (Swanson, Crow, Le Grange, Swendsen, & Merikangas, 2011). Jacobi 
et al. (2011) followed young women at increased risk for eating disorders due to high weight 
and shape concerns, and found that 11% developed sub-threshold or full syndrome eating 
disorders over a three year period. Especially those experiencing critical comments about 
their eating behaviours and with a history of depression were at highest risk with a sensitivity 
of 75% and specificity of 82% (Jacobi et al., 2011). In this survey, median age of onset was 
quite consistently found to be around 12 years of age. Whereas anorexia nervosa was only 
comorbid with oppositional defiant disorder (that is, a pattern of negativistic and hostile 
behaviours that causes significant impairment in social and academic functioning; American 
Psychiatric Association, 2000), bulimia nervosa and binge-eating disorder were strongly 
associated with depressive and anxiety disorders. Disordered eating was further associated 
with social impairment and suicidality. Even though the majority was seeking help for 
emotional or behavioural problems, only a minority sought help specifically for eating 
problems (Swanson et al., 2011). 
A review about the neurobiology of eating disorders in children and adolescents 
identified anorexia nervosa as often associated with obsessive and rigid personality, 
perfectionism, and reduced affect, and bulimia nervosa with intense affect, high impulsivity, 
and emotional dysregulation (Kaye, 2008). Genetic contribution to eating disorders was 
estimated to be as high as 50-80%, with an often chronic and debilitating course of illness, 
and high treatment resistance in anorexia nervosa. Neuroimaging studies detected 
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abnormalities in frontal, temporal, parietal, and cingulate brain areas (Kaye, 2008), similarly 
to other psychiatric disorders, e.g. as prefrontal and hippocampal abnormalities described in 
affective disorders (Thapar et al., 2012, see Section 1.2.1), and frontal, temporal, and 
parietal abnormalities in psychotic disorders (Shenton et al., 2001, see Section 1.2.2) . 
 
1.2.5 Substance use disorders  
High sensation seeking, low harm avoidance and impulse control, poor parenting 
skills, family conflict, lack of bonding, as well as substance disorders in first-degree relatives, 
and early behavioural problems have, amongst others, been identified as risk factors for 
developing substance use problems (Hawkins, Catalano, & Miller, 1992). Furthermore, 
physical and sexual abuse, as well as witnessing violence, increased the risk for substance 
use disorders (Kilpatrick et al., 2000), and males were more often affected (Hawkins et al., 
1992).  
Adolescent binge drinking and marijuana use has discrete, but significant effects on 
neurocognition, such as decreases in executive functions and attention, and memory 
impairment (Squeglia, Jacobus, & Tapert, 2009). These behavioural manifestations may be 
the consequence of grey matter reductions (e.g. of the hippocampus) in case of heavy 
drinking, and alterations in white matter (e.g. in frontal-occipital and superior longitudinal 
fasciculi, and in the splenium of the corpus callosum) and functional brain activation during 
cognitive tasks (e.g. activation increases in the parietal lobe and decreases in occipital and 
cerebellar areas during a spatial working memory task) for both, alcohol and cannabis 
(Squeglia et al., 2009). 
 
1.2.6 Disorders’ interrelations 
Substance use in adolescence can be a coping strategy to deal with stress and 
associated negative emotions (Kilpatrick et al., 2000). Depressive (or other psychiatric) 
disorders often precede substance use disorders, which suggests the notion of self-
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medication with alcohol or illegal drugs to cope with depressive symptoms; substances, in 
turn, can be seen as a depressogens, creating depressive feelings and neurovegetative 
symptoms of depression (Deykin, Levy, & Wells, 1987), ultimately leading to a vicious cycle 
of depression and substance abuse. Childhood trauma has been found to be significantly 
associated with becoming depressed and heavy drinking, and childhood trauma may worsen 
the association between recent life stress and depression (Colman et al., 2013). 
The link between substance use and psychosis is further well established: Arseneault et 
al. (2002) demonstrated that 10% of adolescent cannabis users developed schizophreniform 
disorder in early adulthood, that is, symptoms of schizophrenia which do not reach the time 
criterion of 6 months to be diagnosed as schizophrenia. A dose-response relationship was 
discovered, with more increased risk for developing psychosis in those who consumed 
cannabis more frequently (Moore et al., 2007). The risk for developing psychosis is, 
however, not only elevated in individuals with frequent cannabis use, but in general when 
experiencing mental health problems: Recently, a large Danish nationwide registry study 
identified 25,000 individuals with child or adolescent psychiatric disorders, of which about 
5% were subsequently diagnosed with schizophrenia spectrum disorders (Maibing et al., 
2014). Comparing this number to the risk of developing schizophreniform disorder in the 
general population, it can be concluded that the risk is significantly increased in those 
individuals who experienced mental health problems in childhood or adolescence, according 
to this study, particularly within the first year, but also remaining significantly elevated for up 
to 5 years (Maibing et al., 2014).    
When looking at longitudinal evidence, a large study is to be mentioned that identified 
sub-clinical psychotic symptoms at age 19/20 as risk factors for developing common mental 
disorders (e.g. dysthymia, social phobia, bipolar and obsessive-compulsive disorder) up to 
30 years later (Rössler et al., 2011). A prospective cohort study following youth from age 12 
to 18 found an association between psychotic symptoms at age 12 and depressive 
symptoms at 18, however, not the other way round (Sullivan et al., 2014). The authors 
explain these findings by the possible development of long-term trust issues, low self-
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confidence and isolation due to experiencing psychotic symptoms in early adolescence; 
even if psychotic symptoms resolve, depressive symptoms might persist as consequence of 
these other mediating variables. The lack of association between depressive symptoms at 
age 12 and psychotic symptoms at age 18 is possibly due to the lack of such mediating 
variables that carry out long-term effects, as seen for psychotic symptoms (Sullivan et al., 
2014). Another longitudinal study discovered adolescent substance use to follow 
externalising problems, and substance use in turn, being followed by criminal offences in 
males, and internalising problems in females may be preceded by substance use (Miettunen 
et al., 2014).  
 
1.3 Approaches to mental health 
The previous section outlined how mental disorders share risk factors, and aetiology, 
and how their psychopathology interacts over time with studies usually using a categorical 
approach based on classification systems of mental health. The use of categorical 
approaches to mental health has been well established, however, alternative approaches, 
such as viewing mental health on a continuum, have been proposed due to issues with the 
current classification systems. Therefore, after describing mental health from a categorical 
perspective and discussing issues that are associated with this approach (Section 1.3.1), 
alternative models dealing with these problems will be introduced. First, it will be described 
how mental health can be viewed on a continuum using a dimensional approach such as 
clinical staging (Section 1.3.2). Second, a bifactor model will be introduced which explains 
the psychopathology of mental disorders using a general underlying mental health factor 
(Section 1.3.3), and third, how using nomothetic and idiographic parameters of mental states 
can be used to facilitate intervention (Section 1.3.4). Lastly, issues that are associated with 
implementing these novel approaches into current diagnostic systems and clinical practice 
will be discussed (Section 1.3.5). 
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1.3.1 Categorical approach and issues associated with it 
The DSM and ICD are the most commonly used manuals for diagnosis of psychiatric 
disorders in mental health research and clinical practice. The respectively latest versions are 
DSM-V (American Psychiatric Association, 2013) and ICD-10 (World Health Organisation, 
1992) – both being numerous times revised, yet being classification systems since their first 
versions. Cloninger (1999) critically evaluated the principles underlying this categorical 
approach to mental health: Current classification systems underlie the assumption that 
mental health can be defined as the absence of mental disorder, with mental disorders being 
discrete, categorically defined entities. This categorisation aims to systematically and reliably 
describe cases, to serve as a model of disease aetiology and to effectively plan treatment. 
However, a substantial proportion of individuals present with intermediate or atypical cases, 
and are therefore classified as “not otherwise specified”, or the replacement according to the 
DSM-V as “other specified” and “unspecified”(American Psychiatric Association, 2013). 
Drastically increasing the categories across DSM versions has, however, not solved that 
problem. Another point to mention is that the same medication or psychotherapy technique 
has often proven effective across different diagnostic categories. Early neuropsychiatric 
models assumed specific mental disorders would have their origin in specific areas of the 
brain, which has been overhauled by the contemporary notion of complex, distributed and 
interconnected neuronal networks (Cloninger, 1999,  see Chapter 6). 
Conventional diagnoses built on the DSM and ICD are delineated by contrived 
divisions based on symptom sets (McGorry et al., 2007). This approach is associated with 
three major issues. Due to the possibility of diverse symptom presentations within a 
particular disorder, a so-called within-category heterogeneity may result, which questions the 
validity of considering various symptom constellations to reflect the same diagnosis (Clark, 
1995). A categorical approach further constitutes diagnoses as independently emerging 
conditions. Given the fact that they rather co-occur with other disorders, as e.g. a survey has 
demonstrated for major depression and panic disorder, it was found that patients with life-
time comorbidity were generally more impaired and showed a more severe course than 
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those with one disorder alone (Roy-Byrne, 2000). Related to this is the question to whether 
mental disorders are separated from one another by natural boundaries, which is found to 
have little evidence and it is rather assumed that variation in symptoms follows a continuum 
(Kendell & Jablensky, 2003). Impairment is more frequent in threshold diagnostic categories 
than sub-threshold disorders, but due to the higher overall prevalence of the latter, recent 
findings shift the attention away from diagnostic criteria and thresholds, towards impairment 
and distress (for more information on functional impairment, see Section 1.4.3, Shah, 2015). 
 
1.3.2 Dimensional approach and clinical staging 
A dimensional approach, by contrast, hypothesises that mental disorders, such as 
schizophrenia or affective disorders, develop from a pluripotential state, consisting of 
undifferentiated general symptoms and syndromes and from a background of specific and 
non-specific risk factors, such as genetic predispositions or early environmental and/or 
traumatic conditions (Lin et al., 2013). Depending on individual characteristics like coping 
responses, personality traits, social skills and further protective and risk factors as stated in 
diathesis-stress-models (Ingram & Luxton, 2005), progression of symptoms and acquisition 
of new symptoms might occur, which may be associated with progressive neurobiological 
changes and behavioural and functional decline, until threshold disorders arise (Lin et al., 
2013). Diathesis is defined as predispositional sets of biological and psychological factors 
that make an individual vulnerable to psychopathology. Whereas the term stress has been 
conceptualised in many different ways, one could define stress as all major and minor life 
events that interrupt an individuals’ physiological, cognitive and emotional mechanisms to 
maintain stability. This diathesis-stress-model suggests additivity, that is, whether or not a 
mental disorder will develop, depends on the combined loading of stress and diathesis. E.g., 
minor stressors could be associated with disorder onset in an individual with a high genetic 
loading, whereas only major life events would lead to disorder onset in an individual with low 
vulnerability according to the model (Ingram & Luxton, 2005). 
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1.3.2.1 Clinical staging 
One approach based on some dimensional principles in clinical practice is clinical 
staging. Clinical staging is a more concise form of diagnosis, which in contrast to 
conventional diagnostic practice, not only defines the extent of progression of an illness at a 
particular time point, but also where a person currently lies along the continuum of the 
course of the disease (McGorry et al., 2007). The aims are to delay or even prevent 
progression to more advanced stages or to remit to earlier ones (McGorry et al., 2007) and it 
allows for treatment selection relevant to stage, with a higher effectiveness in earlier stages 
through less invasive interventions than when delivered later in the illness course (McGorry, 
Hickie, Yung, Pantelis, & Jackson, 2006). McGorry (2013) summarises that mental disorders 
are considered to be dynamic syndromes that overlap and share aetiologies and courses 
according to this model. Major psychiatric disorders are often preceded by prodromes, that 
is, sub-threshold stages (microphenotypes) consisting of non-specific symptoms, such as 
anxiety and depression, frequently being associated with persistent stress and disability. 
Access to care is typically only provided for threshold disorder, yet, the need for care often 
exists during the sub-threshold stages as well. This approach defines the stage by symptom 
severity, level of associated distress, and impairment of functioning, and persistence of 
problems in contrast to specification of syndromal content. The model acknowledges that 
persistent and multiple microphenotypes can justify clinical need in their own right, and on 
the grounds of risk for transition to frank disorder (macrophenotypes). It further 
acknowledges a “grey zone” between sub-threshold disorder and distress and more serious 
disorder, and aims to keep balance between over- and under-treatment (McGorry, 2013). 
Table 1.2 illustrates an example of the heuristic representation of a clinical staging model 
that defines stages from 0 to 4 on the basis of clinical symptomatology and the individuals’ 
functioning. It further addresses which populations to target and which sort of intervention is 
likely to be indicated. 
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Table 1.2 
Clinical staging framework for psychotic and severe mood disorders (McGorry, Hickie, Yung, 
Pantelis, & Jackson, 2006) 
Clinical 
stage 
Definition Target populations for 
recruitment  
Potential interventions 
0 Increased risk of psychotic or 
severe mood disorder 
No symptoms currently 
1st degree teenage 
relatives of individuals 
with psychotic and 
severe mood disorders 
Improved mental health 
literacy, family education, 
drug education, brief 
cognitive skills training 
    
1a Mild or non-specific symptoms of 
psychosis or severe mood 
disorder (including neurocog-
nitive deficits) 
Mild functional change or decline 
Screening of teenage 
populations, referral by 
primary care physicians, 
referral by school 
counselors 
Formal mental health 
literacy, family 
psychoeducation, formal 
CBT, active substance 
abuse reduction 
   
1b 
  
 
 
 
 
 
 
 
2 
 
 
Ultra high risk: moderate but 
sub-threshold symptoms, with 
moderate neurocognitive 
changes and functional decline 
to caseness 
 
 
 
 
First episode of psychotic or 
severe mood disorder 
Full threshold disorder with 
moderate-severe symptoms, 
neurocognitive deficits and 
functional decline 
 
Referral by educational 
agencies, primary care 
physicians, emergency 
departments, welfare 
agencies 
 
 
 
 
Referral by primary care 
physicians, emergency 
departments, welfare 
agencies, specialist 
care agencies, drug and 
alcohol services 
 
Family psychoeducation, 
formal CBT, active 
substance abuse 
reduction, atypical 
antipsychotic agents, 
antidepressant 
agents or mood stabilisers 
 
 
Family psychoeducation, 
formal CBT, active 
substance abuse 
reduction, atypical 
antipsychotic agents for 
episode, antidepressant 
agents or mood stabilisers, 
vocational rehabilitation 
   
3a 
  
 
 
 
 
3b 
 
 
 
 
 
 
 
3c 
 
 
 
 
4 
 
Incomplete remission from first 
episode  
 
 
 
 
Recurrence or relapse of 
psychotic or mood disorder 
which stabilises with treatment,  
residual symptoms, or neuro-
cognition below the best level 
achieved following remission 
from first episode 
 
Multiple relapses, provided 
worsening in clinical extent and 
impact of illness is objectively 
present 
 
Severe, persistent or unremitting 
illness as judged on symptoms, 
neurocogntion and disability 
criteria 
 
 
Primary and specialist 
care services 
 
 
 
 
Primary and specialist 
care services 
 
 
 
 
 
 
Specialist care services 
 
 
 
 
Specialised care 
services 
 
As for ‘2’ with additional 
emphasis on medical and 
psychosocial strategies to 
achieve full remission 
 
 
As for ‘3a’ with additional 
emphasis on relapse 
prevention and ‘early 
warning signs’ strategies 
 
 
 
 
As for ‘3b’ with emphasis 
on long-term stabilisation 
 
 
 
As for ‘3c’ but with 
emphasis on clozapine, 
other tertiary treatments, 
social participation despite 
ongoing disability 
Notes. CBT=Cognitive-Behavioural Therapy. 
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Estimations of threshold DSM and sub-threshold disorder (anxiety, mood, attention 
deficit hyperactivity disorder, disruptive, and substance use disorders) from a probability 
sample of youths aged 11-17 years, revealed 12-months prevalence of 16% for threshold, 
and 42% for sub-threshold disorder when disregarding the impairment criterion (Roberts, 
Fisher, Blake Turner, & Tang, 2015). These numbers dropped to 8% and 16%, respectively, 
when considering impairment. 50% of threshold disorders were described by moderate to 
severe impairment, and 38% of sub-threshold disorders (Roberts et al., 2015). This higher 
prevalence of sub-threshold disorders compared to threshold disorders translates into 
significant illness burden of sub-threshold conditions on the population level (Shah, 2015). 
However, efforts to include those cases, e.g. into the DSM to provide access to clinical care, 
may pathologise these conditions to the level of threshold disorders, possibly leading to 
over-treatment and inappropriate medicalisation. Instead, clinical staging models and early 
intervention services could be reconfigured to include distressed and/or help-seeking 
individuals, regardless of diagnosis. This would decouple requiring to provide a diagnosis 
before treating individuals who are in need for clinical care and minimise the risk of 
overtreatment, by still aiming to prevent or delay transition to frank disorder (Shah, 2015). 
 
1.3.2.2 Trunk and branches model 
The Trunk and Branches model is a heuristic representation that has been adapted 
from the clinical staging model (McGorry et al., 2006; Purcell et al., 2015). Stage 
descriptions are very similar to the clinical staging model (as illustrated in Table 1.2), with the 
main difference being that additional branches are described from stage 2 onwards, covering 
not only psychotic and severe mental disorders, but also branches of anxiety, eating and 
substance use disorder. It proposes a stage 0, describing asymptomatic individuals, 
presenting with no or only very few depressive and anxiety symptoms. Stage 1a 
encompasses undifferentiated general symptoms (mild anxiety, depressive and somatic 
syndromes), whereas stage 1b describes individuals with an attenuated form of a 
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distinguishable disorder. Stage 2 describes threshold disorder (e.g. MD, mania, psychosis) 
(see Figure 1.1). Progression might take place, often accompanied by functional decline and 
development of chronic symptoms; however, transition from one stage to the next is not 
inevitable (Purcell et al., 2015), as well as remission of symptoms being likely to take place.  
 
Figure 1.1. Trunk and Branches Model. 
 
1.3.3 Bifactor model 
It was aimed to distinct “normal” from “disordered” behaviour with the introduction of 
DSM-IV, to select a threshold above which the risks associated with labelling and treating 
mental problems would outweigh the risks associated with not labelling and treating these 
problems as a mental disorder (Lahey et al., 2008). However, over time accumulated 
evidence indicated that current diagnostic boundaries do not sufficiently regard child and 
adolescent psychopathology (Sonuga-Barke, 2013). Instead, using a differentiation into 
higher-order liability dimensions of internalising and externalising disorders may be more 
useful (Brodbeck et al., 2014). This liability-spectrum model proposes a distress factor 
including major depressive, dysthymic and generalised anxiety disorder, and a fear factor 
including social, specific and agoraphobia and panic disorder on the internalising dimension. 
Substance disorders count towards the externalising dimension (Krueger & Markon, 2006). 
Internalising disorders appear to be too highly correlated to show meaningful individual 
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contributions in classifying psychopathology in the early ages of childhood and adolescence 
(Lahey et al., 2008). High correlations between diagnoses such as MD and GAD were 
discovered, which seem likely to be reflected by symptoms shared between the two 
diagnostic categories such as insomnia, irritability, and difficulties to concentrate (Lahey et 
al., 2008). Abnormal sleep duration has repeatedly been shown to severely affect 
individuals’ health, cognition and mood (Waters & Bucks, 2011). More recently, low 
prevalence disorders such as bipolar and eating disorders were found to form sub-factors 
within the internalising dimension (Forbush & Watson, 2013). It has furthermore to be 
acknowledged that with only looking at threshold mental disorders, cases of sub-threshold 
depression and anxiety are overseen, which were found to be related to functional 
impairment and suicidality in those adolescents (Balázs et al., 2013). Effect sizes for 
predicting future psychopathology of the internalising and externalising dimensions yielded 
small to moderate effect sizes (Patalay et al., 2015).  
 
 
Figure 1.2. Path diagram of correlations of best-fitting DSM disorders with internalising and 
externalising dimensions (Krueger & Markon, 2006). 
 
 
A so-called bifactor or general-specific model was shown to represent 
psychopathology better than categorical approaches (Brodbeck, Abbott, Goodyer, & 
Croudace, 2011), and better than internalising and externalising dimensions, predicting 
future psychopathology with large effect sizes and significantly predicting young people’s 
functioning (e.g. academic attainment) (Patalay et al., 2015). The bifactor model proposes a 
general distress factor underlying depression and anxiety symptoms accounting for their 
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commonality and being a strong non-specific predictor for future anxiety and affective 
disorders, and further domain-specific factors accounting for the remaining variance. Unique 
information above the general distress component was revealed for the independent factors 
hopelessness-suicidal ideation, and generalised worrying in a study including 14-year old 
adolescents. These specific factors distinguished individual features of DSM disorders and 
also predicted future clinical diagnoses at age 17 (Brodbeck et al., 2014).  A recent cross-
sectional study which looked at a cohort of 13 and 18 years olds, supported the bifactor 
model, by demonstrating that depressive, anxiety and psychotic symptoms were best 
represented with a unitary common mental distress factor, on which psychotic symptoms 
constituted the more severe end of psychopathology (Stochl et al., 2015). Sleep disturbance 
may likely be associated with this common mental distress factor, as it either often 
constitutes a diagnosable symptom as seen in MD and GAD (American Psychiatric 
Association, 2000), or sleep disturbance frequently accompanies psychiatric disorders and 
likely affects their course, e.g. in schizophrenia and alcohol disorder (Krystal, Thakur, & 
Roth, 2008). 
A further factor to consider for the extent of expression of depressive, anxiety and 
psychotic symptoms, are risk factors. The level of vulnerability for psychopathology varies 
according to the existence and interplay of two groups of risk processes – distal and 
proximal vulnerabilities. Distal vulnerabilities include genetic risk factors and childhood 
adversities (maltreatment, life events etc.) that influence prodromal dimensions of 
psychopathology in terms of mood, feelings and behaviour. Proximal vulnerabilities emerge 
later in time during adolescence and influence individuals’ stress response, including 
variations in hormonal levels, such as of cortisol and dehydroepiandrosterone, the extent of 
cognitive control over one’s emotions as well as the presence of psychiatric disorders 
(Goodyer, Croudace, Dunn, Herbert, & Jones, 2010). 
 
CHAPTER ONE: LITERATURE REVIEW                        
	  
	  31	  
1.3.4 Nomothetic and idiographic parameters of mental states 
 Wigman et al. (2013) suggested that mental disorders can be cut down to sets of 
symptoms that are linked through causal relations. A system that combines nomothetic and 
idiographic parameters of mental states, hypothesises that the strength and variability which 
connects these mental states, varies across different stages of psychopathology, that is, 
links between those mental states become stronger and more divergent over the course of 
time. Psychiatric diagnosis can be promoted by coupling a group-based classification (= 
nomothetic component, e.g. diagnostic categories) across early stages, and with progression 
of stages, by an individual-specific psychopathological profile (= idiographic component) 
(Wigman et al., 2013). This model assumes that whereas earlier stages demonstrate greater 
similarity in clinical expression, expression of these mental states increasingly varies across 
individuals in later stages.  
When considering the heterogeneity of diagnostic classifications (see Section 1.3.1, 
e.g. with regards to symptom expression, need for clinical care, course of the illness, risk 
factors, response to treatment, and environmental context of an individual), it appears 
implausible that these labels can provide sufficient clinical utility (van Os, Delespaul, 
Wigman, Myin-Germeys, & Wichers, 2013). Contextual precision diagnosis is an idiographic 
means that can be used across all stages of psychopathology that facilitates a precise 
indexing of treatment needs and monitoring of treatment response. Momentary assessment 
technologies, such Experience Sampling Method, capture the dimensional variation of 
mental states and their interaction with each other and environmental variation, with the 
result of a contextual and precise diagnosis. These novel methods are considered to be an 
important addition to ordinary diagnostic classification in psychiatry (van Os et al., 2013). 
 Wigman et al. (2012) proposed (similarly to the theoretical assumptions of the 
bifactor model) that mental health symptoms are considered to fluctuate as a function of an 
underlying latent construct (that is, in the sense of a general mental health factor that 
underlies depressive, psychotic and anxiety symptoms) and that dimensions of 
psychopathological symptoms reciprocally affect each other over the course of time and 
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share risk factors. In this model, psychotic symptoms are included in addition to depression 
and anxiety symptoms. It has been suggested that some of the individuals at UHR for 
psychosis, in fact, present with depression or anxiety disorders which are complicated by 
sub-clinical psychotic symptoms (Wigman et al., 2012). This is supported by the finding that 
antidepressant treatment was highly effective for part of a UHR group (Cornblatt, Lencz, & 
Obuchowski, 2002). Likewise, neuroleptics have proven to be effective in treating anxiety 
and affective disorders, giving evidence that lack of specificity also appears in daily clinical 
practice (Weiser, van Os, & Davidson, 2005). 
 
1.3.5 Issues associated with novel approaches 
Youth mental health is a fairly new discipline (McGorry et al., 2014), and combining 
dimensional and categorical approaches (McGorry, 2013) would add to understanding the 
complexity of the psychopathology of mental disorders. However, before implementing new 
models of youth mental health in order to facilitate early intervention, evidence for their 
validity is needed (McGorry et al., 2014); giving evidence for better health outcomes and 
economical benefits with this proposed mental health reform is difficult to achieve, given the 
long-term nature of validating mental health outcomes. Yet, the implementation of novel 
youth mental health models which have evolved in the past 10 years, is encouraged by 
evidence-based staging and early intervention in psychosis (McGorry et al., 2014). 
Hickie et al. (2013) applied a clinical staging model to a cohort of young help-seeking 
people with depressive, anxiety, and psychotic symptoms and impairment in role function. 
Even though reliable clinical stage ratings were derived from patient records (Hickie et al., 
2013), staging was implemented without explicit landmarks and cut-offs for the employed 
psychometric measures. Clinical staging models overlap in their essence, however, stages 
are often slightly differently defined. E.g. Hickie et al. (2013) and McGorry et al. (2006) used 
impairment in functioning as criterion for stage definition, whereas others do not include 
functioning as criterion, but rather solely define it with clinical symptomatology (Purcell et al., 
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2015). These inconsistencies, together with a variety of other proposed dimensional 
approaches to mental ill health, complicate the application and integration of these novel 
ideas into clinical practice, and the translation into classification systems such as the DSM 
and ICD.  
 
1.4 Improvement of prediction of clinical outcome 
Various research groups have spent the last two decades aiming to identify individuals 
at heightened risk for developing a psychotic disorder and to provide rationales for early 
intervention to prevent transition. Amongst those are the Australian group of the Personal 
Assessment and Crisis Evaluation (PACE) clinic, the European Prediction of Psychosis 
Study and the North American Prodrome Longitudinal Study group. The disability that is 
accompanied by psychotic illness develops long before its onset - that is why staged 
treatment was considered to be effective during the prodromal phase of psychosis by 
ameliorating, delaying or possibly even preventing frank disorder (McGorry et al., 2009). 
Despite the UHR state being a valid construct and having proven to be consistently 
associated with an increased risk of transitioning to psychosis (Fusar-Poli et al., 2012), the 
prospective identification of this prodromal phase is challenged by the non-specific nature of 
symptoms occurring (Yung, Phillips, & McGorry, 2004). There is a considerable overlap in 
psychiatric symptoms preceding the onset of schizophrenia and psychopathological 
experiences in the general population (Koutsouleris et al., 2009), as well as symptoms 
preceding the onset of other mental illnesses, e.g. depression or anxiety disorders (Lin et al., 
2013). Single prodromal symptoms are only to a limited extent useful as diagnostic markers 
for predicting outcomes on the individual level (Koutsouleris et al., 2009).  
Section 1.4.1 describes how predictive accuracy of the UHR state for psychosis (as the 
best worked example of clinical staging in psychiatry) can be improved as the first step. The 
second step is to refine treatment by selecting treatments relevant to stage (Section 1.4.2) in 
psychosis and other psychiatric disorders. Section 1.4.3 briefly refers to the importance of 
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improving functional (and not only clinical) outcome, and encompasses the relevance of 
monitoring non-psychotic outcomes in individuals at UHR for psychosis. 
 
1.4.1 Improvement of accuracy for the prediction of transition from UHR to FEP 
Various attempts have been undertaken to improve the predictive accuracy of the 
UHR state. For example, a family history of schizophrenia together with functional decline, 
high levels of unusual thought content and paranoia, social impairment and substance 
abuse were found to uniquely contribute to the prediction of psychosis in at-risk individuals 
with positive predictive powers ranging from 43-52% as compared standard criteria (Cannon 
et al., 2008). High levels of negative symptoms, such as emotional and cognitive 
disturbances and low energy, predicted psychosis better than sub-threshold positive 
symptoms; whereas negative symptoms predicted transition with a an estimated hazard ratio 
of 1.83, was the estimated hazard ratio for positive symptoms only 1.28 (Yung et al., 2005). 
Machine learning algorithms, such as multivariate neuroanatomical pattern recognition 
(including structural magnetic resonance imaging (MRI) data, looking at volumetric changes 
over time in order to predict transition) further facilitated early detection and disease 
prediction of the UHR state in psychosis on the individual level: support-vector regression 
revealed reliable prediction of longitudinal brain changes between those individuals who 
transitioned and those who did not with a normalised root mean square deviation of 26% 
(Koutsouleris et al., 2009). 
 
1.4.2 Staged treatment 
More than half of UHR individuals will not transition to psychosis in the medium term 
considering estimates of transition rates of 36% within 3 years (see Section 1.2.2). However, 
clinical interventions during the UHR state do not have the sole purpose to prevent or delay 
transition, but also to manage and improve actual symptom presentation, which is often 
more a concern from the patient’s perspective than the actual risk of transition (Fusar-Poli et 
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al., 2012). McGorry et al. proposed to aim for phase-specific treatment: This means refining 
treatment by employing a sequential approach, with safer treatments in the early stages of 
mental illness (e.g. during the UHR state) according to the clinical staging model, and more 
intense treatment with non-improvement. One example of an early and safe treatment are 
omega-3 fatty acids which were found to be effective in UHR individuals in reducing positive 
and negative psychotic symptoms and improving functioning. However, those were not 
found to be effective in chronic schizophrenia. Apart from neuroleptics, antidepressants and 
cognitive(-behavioural) therapy have been found to be effective in reducing transitions, and 
generally reducing psychiatric symptoms over the follow-up period. The choice of treatment 
underlies risk-benefit considerations depending on the individual’s clinical stage of illness 
(McGorry et al., 2006; McGorry et al., 2009).  
Longitudinal studies show that adolescent sub-syndromal depression increases the 
risk of transition to threshold depressive disorder, and that depression during adolescence 
predicts anxiety, substance use, and bipolar disorder, as well as suicidal behaviour, 
unemployment and general health problems (Thapar et al., 2012). Insomnia can be seen as 
a further independent risk factor: Non-depressed individuals with insomnia were found to be 
at two-fold risk for developing depression as compared to individuals with healthy sleep 
patterns (Baglioni et al., 2011). Early outreach and intervention is therefore not only 
important in UHR individuals but also in other psychiatric disorders: If depressive episodes 
can be detected and treated before such subsequent secondary adverse consequences 
emerge, further episodes could be prevented (Kessler et al., 2001). Furthermore, if risk 
factors for substance abuse can be reliably identified (see Section 1.2.5), a risk-focused 
approach can be employed to prevent substance use problems in adolescents and young 
adults (Hawkins et al., 1992). Similar effects can be found in eating and anxiety disorders: 
Early recognition of disordered eating can prevent transition to frank eating disorder (Rome 
et al., 2003), and early intervention in anxiety disorders in children and youths has led to 
maintenance of outcome improvement and reduced substance involvement or other 
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associated problems years after therapy (Kendall, Safford, Flannery-Schroeder, & Webb, 
2004). 
 
1.4.3 Prediction of nonpsychotic disorders and association with functional outcome 
It is further crucial to determine whether UHR criteria not only detect people at risk for 
developing psychosis but also for non-psychotic disorders (Fusar-Poli et al., 2013): 
Psychotic experiences were commonly found to be associated with other psychopathology, 
such as depressive and anxiety disorders (Lin et al., 2015). Addington et al. (2011) 
investigated clinical and functional outcome of so-called false-positives (or non-transitioning 
individuals), and revealed that 50% of this non-transition sub-group no longer displayed any 
(sub-threshold) psychotic symptoms after 2 ½ years of follow-up. Even though this group 
significantly improved in functioning, functioning was still lower than in a non-psychiatric 
control group, indicating that the UHR state is associated with persistent disability, at least in 
the medium term. Initially, at baseline, 53% of UHR individuals who did not transition had 
comorbid anxiety, 35% depression, 1% mania, and 11% substance use disorder. These 
numbers dropped after 2 years to 32% anxiety, 14% depression, 1% mania, and 4% 
substance abuse disorders. With approximately 35% of the sample developing a psychotic 
illness (Addington et al., 2011), it can be concluded that the UHR state predicts considerable 
psychopathology in about two thirds of the sample in the medium term. The finding of about 
two thirds of UHR individuals presenting with some sort of mental disorder was replicated by 
Lin et al. (2015). Within a follow-up period of up to 14 years, a very high percentage of these 
two thirds presented not only with one, but rather at least another psychiatric disorder. 
Therefore, UHR criteria may also represent a useful system for the identification of young 
people going to develop nonpsychotic disorders (Lin et al., 2015). 
Scott et al. (2014) looked at a large sample of young people with affective disorders 
who were seeking help at clinical services for the first time. Individuals presented with at 
least one comorbid disorder in half, and with polysubstance use in one third of the cases. 
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Comorbid anxiety and daily cannabis and/or nicotine use were significantly associated with 
impaired functioning. This association of comorbidity and substance use with disability 
(which has been observed in a similar pattern in older adult samples) indicates that more 
outcome measures should focus on functional instead of symptom-specific measures (Scott 
et al., 2014). 
 
1.5 Structure of the thesis 
After generally describing the sample, recruitment, and interview and self-report 
measures in Chapter 2 (General Methodology), four empirical chapters are introduced. Each 
of those chapters is divided into the sections introduction, methods, results, and discussion. 
Chapter 3 only encompasses individuals presenting at clinical services with early mental 
health problems, whereas chapters 4-6 compare a subset of this clinical sample with a group 
of HC. Only individuals with either a family history of mental disorders and/or whose mental 
problems subjectively did not improve after 6 weeks, were considered for this sub-group, in 
order to enrich the sample in terms of likelihood of transitioning from sub-threshold to 
threshold disorders, according to the proposed staging model.  
Chapter 3 is a clinical chapter, which describes associations of depressive, psychotic 
and anxiety symptoms, and social and role functioning from baseline assessment until 6 
months after. Associations of symptom sets are examined on a continuum, respectively, but 
also by categorising into individuals who are at UHR for psychosis. The role of social and 
occupational functioning is critically discussed for this categorisation, as well as an outcome 
measure. 
Chapter 4 looks at longer-term stress levels associated with early mental health 
problems. Stress levels are objectively investigated by means of hair cortisol analyses, as 
well as subjectively via self-report. These measures are chosen to evaluate whether distress 
is present in the early stages of mental health problems and how cortisol is associated with 
clinical symptoms and functioning.  
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Chapter 5 illustrates functional neuroimaging findings during a working memory task. 
Individuals with mental health problems are compared with HC concerning task performance 
and differences in brain activation. Clinical participants with high and low symptom and 
functioning scores are furthermore compared with the respectively other group, and HC, and 
cortisol levels (as reported in Chapter 4) are included in analyses of covariance (ANCOVA). 
Chapter 6 comprises another fMRI study, similar to study 5, however, instead of 
including a task, brain activation is observed during rest. Independent component analyses 
(ICA) are employed, and independent components are estimated using a single group ICA, 
and dual regression is used to create individual spatial maps of networks, which are 
compared between groups using permutation tests. 
Chapter 7 summarises main findings and discusses these clinical and neurobiological 
correlates, aiming to integrate them into the early stages of a clinical staging model. 
Implications for clinical practice and future research are reviewed, followed by a conclusion. 
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CHAPTER TWO 
GENERAL METHODOLOGY 
 
This chapter briefly describes the employed research design (Section 2.1), followed 
by a description of participants of the clinical and control group (Section 2.2). The  
procedure underlying this thesis will be explained (Section 2.3), as well as a detailed  
description of  employed measures be given, which are relevant for the majority of empirical 
chapters (Section 2.4). Lastly, it is highlighted how the classification into UHR for psychosis 
and psychotic-like experiences (PLE) is conducted (Section 2.5). 
	  
2.1 Research design 
This thesis used data collected from a cohort study of help-seeking youths with early 
mental health problems. These youths were assessed via interview and self-report at 
baseline, after 3, and 6 months. As outlined in Section 1.5, only those individuals were 
considered for the neurobiological subgroup analyses in Chapters 4-6, who either had a first-
degree family history of mental disorders and/or whose mental problems did not improve 
subjectively 6 weeks after the baseline assessment.  
Neurobiological assessments were arranged upon MRI scanner and individual 
availability, and considering scanning safety issues (e.g. allowing for an appropriate gap 
between acquisition of new tattoos, piercings, and scan), ranging from 0-199 days after the 
clinical baseline assessment. A timeline of the research design is illustrated in Figure 2.1. 
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Figure 2.1. Timeline of research design. 
 
2.2 Participants 
73 clinical participants who were experiencing psychological distress participated in the 
main study. Clinical participants were recruited from the South Birmingham area via services 
specialised in (youth) mental health (Youthspace & Birmingham Healthy Minds) and via local 
advertisements. Inclusion criteria were the ages between 16-25 years, and help-seeking for 
mental health problems at entry to the research programme, however, none of the clinical 
participants had a diagnosed first episode of psychosis or primarily presented with psychotic 
symptoms. Exclusion criteria were a lack of sufficient English and cognitive ability to provide 
informed consent and adequately complete the assessments.  
Youthspace is a youth-focused secondary mental health service that provides support 
for 16-25 years olds with mental health problems. The service sees young people with a 
variety of diagnoses and has no specific exclusion criteria. Youthspace offers a variety of 
treatments and case management provided by a multi-disciplinary team. Birmingham 
Healthy Minds is a primary care psychological therapies service, offering brief psychological 
talking therapy for individuals aged 16 and above who present with depressive and anxiety 
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symptoms. Their exclusion criteria are bipolar disorder, psychosis, suicidality or in need of 
long-term care. Both services operated primarily though GP referral at the time of study 
recruitment. 
 
2.3 Procedure 
The study was approved by the local ethics committee and baseline recruitment 
commenced in August 2012, and ended in August 2013. Individuals were followed up after 3 
and 6 months. Clinical participants were either approached by researchers or clinical staff at 
the early intervention services, and pre-consent to be contacted was collected, or clinical 
participants responded to local advertisements at these facilities and contacted the research 
team themselves.  Figure 2.2 illustrates the recruitment and assessment of clinical 
participants via a STROBE diagram (according to recommendations from von Elm et al., 
2007) - that is, how the clinical sample was achieved. This diagram gives an idea of (1) how 
many individuals were examined for eligibility, (2) were confirmed eligible, (3) were included 
in the study at baseline and how many have completed the follow-up assessments at (4a) 3 
and (4b) 6 months. The starting point of a STROBE diagram would usually estimate - in this 
case, how many clinical participants were potentially eligible. However, despite attempts to 
track this number with the clinical services, no estimation could be attained to date. 
Furthermore, 7 individuals were recruited via poster advertisements. Recruitment via posters 
makes it further difficult to make an estimation for those eligible, since services where 
posters were presented, shared facilities (e.g. with GP practices), and individuals who were 
not primarily attending meetings with Youthspace and Birmingham Healthy Minds, may have 
been eligible to partake in the study. This means a large pool of individuals may have 
potentially been eligible due to their help-seeking behavior for mental health problems.  
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Figure 2.2 STROBE diagram (according to recommendations from von Elm et al., 2007). 
The nature of the study was discussed via telephone and if individuals were interested, 
assessments were conducted at the University of Birmingham or participants’ homes (or in 
rare cases for follow-up assessments conducted via telephone). For clinical participants 
aged 18 and above, informed consent was collected from them, and for clinical participants 
aged 16-17 years, additional parental consent was acquired. Assessments comprised of an 
interview and self-report and were conducted on a one-to-one basis by a member of the 
research team. All members of the research team were trained in the use of each measure. 
Each assessment generally lasted 1-2 hours and participants were reimbursed with £20. 
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2.4 Measures 
Demographic information covered participants’ age, gender, ethnicity, occupation and 
highest qualification, relationship status and whether having children. Individuals were 
assessed for psychotic, depressive, anxiety symptoms and social and role functioning via 
interview and self-report. These measures are described in the following sections, as they 
are relevant for most empirical chapters. Information on other measures (e.g. for the brain 
imaging and hair cortisol analyses, or chapter-specific interview and self-report data) is 
described in the respective empirical chapters. 
 
 2.4.1 Comprehensive Assessment of At-Risk Mental States (CAARMS) 
The CAARMS is a semi-structured interview, designed to determine if individuals 
meet criteria for being at UHR for psychosis and it includes a threshold beyond which 
psychosis is assumed. It is a dimensional instrument to quantify severity (0 = absent/never, 
6 = psychotic and severe) and frequency of psychotic symptoms (0 = absent/never, 6 = 
continuous) on a 7-point scale (Yung et al., 2005). The positive symptoms dimension of the 
CAARMS was administered, comprising of the four sub-scales: Unusual Thought Content 
(e.g. delusional mood, overvalued ideas), Non-Bizarre Ideas (e.g. suspiciousness, 
grandiosity), Perceptual Abnormalities (e.g. distortions, illusions, hallucinations), 
Disorganised Speech (e.g. difficulties with speech and communication).  A combination of 
intensity and frequency ratings allows for the determination if individuals meet criteria for 
being at UHR for onset of a FEP or to indicate the development of a FEP. A score of at least 
3 for both intensity and frequency on at least one sub-scale indicates UHR status, if coupled 
with a decline in functioning or chronic low functioning. Criteria for psychosis are met if 
clinical participants score a 6 on intensity and at least a 4 for frequency on non-bizarre ideas, 
unusual thought content and disorganised speech or a 5-6 on intensity and a 4-6 on 
frequency for perceptual abnormalities. Good to excellent agreement for intra-class 
correlation coefficients were reported for CAARMS sub-scales with an overall score for inter-
rater reliability of 0.85. CAARMS criteria displayed good concurrent (e.g. with the Brief 
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Psychotic Rating Scale) and predictive validity (e.g. higher risk of transition to psychosis in 
individuals with an at-risk mental state) (Yung et al., 2005). For dimensional subsequent 
analyses, an index based on the sum of intensities and frequencies for the four sub-scales 
was calculated. 
 
2.4.2 Social and Occupational Functioning Assessment Scale (SOFAS)  
The SOFAS has been derived from the Global Assessment Scale (Endicott, Spitzer, 
Fleiss, & Cohen, 1976), giving a rating of  overall psychological functioning on a scale from 0 
to 100 (Goldman, Skodol, & Lave, 1992). The SOFAS is usually used to rate an individual’s 
current functioning, however highest and lowest functioning ratings for the past 12 months 
have been employed additionally for the purpose of this thesis to determine a drop in 
functioning. Social and occupational functioning is considered on a continuum from excellent 
functioning to severely impaired functioning, however, this scale was only used for the 
purpose of determining UHR status. 
 
2.4.3 Quick Inventory of Depressive Symptoms (QIDS) 
The QIDS is a clinician-rated 16-item, semi-structured clinical interview to gauge 
severity of depressive symptoms over the past 7 days. Responses to the individual items are 
converted into the 9 DSM-IV symptom criterion domains (American Psychiatric Association, 
2000), e.g. depressed mood, diminished interest, concentration problems. Each symptom 
item is scored on a 0 - 3 scale with total scores ranging from 0 – 27 allowing for a continuous 
approach to evaluate depressive symptomatology (Rush et al., 2003). QIDS scores can be 
classified into none (0-5), mild (6-10), moderate (11-15), severe (16-20) and very severe (21-
27) depressive symptoms. A meta-analysis demonstrated acceptable psychometric 
properties with internal consistencies ranging from 0.65 – 0.87 (Chronbach’s α) and 
concurrent validity, e.g. with the Hamilton Rating Scale for Depression, ranging from 0.72 - 
0.79 (Reilly, MacGillivray, Reid, & Cameron, 2015). 
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2.4.4  Kessler Psychological Distress Scale (K-10) 
The K-10 is a 10-item questionnaire, assessing general psychological distress by 
asking about depressive and anxiety symptoms in the past 30 days. Items prompt individuals 
to answer about how often they felt nervous, anxious, hopeless etc. on a 5-point scale 
ranging from “none of the time“ to “all of the time“, with scores ranging from 10 to 50. A total 
score ranging from 10-19 indicates the individual is likely to be well, 20-24, likely to have a 
mild mental disorder, 25-29, likely to have a moderate mental disorder, and 30-50, to be 
likely to have a severe mental disorder (Kessler et al., 2002). The K-10 is a moderately 
reliable instrument (kappa (ϰ) ranging from 0.42 - 0.74) (Dal Grande, Taylor, & Wilson, 2002) 
and demonstrates good concurrent validity with other mental health instruments such as the 
General Health Questionnaire and current diagnosis of anxiety and affective disorders 
(Andrews & Slade, 2001). 
 
2.4.5 Overall Anxiety Severity and Impairment Scale (OASIS) 
The OASIS is a brief questionnaire to assess severity and impairment across multiple 
anxiety disorders and sub-threshold anxiety. Scoring of this continuous 5-item measure 
follows ratings from 0 (none), 1 (mild), 2 (moderate), 3 (severe) to 4 (extreme), capturing 
frequency and intensity of anxiety, avoidance behaviour and interference of anxiety with 
everyday life and relationships, adding up to total scores ranging from 0 – 20, with a total 
score of 8 or above indicating an anxiety diagnosis (Campbell-Sills et al., 2009). The OASIS 
showed convergence with major anxiety measures (e.g. for social, post-traumatic stress, and 
generalised anxiety), a Chronbach’s α of 0.84 for the five items (Campbell-Sills et al., 2009), 
and one-month re-test reliability of 0.82 (Norman, Hami Cissell, Means-Christensen, & Stein, 
2006). 
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2.4.6 Global Functioning: Social and Role 
The Global Functioning: Social (Auther, Smith, & Cornblatt, 2006) and Role (Niendam, 
Bearden, Johnson, & Cannon, 2006) scale provides clinician-rated, separate overall scores 
on scales from 1 – 10 for current, highest and lowest functioning in the past 12 months, with 
10 indicating a superior functioning and 1 an extreme dysfunction. The Social scale 
evaluates peer relationships and conflict, age-appropriate intimate relationships and 
interaction with family members. The Role scale assesses performance in either school or 
other educational settings, work or as a homemaker. Inter-rater reliability for social and role 
functioning ranged from 0.85 – 0.95, and the social functioning scale was significantly 
correlated with social contacts (r = 0.70) and role functioning with work and school 
functioning (r = 0.57), demonstrating construct validity (Cornblatt et al., 2007). 
 
2.5 Classification of UHR for psychosis, PLE and FEP 
UHR criteria were defined using the CAARMS (Yung et al., 2005), comprising APS and 
BLIPS. For the APS criterion, symptoms must be present for at least once a week, with a 
frequency of at least several times per week. BLIPS refer to psychotic symptoms at the 
severity and frequency of a psychotic episode but spontaneously resolve within 7 days (see 
Section 1.2.2). UHR status was only given if individuals also displayed a 30% drop in 
functioning in the past 12 months or persistent low functioning (score ~ 50), as gauged by 
the SOFAS scale (Goldman et al., 1992). Individuals were referred to as PLE if they 
experienced APS or BLIPS (that is, UHR individuals) without a drop in functioning or chronic 
low functioning. A FEP was defined as at least one fully positive symptom several times a 
week for more than one week, that is, the first time when an individual experiences threshold 
psychotic symptoms. 
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CHAPTER THREE 
THE ASSOCIATION BETWEEN POSITIVE PSYCHOTIC SYMPTOMS 
WITH DEPRESSIVE AND ANXIETY SYMPTOMS AND FUNCTIONING 
 
Attenuated psychotic, depressive and anxiety symptoms constitute common features of 
emerging mental disorders in young people. These symptoms will subside either 
spontaneously or via early intervention for the majority of clinical participants. For a subset of 
clinical participants, however, symptomatology will progress, exerting a major impact on 
individuals’ well-being, social and role functioning. 73 clinical participants presenting with 
mental health issues (Mage ± SD = 20.6 ± 2.6, range 16-26 years, 51 females) were 
assessed for psychotic, depressive, anxiety symptoms and social and role functioning via 
interview and self-report. These individuals were followed up with the same assessment 
battery after 3 (n = 59) and 6 months (n = 55). Clinical measures and functioning were 
longitudinally investigated, the association between symptoms determined, as well as 
predictors for future symptomatology and functioning identified. Clinical participants were 
classified into being at UHR for psychosis, experiencing psychotic(-like) symptoms, and no 
significant psychotic symptoms. No differences were found between UHR clinical 
participants and those with only psychotic-like experiences and no significant psychotic 
symptoms for the severity of depressive or anxiety symptoms, or functioning. Psychotic 
symptoms at baseline partly predicted social and role functioning and psychotic and 
depressive symptoms at 6 months. Overall, the whole population improved after 6 months. 
Psychotic-(like) symptoms in help-seeking young people appear to be associated with more 
severe depressive symptoms and poorer functioning, independent of UHR status, however, 
a robust predictive effect of psychotic symptoms in a general help-seeking population could 
not be confirmed. Neurodevelopmental trajectories of these associations with illness 
progression and transition to psychosis and other psychiatric disorders require wider 
longitudinal exploration. 
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3.1 Introduction 
The major health problem in young people is mental health. While many individuals in 
this age group have transient illness, some persist into adulthood and can severely impair 
psychosocial functioning. Determining who will have these chronic problems can be difficult, 
especially in the early stages of disorder. Adolescents and young adults often present with 
unspecific symptoms and syndromes (Lin et al., 2013) such as depressive and anxiety 
symptoms, as well as PLE in these early stages. 
PLE (or subclinical psychotic symptoms) are a milder form of clinical psychotic 
symptoms, which present with a lower intensity, frequency and level of associated distress 
(Yung et al., 2007). Nonetheless, PLE have been found to be associated with adverse 
outcomes in individuals at UHR for developing psychosis (Yung et al., 2003) and are also 
prevalent in other, non-psychotic psychiatric illnesses (Wigman et al., 2012). In UHR 
individuals PLE are associated with onset of psychotic disorders (Yung et al., 2003), with low 
psychosocial functioning and with the experience of comorbid psychiatric disorders such as 
MD (Rosen, Miller, D'Andrea, McGlashan, & Woods, 2006; Yung et al., 2007). With PLEs 
fluctuating against a background of non-psychotic psychiatric symptoms, this confuses the 
distinction between UHR and non-UHR patient populations (Yung et al., 2007). Situational 
anxiety, nervous tension and depression are, apart from actual PLE (such as hallucinations), 
additional risk factors for developing a psychotic disorder in genetic high-risk individuals 
(Owens, Miller, Lawrie, & Johnstone, 2005).  
PLE are not only associated with psychotic disorders, but are also prevalent in 
depressive and anxiety disorders (Varghese et al., 2011). It has been hypothesised that PLE 
are not only a specific risk factor for developing psychosis, but rather a general, underlying 
predisposition to a range of mental disorders such as dysthymia, bipolar and obsessive-
compulsive disorders, and social phobia (Rössler et al., 2011). In fact, they were found to be 
a risk factor for severe psychopathology, characterised by high comorbidity and suicidal 
behaviour (Kelleher et al., 2012b; Kelleher et al., 2012c). The joint presence of PLE in 
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depressive and anxiety disorders is common and therefore aetiologically relevant, as these 
mental states may reciprocally impact on each other (Wigman et al., 2012). As emotional 
problems often occur prior to or accompany psychosis, it has been inferred that an emotional 
involvement contributes to the development of positive psychotic symptoms (Freeman & 
Garety, 2003). However, since empirical evidence does not support a sharp differentiation 
between psychotic and affective disorders, it has been concluded that they rather share 
common maintenance processes (Freeman & Garety, 2003). Further support for this notion 
of broad endo-phenotypes arises from the fact that many risk factors, such as genetic 
disposition, trauma, and life events, are shared between psychiatric illnesses (Weiser et al., 
2005). 57% of 11-13 and 79% of 13-16 year olds who experienced psychotic symptoms had 
a lifetime diagnosis of at least one non-psychotic psychiatric disorder, indicating an 
increasing predictive power of general psychopathology with increasing age from early to 
mid-adolescence (Kelleher et al., 2012b). 
A meta-analysis of population-based studies found that some sort of psychotic 
symptoms occur in about 7.5% of 13 to 18 year olds, with a general decline from childhood 
to adolescence (Kelleher et al., 2012a). Psychotic symptoms during childhood predict 
increased rates of psychotic symptoms in adulthood (Poulton et al., 2000; Welham et al., 
2009), and persisting psychotic symptoms were found to be associated with a greater risk for 
transition to a FEP in a dose-response fashion (Dominguez, Wichers, Lieb, Wittchen, & van 
Os, 2011). A psychosis-proneness persistence model suggests a possible synergism 
between environmental factors (such as trauma, cannabis use, and urbanicity) and psychotic 
symptoms, in predicting the subgroup that will present with persistent psychotic symptoms 
(Cougnard et al., 2007) and eventually transition to threshold disorder. Given that these risk 
factors occur only in a subset of individuals with psychotic symptoms, this may explain why 
most developmental expression of psychotic symptoms remains transient.  
The prediction of psychosis still comprises substantial uncertainty despite diverse 
attempts to increase sensitivity and specificity (Ruhrmann, Schultze-Lutter, & Klosterkotter, 
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2010). The criterion of 30% decline in functioning or chronic low functioning has been added 
to the UHR criteria that are using the CAARMS (Yung et al., 2008). However, the European 
Prediction of Psychosis study identified a substantial loss of sensitivity in transitions, when 
this drop in functioning was incorporated. Except for the purpose of an enrichment strategy 
that theoretically predicts transition, the inclusion of this drop in functioning may be too 
restrictive (S. Ruhrmann, personal communication, 11 June 2014). Therefore, in this study, 
both options - with and without drop in functioning were considered when looking at clinical 
and functional outcome.  
Recent studies for transition rates from UHR status to a FEP are estimated to be 22% 
within 12 months (Fusar-Poli, 2012) and 3-year persistence rates of psychotic symptoms in 
two general population samples were as high as 26-31% (Cougnard et al., 2007). Even 
though mental health symptoms (including psychotic symptoms) are transient for the 
majority of children and adolescents (Van Os, Linscott, Myin-Germeys, Delespaul, & 
Krabbendam, 2009), there is a need for specialist mental health services, for those whose 
problems do not resolve on their own (Wang, Sherrill, & Vitiello, 2007). Early intervention in 
psychosis was found to yield better clinical and functional outcomes (Killackey & Yung, 
2007) and significantly reduced incidence rates in at-risk adolescents (Clarke et al., 1995), 
and significantly reduced symptom scores in adolescents with depressive disorders (March 
et al., 2004). Further, interventions in depressed adolescents, such as interpersonal 
psychotherapy, were found to improve social-interpersonal functioning (Mufson, Weissman, 
Moreau, & Garfinkel, 1999).  
A recent study by Hickie et al. (2013) employed a clinical staging model of mental 
disorders to help-seeking young people, with the majority being assigned to the early stages 
of mental health problems, which has been designed in a similar fashion to the current study. 
Even though individuals may not meet specific criteria for frank disorders, the early phases 
of mental illnesses are often symptomatic and associated with functional impairment and 
disability. Participants in this study accessed specialised treatment, however, up to one third 
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of individuals progressed to more advanced stages, with the highest risk of transition being 
within the first 12 months after presentation (Hickie et al., 2013). 38% of this cohort were 
experiencing sub-threshold psychotic symptoms and a further 7% symptoms classified as 
frank psychotic. 22% were experiencing no, 32% mild, 28% moderate, 14% severe and 4% 
very severe depressive symptoms at baseline (Purcell et al., 2014). 
A neurodevelopmental model, e.g. of schizophrenia, proposes impaired academic and 
social functioning during adolescence as signs of a biological vulnerability to schizophrenia 
(Cornblatt et al., 2007; Cornblatt et al., 2003) and therefore targets of early intervention. On 
the other hand, more than half of the patients treated for schizophrenia in adolescence 
displayed educational, occupational and social dysfunction 10 years after their first episode 
(Lay, 2001), illustrating how psychotic symptoms impact on functioning, and vice versa.  This 
association between functioning and clinical symptoms has also been demonstrated in other 
mental health issues: High social functioning, in terms of belonging to a high-status crowd, 
positive qualities in friendships and presence of a dating relationship protected against 
feeling socially anxious, whereas peer victimisation and negative interactions in friendships 
predicted high social anxiety and depressive symptoms (La Greca & Harrison, 2005). 
Experiencing a depressive episode during adolescence predicted impaired psychosocial, 
interpersonal and occupational functioning in young adulthood (Lewinsohn, Rohde, Seeley, 
Klein, & Gotlib, 2003) and educational underachievement and unemployment later in 
adolescence and early adulthood (Fergusson & Woodward, 2002).  Patients with non-
psychotic psychiatric disorders but additional psychotic symptoms showed lower global 
functioning than those without psychotic symptoms, potentially moderated by poor coping 
strategies such as avoidance-oriented coping (Wigman et al., 2014), implicating an additive 
effect of specifically psychotic symptoms over depressive and anxiety symptoms. Overall, 
this gives evidence that social and role functioning and clinical symptoms are mutually 
impacting on each other. 
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Psychotic symptoms appear to be especially important, posing a specific risk factor for 
developing psychosis. This is further supported by UHR criteria significantly predicting the 
onset of psychotic disorders (Yung et al., 2008). However, psychotic symptoms are a risk 
factor for a range of other mental disorders as well (Rössler et al., 2011). Therefore, the aim 
of this study was to determine whether UHR and non-UHR patient populations actually differ 
concerning clinical measures, such as depressive and anxiety symptoms, and functioning, to 
ultimately infer how psychotic symptoms are related to other clinical outcomes. Secondly, 
the general course of (sub)clinical psychotic and depressive symptoms and functioning was 
monitored and the association between (sub)clinical psychotic, depressive and anxiety 
symptoms and functioning was longitudinally investigated. It was hypothesised that clinical 
measures and functioning would improve after six months due to the clinical care the clinical 
participants received, and the fact that psychotic symptoms are often found to be transitory 
(Van Os et al., 2009). Further, psychotic and depressive symptoms were anticipated to co-
occur and impact on each other (Wigman et al., 2012), and psychotic symptoms at baseline 
to predict psychotic symptoms and other clinical measures after 6 months, based on the 
finding that psychotic symptoms are not only a risk factor for developing psychosis but also 
other psychopathology (Kelleher et al., 2012c; Rössler et al., 2011). Finally, clinical 
symptoms were expected to be positively associated with each other, and negatively 
associated with functioning over time. 
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3.2 Methods 
3.2.1 Participants & procedure 
All 73 clinical participants who were help-seeking and experiencing psychological 
distress participated in this study. Recruitment, inclusion and exclusion criteria for clinical 
participants are described in Section 2.2 and the study procedure is described in Section 2.3 
in detail.  
 
3.2.2 Treatment interventions 
35 clinical participants were taking antidepressant medication and an additional five 
were prescribed other (valproic acid, anticonvulsant, and antipsychotic) medication for 
treatment of psychiatric conditions at baseline. One participant had reported a diagnosis of 
epilepsy, but did not receive anticonvulsant medication due to being seizure-free for years. 
No other participant reported a diagnosis of epilepsy. 42 clinical participants were receiving 
counselling or some sort of therapy (e.g. cognitive-behavioural or -analytic therapy) and 18 
were referred, attended triage meetings or were on the waiting list for therapy.  
 
3.2.3 Measures 
Demographic information (age, gender, ethnicity, occupation and highest 
qualification, relationship status and whether being a parent) and information on clinical and 
functioning measures was gathered via interview and self-report. These information included 
psychotic (CAARMS), depressive (QIDS), and anxiety (OASIS) symptoms, psychological 
distress (K-10), and functioning (Global functioning: Social and Role scale) as described in 
Section 2.4. Obtaining total scores of the employed measures and classification of UHR 
status followed the same procedure as described in Sections 2.4 and 2.5.  
In order to establish whether UHR clinical participants differ in clinical features, such 
as depressive and anxiety symptoms, and functioning from clinical participants who 
experience psychological distress but do not fulfill UHR criteria, the sample was classified in 
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clinical participants with UHR status (n = 16) and clinical participants without UHR status 
(“non-UHR clinical participants”, n = 53). 4 individuals met criteria for a psychotic episode at 
baseline assessment according to the CAARMS, and were submerged with UHR (n = 16+2) 
and non-UHR (n = 53+2) individuals. Individuals with subclinical psychotic symptoms but 
without a 30% drop in functioning/chronic low functioning were referred to as PLE. All 
constellations of an intensity and frequency of less than 3 were considered as no significant 
psychotic symptoms. 
 
3.2.4 Statistical Analysis 
Independent samples t-tests and analyses of variance (ANOVA) were used when 
conducting group comparisons of age and total scores of clinical measures, where 
parametric assumptions were met. Otherwise, Mann-Whitney U-tests and Kruskal-Wallis 
tests were conducted. For analysis of categorical data, such as gender, ethnicity, occupation 
and highest education, Χ
 
2 - tests were used to evaluate group differences. Paired t-tests and 
Wilcoxon Signed Ranks tests were further employed to longitudinally analyse clinical 
symptoms and functioning from baseline to 6 months and repeated measures ANOVA and 
Friedman tests from baseline to 3 and 6 months. One-way ANOVA were used to disentangle 
the influence of (sub)clinical psychotic symptoms on functioning. Multiple linear and 
hierarchical regressions were conducted to investigate which clinical symptoms potentially 
predict depressive and psychotic symptoms at 6 months, and whether psychotic, depressive, 
and anxiety symptoms at baseline predicted social and role functioning after 6 months, and 
whether functioning predicted clinical outcomes at 6 months. 
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3.3 Results 
3.3.1 Demographics and UHR vs non-UHR group comparison 
The total sample (n = 73, 51 females) had a Mage ± SD of 20.6 ± 2.6 years and was 
predominantly White-British. UHR individuals only differed from non-UHR1 clinical 
participants concerning their relationship status with more UHR clinical participants being in 
a relationship than non-UHR, and a better role functioning in non-UHR clinical participants 
than UHR. There were no further significant differences concerning demographics such as 
age, gender, ethnicity, occupation, highest level of education, or concerning depressive and 
anxiety symptoms, general distress or social functioning at baseline (see Table 3.1). 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  For the purpose of this analysis, of the non-UHR clinical participants (n=55), 15 individuals were 
categorised as individuals with PLE and 40 as no significant psychotic symptoms, as opposed to 
individuals classified as UHR (n=18).  	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Table 3.1 
Demographic information, clinical measures, and functioning scores for the total sample, and 
comparing UHR clinical participants with clinical participants who are not at UHR for 
psychosis at baseline 
 Total sample  
(n=73) 
UHR 
(n=18)  
Non-
UHR 
(n=55) 
Test statistics 
Demographics 
    Age (M±SD) in years 
   Gender (m/f) 
 
   Ethnicity 
      White1 
      Asian2 
      Black3 
      Mixed-race4 
 
20.6±2.6 
22/51 
 
 
61 
3 
3 
6 
 
20.9±3.0 
5/13 
 
 
16 
1 
0 
1 
 
20.5±2.5 
17/38 
 
 
45 
2 
3 
5 
 
 
t(71)=-0.52, p=0.60 
Χ
 
2 (1)=0.63, p=0.80 
 
 
 
 
Χ
 
2(3)=1.39, p=0.71 
 
   Occupation 
      University student5 
      College/A-Levels 
      Unemployed 
      Employed6 
      Homemaker 
 
   Highest qualification 
      University7 
      A-Levels8 
      GSCE9 
      No qualification 
 
   Relationship status 
      Single/relationship 
 
18 
22 
17 
12 
4 
 
 
6 
33 
28 
6 
 
 
44/29 
 
1 
5 
3 
7 
2 
 
 
1 
7 
9 
1 
 
 
6/12 
 
17 
17 
9 
10 
2 
 
 
5 
26 
19 
5 
 
 
38/17 
 
 
 
Χ
 
2(4)=7.46, p=0.11 
 
 
 
 
 
Χ
 
2(3)=1.47, p=0.69 
 
 
 
 
Χ
 
2 (1)=7.24, p=0.01** 
   Having children (yes/no) 9/63 3/15 6/48 Χ
 
2 (1)=0.38, p=0.54 
     
Clinical measures     
    QIDS score (M±SD) 
       Range 
10.9±4.1 
3-19 
 
10.4±3.8 
 
 
12.2±4.8 
 
 
t(71)=-1.57, p=0.12 
 
    K10 score (M±SD) 
       Range 
 
    OASIS (M±SD) 
        Range 
 
30.7±8.1 
10-50 
 
9.3±4.6 
0-20 
 
30.4±8.2 
 
 
8.9±5.5 
 
31.5±7.8 
 
 
9.6±4.5 
 
t(68)=-0.50, p=0.62 
 
 
t(67)=0.47, p=0.64 
 
Functioning     
    Social Functioning (Median) 
       Range 
7 
3-9 
6 7 
 
U=409.5, Z=-1.12, p=0.26 
 
     
    Role Functioning (Median) 
       Range 
6 
1-9 
3 
3 
7 
7 
U=329, Z=-2.15, p=0.03* 
 
Notes. UHR=ultra-high risk, M=mean, SD=standard deviation, m=male, f=female, 1 White-British & 
White-Other, 2 Asian-Pakistani, Asian-Bangladeshi & Other Asian, 3 Black-African, 4 Mixed-Race 
White-Black-Caribbean, 5 Undergraduate and postgraduate university students, 6 Working full or part-
time, 7 Bachelor or Master degree, 8 A-Levels, National Vocational Qualification (NVQ) Level 4, or 
equivalent, 9 General Certificate of Secondary Education (GCSE, year-10 equivalent) or NVQ level 1 
or 2, ** p < 0.01.                                                                                                                                                          
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Clinical participants who did not participate in the 6 months follow-up assessment (n 
= 18) did not differ significantly from the original baseline sample (n = 73) concerning 
demographics and clinical measures at baseline (see Table 3.2), indicating that drop-out 
rates did not influence the results presented in the following. 
Table 3.2 
Comparison of baseline demographic information and baseline clinical measures between 
baseline sample and those who were not followed up  
 Baseline 
(n=73) 
No follow-up 
(n=18) 
Test statistics p-value 
Demographics 
    Age (M±SD) in years 
   Gender (m/f) 
 
   Ethnicity 
      White1 
      Asian2 
      Black3 
      Mixed-race4 
 
20.6±2.6 
22/51 
 
 
61 
3 
3 
6 
 
20.1±2.5 
5/13 
 
 
13 
0 
1 
4 
 
 
t(89)=0.4 
Χ
 
2(1)=0.4 
 
 
 
  Χ
 
2(3)=3.61 
 
 
0.41 
0.84 
 
 
 
0.31 
 
   Occupation 
      University student5 
      College/A-Levels 
      Unemployed 
      Employed6 
      Homemaker 
 
   Highest qualification 
      University7 
      A-Levels8 
      GSCE9 
      No qualification 
 
   Relationship status 
      Single/relationship 
 
   Having children (yes/no) 
 
   Clinical measures    
      CAARMS total (Mscore±SD) 
      QIDS (Mscore±SD) 
      Social Functioning (Median) 
      Role functioning (Median) 
      OASIS (Mscore±SD) 
 
18 
22 
12 
17 
4 
 
 
6 
33 
28 
6 
 
 
44/29 
 
9/63 
 
 
13.7±8.3 
10.9±4.1 
7 
6 
9.3±4.6 
 
0 
8 
2 
6 
2 
 
 
1 
5 
8 
4 
 
 
8/10 
 
4/13 
 
 
13.8±6.6 
11.6±5.1 
6 
6 
9.5±5.9 
 
 
 
Χ
 
2(4)=6.87 
 
 
 
 
 
Χ
 
2(3)=3.9 
 
 
 
 
Χ
 
2(1)=0.13 
 
Χ
 
2(1)=1.34 
 
 
t(89)=0.08 
t(89)=0.61 
U=650.5, Z=-0.67 
U=608.5, Z=-0.49 
t(89)=0.16 
 
 
 
0.14 
 
 
 
 
 
0.27 
 
 
 
 
0.72 
 
0.25 
 
 
0.94 
0.54 
0.95 
0.62 
0.87 
      K-10 (Mscore±SD) 30.7±8.1 31.3±9.8 t(89)=2.5 0.8 
Notes. M=mean, SD=standard deviation, m=male, f=female, 1 White-British & White-Other, 2 Asian-
Pakistani, Asian-Bangladeshi & Other Asian, 3 Black-African, 4 Mixed-Race White-Black-Caribbean, 5 
Undergraduate and postgraduate university students, 6 Working full or part-time, 7 Bachelor or Master 
degree, 8 A-Levels, National Vocational Qualification (NVQ) Level 4, or equivalent, 9 General 
Certificate of Secondary Education (GCSE, year-10 equivalent) or NVQ level 1 or 2, 
CAARMS=Comprehensive Assessment of At-Risk Mental States, QIDS=Quick Inventory of 
Depressive Symptoms, OASIS=Overall Anxiety Severity and Impairment Scale, K-10=Kessler 
Psychological Distress Scale. 
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Depressive and anxiety symptoms, psychological distress and social and role 
functioning at baseline did not differ significantly between clinical participants with no 
significant psychotic symptoms, UHR clinical participants and individuals experiencing PLE2 
(see Table 3.3). 
 
Table 3.3 
Clinical measure scores for clinical participants with no significant symptoms, UHR clinical 
participants and clinical participants with PLE at baseline 
Measure No 
sympto
ms 
(n=40) 
PLE (n=15) UHR (n=18) Test statistics Effect size1 
η2 
QIDS score 
   M±SD 
 
K-10 score 
   M±SD 
   
 
10.3±3.5 
 
 
30.2±7.6 
 
10.7±4.6 
 
 
31.0±9.6 
 
10.9±4.6 
 
 
31.5±7.8 
 
 
F(2,70)=1.27, p=0.29 
 
 
F(2,67)=0.18, p=0.84 
 
0.035 
 
 
0.005 
OASIS 
   M±SD 
 
Social 
Functioning 
   Median 
 
Role 
Functioning 
   Median 
 
9.1±4.2 
 
 
7 
 
 
7 
 
10.1±5.3 
 
 
6 
 
 
6 
 
9.0±4.8 
 
 
6 
 
 
3 
 
 
F(2,70)=0.27, p=0.76 
 
 
Χ
 
2(2)=1.64, p=0.44 
 
 
Χ
 
2(2)=4.70, p=0.10 
 
0.008 
 
 
     0.023 
 
 
0.062 
Notes. UHR=ultra-high risk, PLE=psychotic-like experiences, QIDS=Quick Inventory of Depressive 
Symptoms, K-10=Kessler Psychological Distress Scale, M=mean, SD=standard deviation, 
OASIS=Overall Anxiety Severity and Impairment Scale.                                                                          
1 For practical reasons all effect sizes have been calculated assuming the data meets parametric 
assumptions.                                                                    
 
3.3.2 Development of (sub)clinical psychotic symptoms  
At baseline, 40 clinical participants (54.8%) presented with no significant psychotic 
symptoms (6 of those scoring 0 on all subscales), 13 experienced PLE (17.8%), whereas 
another 16 individuals were classified as UHR for psychosis (21.9%) and 4 clinical 
participants fulfilled criteria for a psychotic episode (5.5%). Table 3.4 illustrates the 
development of all four groups after 6 months: the majority of the sample remained without 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  Clinical participants with psychotic symptoms according to the CAARMS at baseline (n=4) were 
submerged with UHR clinical participants (n=16) and clinical participants with PLE (n=13) due to the 
small sample size, depending on whether clinical participants experienced a drop in 
functioning/chronic low functioning or not, resulting in 18 UHR clinical participants and 15 clinical 
participants with PLE.	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significant psychotic symptoms (30.1%), 13.7% developed subclinical psychotic symptoms, 
13.6% with subclinical psychotic symptoms at baseline remitted to no significant psychotic 
symptoms, 10.9% remained with subclinical psychotic symptoms, 2.7% transitioned to 
threshold psychotic symptoms and 4.1% remitted from threshold to subclinical psychotic 
symptoms. 24.7% of individuals were lost for follow-up. 
Table 3.4 
Development of (sub)clinical psychotic symptoms after 6 months in percentages (%)  
                T1 
T2 
no symptoms1 
 
PLE UHR  Psychotic 
no symptoms1 
 
PLE 
 
UHR  
 
psychotic 
 
30.1 
 
5.5 
 
8.2 
 
0 
6.8 
 
1.4 
 
2.7 
 
0 
6.8 
 
0 
 
6.8 
 
2.7 
 
0 
 
0 
 
4.1 
 
0 
lost2 11 6.8 
 
5.5   1.4 
 
Notes. T1=Baseline, T2=6 months follow-up, UHR=ultra-high risk, PLE=psychotic-like experiences,     
1 no significant psychotic symptoms, 2 lost for follow-up. 
 
3.3.3 Development of depressive and anxiety symptoms along classification of 
psychotic symptoms 
At baseline, the majority of the sample presented with mild to moderate depressive 
and no significant psychotic symptoms. After 6 months, a decline in depressive symptoms 
was evident, with most clinical participants falling in the category of none to mild depressive 
and no significant psychotic symptoms. No clinical participant met criteria for very severe 
depressive symptoms at either time point (see Table 3.5). 
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Table 3.5 
Severity of depressive symptoms for individuals at UHR, with PLE or no significant psychotic 
symptoms at baseline (T1) and after 6 months (T2) in percentages (%) 
Notes. T1=Baseline, T2=6 months follow-up, UHR=ultra-high risk, PLE=psychotic-like        
experiences, 1 no significant psychotic symptoms.                                                       
 
Individuals were classified into having an anxiety diagnosis or not, according to 
OASIS total score. At baseline, the majority of clinical participants presented with an anxiety 
diagnosis, and no significant psychotic symptoms. Over time, this pattern changed to the 
majority remitting to no anxiety diagnosis with no significant psychotic symptoms (see Table 
3.6).                                            
Table 3.6 
Frequency of anxiety diagnosis according to classification of psychotic  
symptoms at baseline and after 6 months in percentages (%) 
 
 
 
 
 
 
 
               
Notes. T1=Baseline, T2=6 months follow-up, UHR=ultra-high risk, PLE=psychotic-like        
experiences, 1 no significant psychotic symptoms.                                                       
 
 none Mild moderate severe very severe 
                    no symptoms1 
                  
T1                PLE 
     
                    UHR 
 
 
                    no symptoms1 
 
5.5 
 
2.7 
 
2.7 
 
 
23.4 
23.3 
 
6.8 
 
4.1 
 
 
25.5 
21.9 
 
6.8 
 
11 
 
 
7.3 
4.1 
 
4.1 
 
6.8 
 
 
1.8 
0 
 
0 
 
0 
 
 
0 
T2                PLE 
 
                    UHR 
3.6 
 
9.1 
7.3 
 
9.1 
1.8 
 
5.5 
3.6 
 
1.8 
0 
 
0 
 Anxiety diagnoses No anxiety diagnosis 
                    no symptoms1 
                  
T1                PLE 
     
                    UHR 
 
 
                    no symptoms1 
 
38.4 
 
12.3 
 
15.1 
 
 
25.9 
16.4 
 
8.2 
 
9.6 
 
 
31.5 
T2                PLE 
 
                    UHR 
7.4 
 
13 
9.3 
 
13 
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3.3.4 Longitudinal analyses of clinical measures and functioning comparisons 
Paired t-tests and Wilcoxon Signed Ranked tests revealed that clinical participants 
showed significant improvement in psychotic, depressive and anxiety symptoms and social 
functioning from baseline as compared to after 6 months, however, there was only a trend 
for role functioning (see Table 3.7).  
Table 3.7 
Longitudinal analyses of clinical measures and functioning from baseline to                            
6 months follow-up 
 Mean BL Mean 6 
months 
Test Statistic p-value 
CAARMS total 
 
QIDS 
 
Social Functioning 
 
Role functioning 
 
OASIS 
 
13.6 
 
10.6 
 
6.5 
 
5.3 
 
9.1 
11.3 
 
7.6 
 
7.0 
 
5.7 
 
6.6 
t(54)=2.18 
 
Z=-4 
 
Z=-2.18 
 
Z=-1.73 
 
Z=-3.6 
0.033* 
 
<0.001*** 
 
0.029* 
 
0.083 
 
<0.001*** 
K-10 30.5 24.0 t(53)=5.33 <0.001*** 
Notes. CAARMS=Comprehensive Assessment for At-Risk Mental States, QIDS=Quick              
Inventory for Depressive Symptoms, OASIS=Overall Anxiety Severity and Impairment                     
Scale, K-10=Kessler Psychological Distress Scale, * p < 0.05, *** p < 0.001. 
 
When looking at the trajectories from baseline over 3, up to 6 months, repeated 
measures ANOVA and Friedman tests confirmed improvements for depressive and anxiety 
symptoms, a trend for social and role functioning, but no significant improvement for 
psychotic symptoms. Strongest improvement took place during the first three months of the 
follow-up period, instead of the second half (see Table 3.8). 
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Table 3.8 
Longitudinal analyses of clinical measures and functioning from baseline, 3 and 6 months 
follow-up 
 M±SD/  Median 
BL 
M±SD/Media
n 3 months 
M±SD/Median 6 
months 
Test Statistic p-value  
 
CAARMS 
total (n=49) 
 
QIDS (n=50) 
 
Social 
Functioning 
(n=50) 
 
Role 
functioning 
(n=50) 
 
OASIS 
(n=48) 
 
K-10 (n=50) 
13.3±9 
 
 
11 
 
7 
 
 
 
6 
 
 
 
9 
 
 
30.8±7.2 
11.3±9.2 
 
 
8 
 
7 
 
 
 
7 
 
 
 
7 
 
 
25.1±7.4 
11.5±8.7 
 
 
6 
 
7 
 
 
 
7 
 
 
 
7 
 
 
24.3±8.6 
F(1,48)=2.35 
 
 
Χ
 
2 (2)=17.36 
 
Χ
 
2 (2)=4.98 
 
 
 
Χ
 
2 (2)=5.7 
 
 
 
Χ
 
2 (2)=7.42 
 
 
F(1,49)=25.87 
p=0.132 
 
 
<0.001*** 
 
0.083 
 
 
 
0.058 
 
 
 
0.024* 
 
 
<0.001*** 
      
Notes. M=mean, SD=standard deviation, CAARMS=Comprehensive Assessment for At-Risk Mental 
States, QIDS=Quick Inventory for Depressive Symptoms, OASIS=Overall Anxiety Severity and 
Impairment Scale, K-10=Kessler Psychological Distress Scale, * p < 0.05, *** p < 0.001. 
 
3.3.5 Co-occurrence of depressive symptoms and anxiety 
Comorbidity affects more than half of all individuals with mental disorders (Clark, 
1995). Section 3.3.3 illustrated how many individuals of this sample are affected by 
(sub)clinical psychotic and depressive or anxiety symptoms a the same time. To complete a 
comorbidity overview of this sample, the rates of co-occurence for depression and anxiety 
are the following in this cohort: 12 individuals with an anxiety diagnosis experienced mild, 22 
moderate, and 11 severe depressive symptoms at baseline assessment. 
	  
3.3.6 Association between depressive and psychotic symptoms 
Multiple linear regression revealed that only psychotic symptoms at baseline 
predicted psychotic symptoms (F (4, 49) = 8.72, p < 0.001, R2 = 0.21, Cohen’s f2 = 0.266) 
and depressive symptoms at 6 months (F (4, 49) = 3.3, p = 0.018, R2 = 0.21, Cohen’s f2 = 
0.266). In the model, depressive and anxiety symptoms and general distress at baseline 
were not predictive for depressive and psychotic symptoms after 6 months (all p > 0.05, see 
Table 3.9). 
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Table 3.9 
Summary of Multiple Regression Analysis for variables predicting psychotic and depressive 
symptoms at six months (n=55) 
 
   Psychotic symptoms prediction  Depressive symptoms prediction 
 B SE  β B SE Β 
 
CAARMS total 
 
QIDS total 
 
OASIS total 
 
 
0.431 
 
0.415 
 
-0.054 
 
0.12 
 
0.33 
 
0.289 
 
0.441** 
 
0.184 
 
-0.025 
 
 
0.166 
 
0.09 
 
0.055 
 
0.073 
 
0.199 
 
0.174 
 
0.326* 
 
0.077 
 
0.051 
 
K-10 total 0.209 0.17 0.186 0.076 0.102 0.13 
Notes. B=Beta, SE =Standard Error, CAARMS=Comprehensive Assessment of At-Risk Mental 
States, QIDS=Quick Inventory for Depressive Symptoms, OASIS=Overall Anxiety Severity and 
Impairment Scale, K-10=Kessler Psychological Distress Scale, * p < 0.05. 
 
3.3.7 Prediction of functioning at 6 months  
Repeated measures ANOVA with baseline classification into no significant psychotic 
symptoms, PLE and UHR status showed no significant association with social and role 
functioning, and no significant interaction effect from baseline to 6 months (all p > 0.05). Due 
to the non-parametric nature of social and role functioning, Kruskal-Wallis tests were 
conducted, and confirmed no effect of this classification on social and role functioning at 6 
months. In order to maximise power, Mann-Whitney-U-tests revealed that baseline 
categorisation comparing those who experience clinical or subclinical psychotic symptoms 
(PLE, UHR, and psychotic symptoms) with those without significant psychotic symptoms, 
also did not predict social and role functioning after 6 months (all p > 0.05).  
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Table 3.10 
Spearman correlations (one-tailed) and p-values of clinical measures and social and role 
functioning at BL and 6 months  (n=55) 
              \   BL 
6 months  
Social Role CAARMS QIDS OASIS K-10 
 
CAARMS  
 
 
QIDS  
 
 
OASIS  
 
 
-0.409** 
0.001 
 
-0.216 
0.057 
 
-0.103 
0.229 
 
 
-0.455** 
<0.001 
 
-0.207 
0.065 
 
-0.282* 
0.019 
 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
 
 
- 
 
 
- 
 
 
- 
 
K-10  -.0158 
0.125 
-0.36* 
0.033 
- - - - 
       
Social1 - - -0.367** 
0.003 
-0.28* 
0.019 
-0.406** 
0.001 
-0.349** 
0.005 
       
Role2 - - -0.417** 
0.001 
-0.255* 
0.03 
-0.18 
0.094 
-0.326** 
0.008 
Notes. BL=baseline, CAARMS=Comprehensive Assessment of At-Risk Mental States, QIDS=Quick 
Inventory for Depressive Symptoms, OASIS=Overall Anxiety Severity and Impairment Scale,              
K-10=Kessler Psychological Distress Scale, 1 Social functioning, 2 Role functioning, * p < 0.05, ** p < 
0.01. 
 
One-tailed Spearman correlations revealed, as hypothesised, significant negative 
correlations between baseline clinical measures and social and role functioning at 6 months 
(see Table 3.10). A linear regression showed that CAARMS, QIDS, OASIS, and K-10 at 
baseline were significant in predicting social functioning at 6 months (F (4, 49) = 4.34, p = 
0.004, R2 = 0.262, Cohen’s f2 = 0.355) and role functioning at 6 months (F (4, 49) = 4.202, p 
= 0.005, R2 = 0.255, Cohen’s f2 = 0.342). These effects were driven by CAARMS total score 
for social (p = 0.019) and role functioning (p = 0.003), and partly via a trend for OASIS total 
score (p = 0.058) for social functioning (p > 0.05, for all other scores).  
A hierarchical multiple linear regression analysis was then conducted, in order to 
control for the effect of functioning at baseline, when predicting functioning at 6 months. 
Baseline social and role functioning was included in block 1 and baseline clinical symptom 
scores in block 2. The analysis revealed a significant prediction for block 1 (F (1, 51) = 
20.23, p < 0.001, R2 = 0.442) and block 2 (F (6, 47) = 7.41, p < 0.001, R2 = 0.486) with social 
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functioning at 6 months as dependent variable. However, only lower social functioning at 
baseline significantly predicted lower social functioning at 6 months (p < 0.001) (see Table 
3.11). The effect size attributable for the addition of block 2 is Cohen’s f2 = 0.117.  A 
hierarchical multiple linear regression analysis with baseline social and role functioning in 
block 1 and baseline clinical symptom scores in block 2, and role functioning at 6 months as 
dependent variable, revealed a significant prediction for block 1 (F (1, 51) = 30.59, p < 0.001, 
R2 = 0.545) and block 2 (F (6, 47) = 6.47, p < 0.001, R2 = 0.58). The effect size attributable 
for the addition of block 2 is Cohen’s f2 = 0.083. Role functioning at baseline significantly 
predicted role functioning at 6 months, and social functioning at baseline demonstrated a 
trend in predicting role functioning at 6 months (p = 0.08), however, no clinical measure 
significantly predicted role functioning at 6 months (all p > 0.05) (see Table 3.11).   
Table 3.11 
Summary of Multiple Regression Analysis for functioning and clinical variables predicting 
social and role functioning at six months (n=53) 
 
   Social functioning prediction   Role functioning prediction 
 B SE  Β B SE Β 
 
Social functioning 
 
Role functioning 
 
CAARMS total 
 
QIDS total 
 
OASIS total 
 
 
0.554 
 
0.086 
 
-0.038 
 
0.036 
 
-0.054 
 
0.11 
 
0.068 
 
0.023 
 
0.058 
 
0.053 
 
0.588*** 
 
0.147 
 
-0.213 
 
0.087 
 
-0.139 
 
 
0.319 
 
0.673 
 
-0.053 
 
0.062 
 
0.088 
 
0.178 
 
0.111 
 
0.037 
 
0.095 
 
0.086 
 
0.188 
 
0.637*** 
 
-0.164 
 
0.083 
 
0.126 
 
K-10 total -0.006 0.032 -0.03 -0.007 0.051 -0.02 
Notes. B=Beta, SE =Standard Error, CAARMS=Comprehensive Assessment of At-Risk Mental 
States, QIDS=Quick Inventory for Depressive Symptoms, OASIS=Overall Anxiety Severity and 
Impairment Scale, K-10=Kessler Psychological Distress Scale, *** p < 0.001. 
 
3.3.8 Prediction of clinical measures at 6 months  
Role functioning at baseline was associated with CAARMS, OASIS and K-10 total 
score at 6 months and social functioning at baseline with CAARMS total score at 6 months 
(see Table 3.10). Multiple linear regression analyses revealed that social and role 
functioning was predictive of psychotic symptoms after 6 months (F (2, 52) = 7.7, p = 0.001, 
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R2 = 0.23, Cohen’s f2 = 0.23), but not for depressive and anxiety symptoms (all p > 0.05, see 
Table 3.11). Hierarchical regression with the respective clinical measure at baseline in block 
1 and social and role functioning at baseline in block 2, showed significant predictions for 
block 1, respectively, but no significant prediction for psychotic, depressive and anxiety 
symptoms after 6 months, indicating that social and role functioning do not predict clinical 
variables. This finding has been confirmed by the calculation of effect sizes: the effect size 
attributable for the addition of block 2 for depressive symptoms revealed a Cohen’s f2 of 
0.026) and for psychotic symptoms of a Cohen’s f2 of 0.102. 
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3.4 Discussion 
The present study quantified and monitored clinical symptoms and their interaction over 
time with each other and with functioning, in a sample of young, help-seeking individuals 
with mental health issues. Even though clinical participants were mainly recruited from 
general (and not UHR-specific) early intervention services, 1/4 were classified as UHR for 
psychosis and an additional 1/5 as experiencing PLE. No difference was found between 
UHR and non-UHR clinical participants concerning the severity of depressive and anxiety 
symptoms and social functioning. Both baseline and 6 months assessments displayed a 
similar distribution of individuals with and without some sort of psychotic symptoms, 
however, clinical participants showed a dynamic pattern of transition and remission. Social 
and role functioning and clinical symptoms were associated with each other from baseline to 
6 months. No robust prediction could be revealed, and if so, associations were mainly 
discovered for psychotic symptoms as compared to depressive and anxiety symptoms, but 
only when a total score index of psychotic symptoms was included as compared to 
psychosis classifications. The best predictor for social and role functioning at 6 months 
appeared to be social and role functioning itself, respectively, with social functioning also 
displaying a trend in predicting role functioning but not the other way round. Overall, the 
whole population improved after 6 months, with most improvement happening during the first 
3 months of the follow-up period. 
The finding of 17% transition rates from UHR status to threshold psychotic symptoms 
and 17% of UHR persistence rates after 6 months, are comparable to previous literature with 
transition rates to psychosis of 22% after one year (Fusar-Poli, 2012) and 3-year persistence 
rates of psychotic symptoms of up to 31% (Cougnard et al., 2007). Rates of 39% of 
individuals with sub-threshold psychotic symptoms and 6% with frank psychotic symptoms, 
and classification of the majority of the sample as experiencing mild to moderate depressive 
symptoms, are comparable with rates of a study conducted in a similar setting in Australia 
(Purcell et al., 2014). The finding that the majority of developmental psychotic experiences in 
childhood and adolescence are transient (Van Os et al., 2009) is consistent with the findings 
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of remission of 3 out of 4 individuals of the current sample, remitting to subclinical psychotic 
symptoms after experiencing threshold psychotic symptoms at baseline, and about one third 
at UHR and experiencing PLE remitting to no significant psychotic symptoms. The 
improvement concerning psychotic symptoms and overall symptomatology and functioning 
at follow-up might well be due to the clinical care that participants had received (e.g. 
medication and psychological interventions). However, neither standardised treatments nor a 
waiting-list control group were implemented that could verify the effect of treatment on the 
overall improvement of the sample.  
Neither help-seeking youths with diffuse mental health problems who were classified as 
UHR and non-UHR, nor UHR individuals and those with PLE differed significantly 
concerning depressive and anxiety symptoms and social functioning. This supports the idea 
that psychological distress and social impairment appears to be equally present in all sub-
groups. However, non-UHR clinical participants presented with significantly better role 
functioning. This has been confirmed when calculating effect sizes: there were only small 
effect sizes for depressive and anxiety symptoms, psychological distress and social 
functioning; however, there was a medium effect size for role functioning. Altogether, this 
indicates that the required drop in functioning or chronic low functioning for defining UHR 
status is rather driven by role instead of social functioning. The inclusion of a functioning 
drop/chronic low functioning for the definition of UHR status may be helpful in enriching the 
number of actual transitions to psychosis for conceptual purposes (Yung et al., 2008), but 
does not appear to be an indicator of actual need for treatment and clinical care. It actually 
emphasises that individuals who are generally at risk for developing mental health disorders, 
should not be neglected in terms of clinical care since their symptomatology appears to be 
equally relevant to UHR samples. It remains to be longitudinally investigated whether non-
UHR clinical populations are equally at risk for developing severe, non-psychotic mental 
disorders. 
The present study confirms other work that depressive and psychotic symptoms often 
co-occur (Kelleher et al., 2012b; Wigman et al., 2012), as almost the whole sample 
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displayed at least some mild or low frequency psychotic symptoms, and only 6 out of 73 
clinical participants did not present with any sort of psychotic symptoms. Psychotic 
symptoms further seem to predict both psychotic and depressive symptoms at 6 months, 
which is in agreement with the finding that these mental states mutually affect each other 
(Wigman et al., 2012), however, this data suggests that psychotic symptoms rather affect 
other mental states (such as depressive and anxiety symptoms) than the opposite direction.  
 Wigman et al. (2014) found that patients with non-psychotic psychiatric disorders but 
additional psychotic symptoms showed lower global functioning than those without psychotic 
symptoms. The current study validates this finding and the interpretation that psychotic 
symptoms complicate anxiety and depressive disorders (Wigman et al., 2012), as only 
psychotic, but neither depressive nor anxiety symptoms at baseline, significantly predicted 
psychotic and depressive symptoms at follow-up. Effect size calculations confirmed this 
effect of psychotic symptoms at baseline predicting psychotic and depressive symptoms at 6 
months with medium to large effect sizes. Further, the prediction of social and role 
functioning at follow-up by means of clinical baseline measures revealed that psychotic 
symptoms were the only significant predictor in the model. The overall model achieved large 
effect sizes. Therefore improving coping skills might be a target for early intervention that 
may contribute to better clinical and functional outcomes in patients who are presenting with 
psychotic symptoms (Wigman et al., 2014). Clinical symptoms at 6 months were predicted 
with medium to large effect sizes by social and role functioning; however, this effect 
disappeared when controlling for social and role functioning in a hierarchical regression, 
achieving only small effect sizes. Similarly, the effect of clinical (especially psychotic) 
symptoms being predictive for functioning disappeared when controlling for clinical symptom 
scores in a hierarchical regression, which has also been confirmed by a reduction in effect 
sizes to small to medium. 
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Considering recent transition rates (Fusar-Poli, 2012) and the finding that the majority 
of psychotic symptoms in childhood are transient (Van Os et al., 2009), not everybody who is 
at risk for developing psychosis will eventually transition to a  psychotic illness. In fact, this 
at-risk state may indicate a rather general underlying tendency toward common mental 
disorders (Rössler et al., 2011), instead of proneness to psychosis only. However, given the 
impairment associated with schizophrenia and other mental disorders, it is important to 
unravel risk factors, for those who are going to have adverse mental health outcomes. One 
factor that might be associated with transition is the age of at-risk individuals. Bartels-
Velthuis, van de Willige, Jenner, van Os, and Wiersma (2011) demonstrated that auditory 
hallucinations in early adolescence were strongly predictive of psychopathology, as 
compared to only a minor association when assessed during childhood. This finding was 
independent of whether psychotic symptoms were persistent or newly occurring, implying 
that psychotic symptoms may need to be more closely monitored during adolescence, and 
posing a greater risk factor for developing mental health problems, as compared to when 
occurring during childhood.  
It can further be said, that such vulnerability markers indicate not only risk for future 
psychosis (and other mental disorders), but also constitute a clinical condition that requires 
treatment itself (Cornblatt et al., 2003). This notion is confirmed by the clinical description of 
the current sample, considering that individuals mainly presented with rather general 
depressive and anxiety symptoms and either sub-clinical psychotic symptoms equivalent to 
UHR description (Yung et al., 2005), or of even less intensity and frequency. All clinical 
participants were so affected by their clinical symptoms and associated distress and 
impairment, that they were seeking help from secondary mental health care professionals. 
There were several limitations to the current study. Similarly to Hickie et al. (2013), 
clinical assessments were conducted by a number of different researchers, and treatments 
provided were not standardised, and not available for all clinical participants. The cohort was 
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followed-up within only six months, though the data show that in adolescence and early 
adulthood, even such a short time period can coincide with multiple personal developments 
and happenings, both positively and negatively affecting mental health outcomes, well-being 
and functioning, without requiring a more extensive follow-up period. 
The implemented interview and self-report measures comprise different time 
windows for symptom assessment, and therefore might encompass dissimilar impact. For 
example, the QIDS captures depressive symptoms in the past week only, whereas the 
CAARMS refers to psychotic symptoms in the past year. This gives the CAARMS the 
opportunity to yield a comparatively higher total score, since symptoms can accumulate over 
one year as compared to accumulation over one week only. Therefore, the impact of 
psychotic symptoms might be over-represented for prediction of symptoms and functioning 
at follow-up. 
Even though the sample was quite small for a cohort study, it was decently sized and 
given the detailed and comprehensive psychopathological assessments that were 
conducted. Effect size calculations overall confirmed findings of statistical tests. The sample 
comprised of a very heterogeneous clinical presentation. Across the sample, almost the 
whole continuum of all dimensional measures was covered, indicating that participants 
differed widely from none to severe symptom presentation across diagnostic categories. 
However, the presented findings are not fixed to diagnostic categories during the early 
stages of mental health, constituting a different approach to mental health, that aims to 
circumvent issues around comorbidity (Clark, 1995) and the question of the existence of 
natural boundaries between mental disorders (Kendell & Jablensky, 2003), which constitutes 
a main advantage of this study using this approach. Lastly, psychiatric medication intake 
was not controlled for, and the majority of the sample was taking antidepressant medication 
or medication addressing psychotic experiences and symptoms of bipolar disorder. 
Medication intake may have affected the results of this study; however, the study was built 
on an approach looking at mental health issues in their natural occurrence without specific 
selection and inclusion criteria. 
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In conclusion, the current study emphasised the importance of looking at youth 
mental health from a dimensional perspective. Psychotic, depressive and anxiety symptoms 
and functioning were, as expected associated with each other, yet, no robust predictions for 
future clinical and functional outcomes can be made; of all measures used, psychotic 
symptoms appear to be most predictive, however only when looked at on a continuum 
instead of using classification systems.
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CHAPTER FOUR 
LONGER-TERM INCREASED CORTISOL LEVELS 
 
Disturbance of HPA axis activity is commonly reported in a range of mental disorders by 
means of point measures such as blood, saliva and urine samples. These short-term indices 
do not account for potential damaging effects of longer-term increased cortisol levels. Hair 
strands of 30 young people (16-25 years) presenting with mental health problems (Mage ± SD 
= 20.9 ± 2.5, 26 females) and 28 healthy controls (HC, Mage ± SD = 20 ± 2.9, 26 females) 
were analysed for cortisol concentrations, representing the past 3 (hair segment 1) and 3 to 
6 (hair segment 2) months prior to hair sampling. Clinical participants completed a semi-
structured interview and self-report assessment on psychiatric symptoms, functioning and 
lifestyle factors. All participants completed the Perceived Stress Scale. Hair cortisol 
concentrations representing the past 3 (but not 3 to 6) months were significantly increased in 
clinical participants compared to HC. Perceived stress in the past month was significantly 
higher in clinical participants compared to HC, but was not significantly correlated with hair 
cortisol concentrations. Hair cortisol levels were only significantly associated with 
psychological distress but no other psychiatric symptoms, functioning and lifestyle indices. 
Hair segment analyses revealed longer-term increased levels of cortisol in the past 3 months 
in young people with early mental health problems. Further insight into the role of cortisol on 
the pathogenesis of mental illnesses requires longitudinal studies relating cortisol to 
psychopathology and progression of illness. 
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4.1 Introduction 
Disturbances in HPA axis diurnal activity and responsivity are common findings in a 
range of mental disorders (e.g. Knorr, Vinberg, Kessing, & Wetterslev, 2010; Meewisse, 
Reitsma, De Vries, Gersons, & Olff, 2007; Yehuda, Boisoneau, Mason, & Giller, 1993). One 
of the most commonly reported parameters of the HPA axis is the glucocorticoid hormone 
cortisol. Over- and under-activity of cortisol concentrations have been reported by means of 
blood, saliva and urine samples in mood disorder (Cervantes, Gelber, Kin, Nair, & Schwartz, 
2001; Vreeburg et al., 2009), psychosis (Ryan, Sharifi, Condren, & Thakore, 2004), 
posttraumatic stress disorder (PTSD) (Yehuda et al., 1990), panic disorder (Bandelow et al., 
2000) and GAD (Mantella et al., 2008), somatisation syndrome (Rief, Shaw, & Fichter, 
1998), and eating (Monteleone et al., 2001) and substance use (Adinoff, Ruether, Krebaum, 
Iranmanesh, & Williams, 2003) disorders. Despite this, there is considerable variability 
across (Yehuda et al., 1993) and within diagnostic categories (for meta-analyses in 
depression, see Knorr et al., 2010; and PTSD, see Meewisse et al., 2007), which is why it is 
important to investigate whether cortisol fluctuations can be explained by other factors as 
well, such as inter-individual differences and stressor characteristics (Miller, Chen, & Zhou, 
2007). 
 Stalder and Kirschbaum (2012) reviewed the analysis of cortisol in hair and stated 
that established analyses of cortisol in saliva, plasma, and urine have proven to be useful 
and reliable tools for documenting real-time circulating cortisol levels (plasma, saliva) or 
mean cortisol excretions over a specific time, usually 24 hours (urine). In contrast to this, hair 
cortisol represents a reliable, longer-term measure (generally up to months) to gauge stress 
and endogenous cortisol concentrations. The advantages of hair cortisol assessments lie in 
providing a retrospective calendar of hair cortisol levels over an extended time period that is 
virtually not possible to achieve with any other of the previously reported methods. It further 
constitutes a non-invasive sampling method, samples can be easily stored at room 
temperature for an extended time period, and sampling avoids problems of adherence as 
often experienced with, e.g. saliva samples. However, hair cortisol concentrations decrease 
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from more proximal to distal segments in human scalp hair, limiting the retrospective period 
of examination (Stalder & Kirschbaum, 2012). 
Considering a generally accepted human scalp hair growth rate of 1cm per month 
(Wennig, 2000) and taking hair samples from the scalp-near posterior vertex region, this 
method allows for retrospective capture of cortisol concentrations for up to 6 months 
(Dettenborn et al., 2012). Recent studies in clinical populations have demonstrated 
increased hair cortisol concentrations in depression (Dettenborn et al., 2012), post-traumatic 
stress disorder (PTSD) (Steudte et al., 2011a), and  in alcohol-dependent individuals 
(Stalder et al., 2010), and decreases in GAD (Steudte et al., 2011b), and PTSD (Steudte et 
al., 2013). Occupational impairment in terms of unemployment has further been shown to be 
associated with increased hair cortisol (Dettenborn, Tietze, Bruckner, & Kirschbaum, 2010). 
Strong test-retest associations for repeated hair cortisol measurements have been revealed, 
indicating high intra-individual stability. Structural equation modelling showed that, if no 
major life events or other stressors are present, hair cortisol assessments comprise a strong 
trait component which explains between 59-82% of variance in cortisol levels (Stalder et al., 
2012). A recent systematic review on hair analyses revealed variations in hair cortisol 
(Staufenbiel, Penninx, Spijker, Elzinga, & van Rossum, 2013) that are similar to 
aforementioned meta-analyses and reviews on more established cortisol measures (Knorr et 
al., 2010; Meewisse et al., 2007). Despite some inconsistencies hair cortisol appeared to be 
increased in depression, and decreased in anxiety disorders (Staufenbiel et al., 2013). 
The period of adolescence and young adulthood is characterised by a greatly 
increased vulnerability for the development of mental disorders. Half of the lifetime cases of 
mental disorder start by age 14 and three quarters by age 24 (Kessler et al., 2005). It is 
hypothesised that adolescence is accompanied by a biological sensitivity to stress and that 
age-related cortisol increase may trigger the expression of symptoms in vulnerable 
individuals (Walker et al., 2010). Higher cortisol levels predicting a higher risk of conversion 
to psychotic disorder in at-risk individuals, supports this hypothesis (Walker et al., 2010). The 
pathogenesis of childhood anxiety disorders appears similar: high levels of cortisol may 
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induce changes to subcortical circuits (such as involving the amygdala), which possibly 
make children vulnerable to developing anxiety symptoms (Muris, 2006). Rao, Hammen, 
Ortiz, Chen, and Poland (2008) exposed adolescents with depressive disorder and HC to 
psychosocial stress. Both groups showed increased cortisol levels, but individuals with 
depression displayed an increased and sustained cortisol response. This supports the notion 
that stressful events play a role in the development and maintenance of depressive 
symptoms (Rao et al., 2008). 
The time between the onset of the disorder (or stressful or traumatic event) and hair 
collection appears to be a crucial element in explaining the diversity of cortisol findings. Luo 
et al. (2012) reported increased hair cortisol one month after a traumatic event in 
adolescents with PTSD, with levels decreasing after 7 months (for review, see Staufenbiel et 
al., 2013). Increased cortisol levels are therefore likely to reflect the on-going stress and not 
the disorder itself (Staufenbiel et al., 2013). A significant difference was observed between 
early- and late-onset bipolar disorder. Patients with a late onset disorder (≥ 30 years) 
presented with higher hair cortisol than the early-onset group and HC (Manenschijn et al., 
2012). This finding suggests that early onset bipolar disorder may be more strongly linked to 
a genetic vulnerability while late onset is usually triggered by life events and stress 
(Staufenbiel et al., 2013). Taken together, these findings suggest that HPA axis activity is 
elevated at the time of stressor onset with declining cortisol levels as time passes (Miller et 
al., 2007). However, it is unclear what the exact timeline of these hormonal changes is, that 
is, for how long this hypothesised cortisol increase presumably persists, until decline (below 
normal) takes over. 
An alternative to explaining the heterogeneity of HPA axis findings by classifying 
mental ill health into disorder-specific categories is to use a dimensional approach such as 
clinical staging (Section 1.3.2). Within this framework, mental disorders are assumed to 
develop from a pluripotential state, consisting of undifferentiated general symptoms (such as 
depressive and anxiety symptoms), and from a background of specific and non-specific risk 
factors (Lin et al., 2013; McGorry et al., 2006), which are associated with non-specific 
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distress (McGorry, 2013). This idea is supported by the recent finding of a common mental 
distress factor underlying depressive, anxiety, and psychotic phenomena in adolescents 
(Stochl et al., 2015). It can therefore be inferred from the clinical staging model that the early 
stages of mixed mental health problems are coinciding with elevated cortisol levels. There 
has been no such study that has looked at longer-term cortisol levels in youth with early 
mental health problems from a clinical staging perspective. 
The aim of this study was to investigate the pathogenesis of mental disorders in 
adolescents and young adults, and whether diverse psychiatric symptoms are associated 
with altered longer-term cortisol levels. Young people were included who had sought help for 
mental health problems, as well as HC. The hypothesis was tested whether early stages of 
mental health problems are associated with significant distress (McGorry, 2013) and 
therefore elevated cortisol levels. The association between cortisol levels and general 
psychological distress, depressive, anxiety, and psychotic symptoms, alcohol and tobacco 
use, and childhood traumatic experiences was further investigated. 
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4.2 Methods 
4.2.1 Participants & Procedure 
Thirty-one clinical participants and 28 HC were included in this study. Clinical 
participants from the main study as described in Chapter 3, who either had a family history of 
mental health problems or those who felt their mental health problems did not improve 6 
weeks after the baseline clinical assessment, were asked to take part in this study. Clinical 
participants were either approached during or after the interview if they had a family history, 
or given a telephone call 6 weeks after and explained the neurobiological assessments. HC 
were recruited via staff from university and local advertisements. HC were age, gender, 
occupation and education matched to the clinical participants, and had no personal or first-
degree family history of mental illness. A personal history was excluded by using the 
Structured Clinical Interview for DSM-IV-TR (American Psychiatric Association, 2000) Axis I 
Disorders. Exclusion criteria for both groups were a hair length of less than 3 cm at the 
posterior vertex region, a lack of sufficient English and cognitive ability to provide informed 
consent and adequately complete assessments. The study was approved by the local 
research ethics committee and participants provided written informed consent. 
 
4.2.2 Measures 
Demographic information (age, gender, ethnicity, occupation and highest 
qualification) and information on clinical and functioning measures was gathered via 
interview and self-report. These information included psychotic (CAARMS), depressive 
(QIDS), and anxiety (OASIS) symptoms, psychological distress (K-10), and functioning 
(Global functioning: Social and Role scale) as described in Section 2.4. Obtaining total 
scores of the employed measures and classification of UHR status followed the same 
procedure as described in Sections 2.4 and 2.5.  
Information on regular medication intake was collected and covered exposure to 
contraceptive hormones (oral intake, patches or implants) or glucocorticoids, and psychiatric 
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medication (antidepressants, neuroleptics, beta-blockers, anticonvulsants) in the past 6 
months. All participants self-reported demographic and hair-related information (number of 
hair washes per week, hair treatments) and completed the 10-item Perceived Stress Scale 
(PSS) (Cohen, Kamarck, & Mermelstein, 1983). The PSS evaluates the extent to which 
situations in one’s life are appraised as stressful and the degree to which a person rates 
their life as unpredictable, uncontrollable, and overloading (Cohen et al., 1983). Information 
from the baseline assessments of the clinical group was used for the CAARMS, QIDS, 
OASIS, K-10, Global functioning: Social and Role scale (see Section 2.4).  
Information on childhood trauma, ruminative style, and lifestyle factors, which was collected 
during the baseline assessment as well, was further included in the analyses:  
Ruminative style (Leach, Christensen, Mackinnon, Windsor, & Butterworth, 2008) 
was measured on a 10-item scale, requiring participants to indicate on a 4-point scale how 
often they engage with certain thoughts when they are feeling down or depressed. Total 
scores range from 10 – 40.  
The Childhood Trauma Questionnaire, short form (CTQ-SF) (Bernstein et al., 2003) 
is a 28-item instrument generating information on traumatic childhood experiences using a 5-
point scale. Subscales are sexual, physical and emotional abuse, and emotional and 
physical neglect, with subscale scores ranging from 5 – 25, and a total score from 25-125. 
The CTQ demonstrates good internal consistencies with Chronbach’s α ranging from 0.79 – 
0.94, and high retest-reliability over up to 6 months with an intra-class correlation of 0.88, as 
well as concurrent validity with the Childhood Trauma Interview (Bernstein et al., 1994). 
Lifestyle factors were frequency of smoking and alcohol consumption in the past 3 
months, and a total score for tobacco and alcohol acuity as measured by the Alcohol, 
Smoking and Substance Involvement Screening Test (ASSIST) (Humeniuk et al., 2008), and 
body mass index (BMI). The ASSIST is a brief screening questionnaire for hazardous, 
harmful and dependent use of alcohol, tobacco and other psychoactive substances 
(cannabis, cocaine, amphetamines, sedatives, hallucinogens, inhalants, opioids, and other 
non-specified drugs). It provides general information about substances people have ever 
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used, and in more detailed format, information about substances used in the past 3 months, 
problems related to peoples’ substance use, risk of current and future harm and 
dependence, by asking 7 questions for every substance group and scoring them individually 
to a total score for each substance. Scores ranging from 0 to 39 can be classified into low 
(for alcohol 0 - 10, all other substances 0 - 3), moderate (alcohol 11-26, other substances 4-
26) and high (all 27+) substance acuity (Henry-Edwards, Humeniuk, Ali, Poznyak, & 
Monteiro, 2003). The calculation of Cronbach’s α revealed good inter-item correlation for the 
individual scales ranging from 0.77 to 0.94. Concurrent validity of the ASSIST was obtained 
by similar, established measures, e.g. the Addiction Severity Index with correlations for scale 
scores ranging from 0.76 to 0.88 (Humeniuk et al., 2008). No clinical participant reached a 
total score for any psychoactive substance (other than tobacco and alcohol) in the range of 
moderate acuity or above (except moderate acuity for six clinical participants for cannabis, 
and for two participants for sedatives). These categories were disregarded from further 
analyses due to small sample sizes. 
 
4.2.3 Hair cortisol analyses 
Hair strands of approximately 3mm diameter were taken from a posterior vertex 
position, as close to the scalp as possible. Cortisol concentrations were determined from the 
hair segment most proximal to the scalp (hair segment 1; 3cm in length), and the following 
3cm segment (hair segment 2) in accordance with the protocol of Stalder et al. (2012) at the 
department of biopsychology, Technical University, Dresden, Germany. Segments were 
gently mixed with 2.5ml isopropanol for 3 minutes. After drying, 7.5mg of whole, non-
pulverised hair was incubated in 1800µl methanol for 18 hours at 45°C. Cortisol levels were 
determined using a commercially available immunoassay with chemiluminescence detection 
(CLIA, IBL-Hamburg, Germany). H 
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4.2.4 Statistical analyses  
Hair samples from 31 clinical participants and 28 HC were collected. Initially 57 
clinical participants and 35 HC were approached, of which 5 male and 1 female were clinical 
participant, and 4 male and 3 female HC could not partake due to too short or too little hair, 
in which case hair was shorter than 3cm or cutting would have left visible marks. Whereas 
those males were predominantly White-British, all 4 women were either mixed-race or Black-
African. 14 of the other 21 did not partake due to passive refusal, 2 moved away after being 
approached, 1 was too busy, and 4 did not meet criteria for the neuroimaging studies, 
resulting in an overall refusal rate of 47%. Data of the first hair segment of one clinical 
participant was excluded due to an extreme outlier (> 90 standard deviations above the 
mean), providing data for 30 clinical participants and 28 HC in the first hair segment, and 
due to short hair, data for 24 patients and 24 HC in the second hair segment. Cortisol data 
was positively skewed (skewness first segment = 2.6, skewness second segment = 3.73, 
kurtosis first segment = 7.65, kurtosis second segment = 19.24), but analysed using t-tests 
which are robust against violation of parametric assumptions, and ANCOVA. 
Independent samples t-tests were performed for group comparisons of cortisol, age, 
and PSS scores between clinical participants and HC, and between clinical participants 
taking antidepressants and those who were not, to discern whether antidepressant treatment 
could be associated with alterations in cortisol concentrations. For categorical data, Χ
 
2 - 
tests were used to evaluate group differences. Spearman correlations were conducted to 
discern associations of cortisol levels with clinical measures and lifestyle factors in the 
clinical group, and for associations between the first and second hair segment. A paired 
samples t-test was conducted to compare mean hair cortisol levels in the first and second 
segment, as well as a repeated measured ANOVA to illustrate cortisol levels’ interaction 
over time. ANCOVA were employed to compare clinical participants and HC, with ethnicity 
as covariate, since groups differed significantly and ethnicity can be a confounding variable 
(Wennig, 2000; Wosu et al., 2015).  
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4.3 Results 
4.3.1 Demographics & clinical description 
Clinical participants and HC did not differ significantly in terms of age, gender, years 
of education and occupation, but differed significantly with regards to ethnicity (see Table 
4.1). Median time between gathering state-specific clinical measures (QIDS, CAARMS, K-
10, OASIS, functioning, smoking, alcohol consumption, BMI) and hair collection/gathering 
hair-related variables (PSS-scores and medication intake, and demographics for HC) was 
63.5 days (range 0 - 199 days). State-specific measures, along with data on ruminative style, 
and childhood trauma are presented in Table 4.2. 
 
Table 4.1 
Demographic and hair-related information on clinical participants and HC 
 Clinical 
Participants 
(n = 30) 
HC (n = 28) Test statistic p-value 
Demographics 
    Age (M ± SD) in years 
   Gender (m/f) 
 
Ethnicity 
      White 
      Asian 
      Black 
      Mixed-race 
 
Occupation 
      University student1 
      College/A-Levels 
      Unemployed 
      Employed2 
 
Years of education 
      >13 
      13 
      <13 
 
Hair-related variables 
   Washes per week (x ̃) 
   Hair treatment3 (%) 
 
 
21±2.4 
4/26 
 
 
26 
1 
2 
1 
 
 
9 
9 
7 
5 
 
 
5 
15 
10 
 
 
3.5 
63.3 
 
20±2.9 
2/26 
 
 
16 
5 
1 
6 
 
 
9 
8 
2 
9 
 
 
7 
14 
7 
 
 
3.5 
42.9 
 
t(56)=1.32 
Χ
 
2(1)=0.6 
 
 
 
Χ
 
2(3)=8.9 
 
 
 
 
 
Χ
 
2(3)=3.92 
 
 
 
 
 
Χ
 
2(2)=0.83 
 
 
 
U=372.5, Z=-0.52 
Χ
 
2(1) 2.44 
 
0.19 
0.44 
 
 
 
0.03* 
 
 
 
 
 
0.27 
 
 
 
 
 
0.66 
 
 
 
0.6 
0.12 
Stress questionnaire 
   PSS score, M ± SD 
 
26.1 ± 4.5 
 
12 ± 5.1 
 
t(56)=11.20 
 
<0.001*** 
Notes. HC=healthy controls, M=mean score, SD=Standard deviation, m=male, f=female                       
1 Undergraduate and postgraduate university students, 2 Working full or part-time, volunteering, and 
non-paid internships, 3 Hair treatment in the past 6 months (hair coloration, dye, and perm), PSS = 
Perceived Stress Scale, * p < 0.05, *** p < 0.001. 
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Table 4.2 
Clinical measure, functioning scores and lifestyle factors of clinical participants  
Measure M ± SD or 
Median 
Range 
QIDS (n=30) 
 
Ruminative Style (n=29) 
 
CAARMS (n=30) 
 
K-10 (n=30) 
 
OASIS (n=30) 
 
CTQ-SF (n=25) 
 
ASSIST alcohol (n=30) 
 
ASSIST smoking (n=30) 
 
10.3±4 
 
30.7±5.2 
 
14.3±10 
 
29.7±7.0 
 
8.9±4.6 
 
50.4±18.2 
 
6.9±5.5 
 
3 
4–20 
 
19–40 
 
0–30 
 
19–43 
 
0–17 
 
27–83 
 
0-19 
 
0-31 
BMI (n=28) 
 
Smoking frequency1 (n=30) 
 
Alcohol consumption1 (n=30) 
22.7 
 
“monthly” 
 
“weekly” 
16.9–6.4 
 
“never” - “daily” 
 
“never” - “daily” 
Notes. QIDS=Quick Inventory of Depressive Symptoms, CAARMS= 
Comprehensive Assessment of At-Risk Mental States, K10=Kessler Psychological  
Distress Scale, OASIS=Overall Anxiety Severity and Impairment Scale, ASSIST=  
Alcohol, Smoking and Substance Involvement Screening Test, BMI=Body Mass  
Index, M=mean score, SD=Standard deviation, 1 Median scores for smoking and  
alcohol consumption frequency in the past three months are calculated based on  
self-report data ranging from 0 (never), 2 (once or twice), 3 (monthly), 4 (weekly), and  
6 (daily or almost daily). 
 
 
23 clinical participants described their major mental health problem(s) as depression, 
4 as bipolar disorder, 13 as anxiety, 2 as eating disorders, 1 as obsessive-compulsive 
disorder, 10 were classified as UHR for psychosis, and 20 reported to have self-harmed, and 
18 to have attempted suicide. 
 
4.3.2 Hair cortisol and perceived stress: Clinical participants vs HC 
There was a significant elevation of cortisol concentrations for clinical participants 
compared to HC for the first hair segment, representing the past 3 months of exposure prior 
to sampling (t (56) = 2.489, p = 0.016, d = 0.66) (see Figure 4.1, A). There were no group 
differences in cortisol levels for the second segment representing the past 3 to 6 months 
prior to sampling (p = 0.495, d = 0.2). Repeated analyses without individuals taking 
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glucocorticoids did not change the findings for the first (t (54) = 2.501, p = 0.015) and second 
segment (p = 0.473). Clinical participants perceived significantly more stress in the past 
month compared to HC (t (56) = 11.202, p < 0.001) (see Table 1); however, there were no 
statistically significant correlations between cortisol concentrations in the first segment and 
perceived stress, for the whole sample (r = 0.219, p = 0.099) or groups compared 
individually (rClinical = 0.144, p = 0.448; rHC = -0.201, p = 0.305). Hair cortisol of the first and 
second hair segment significantly correlated with each other (r48 = 0.286, p = 0.049). A 
paired-samples t-test did not reveal a significant decrease of cortisol over time (t (47) = 
1.601, p = 0.116). There was no significant Group x Time interaction of cortisol levels (F (1, 
46) = 1.704. p = 0.20; see Figure 4.1, B). The main finding of elevated cortisol 
concentrations in the first hair segment in clinical participants compared to HC remained 
significant after controlling for ethnicity (F (1, 55) = 4.77, p = 0.012).  
 
 
Figure 4.1. (A) Hair cortisol concentrations (1st segment) in clinical participants with mental 
health problems (n=30) compared to healthy controls (HC; n=28, p 0.016); (B) decrease in 
hair cortisol in clinical participants and HC from first (nClinical=24; nHC=24) to second hair 
segment (nClinical=24; nHC=24). 
 
 
4.3.3 Hair cortisol, clinical measures, functioning, and lifestyle 
Hair cortisol concentrations in the first segment were significantly correlated with K-
10 total score (r = 0.506, p = 0.005, n = 29), and a trend existed for QIDS total score (r = 
0.353, p = 0.052, n = 30), and Ruminative Style score (r = 0.312, p = 0.099, n = 29). No 
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further correlations were observed with measures and first and second hair segment (all p > 
0.05).  
 
4.3.4  Hair cortisol and medication 
Both groups were matched in terms of glucocorticoid and contraceptive hormone 
use, making this unlikely to account for group differences in cortisol in the first hair segment: 
One clinical participant and one HC were using glucocorticoids at the time of hair collection, 
of which neither produced abnormally elevated cortisol levels in either hair segment. 24% of 
the clinical participants and 36% of HC were exposed to contraceptive hormones at the time 
of hair collection.  
72% of the clinical participants were taking antidepressants, 3.4% neuroleptics, 3.4% 
anti-convulsive medication, and 3.4% were taking beta-blockers at the time of hair collection. 
There were no significant differences for cortisol levels in the first (1st) and second hair (2nd) 
segment in those clinical participants taking antidepressants and/or other psychiatric 
medication (n1st  = 21; n2nd = 16) as compared to those patients who were not (n1st = 9; n2nd = 
8) (p > 0.05).  
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4.4 Discussion 
 
The present study identified elevated hair cortisol concentrations representing the past 3 
months prior to hair sampling in adolescents and young adults with mental health problems 
compared to healthy participants. Perceived stress was also elevated in clinical participants, 
yet, there was no correlation between cortisol and perceived stress score. There was only a 
significant, positive correlation between hair cortisol in the first segment and K-10 total score, 
and a trend for QIDS and ruminative style total score; no other significant correlations 
between cortisol and clinical measures, functioning and lifestyle factors were observed.  
The finding of longer-term elevated cortisol levels in young individuals with mental health 
problems is in line with the presumption of the experience of non-specific but significant 
psychological distress in the early stages of mental health problems (McGorry, 2013), and 
therefore with dimensional approaches to mental health such as clinical staging (Lin et al., 
2013; McGorry et al., 2006). This supports the idea that this state of undifferentiated 
symptoms in the early stages of a mental health disorder is associated with an increase in 
cortisol levels and self-reported stress levels. However, whether decreases in cortisol levels 
coincide with illness progression (dependent or independent of diagnostic category), and 
whether cortisol levels decline (to normal) with remission of symptoms, remains to be 
investigated longitudinally.  
Clinical participants were experiencing their mental health problems for at least 6 
months, although they had only sought help quite recently. Considering that these problems 
existed for quite a while before individuals actually sought help, the time when the young 
people started seeking help can be seen as a crisis point, when their problems started to 
worsen (possibly due to a significant event or stressor). It is possible that help-seeking 
behaviour can be seen as an indicator for significant worsening of individuals’ mental states, 
with significant increases in cortisol levels only in the past 3 months, which coincided with 
the help-seeking behaviour. Although there was no significant time-by-group interaction, 
visual inspection of the data suggests a much more pronounced increase for the clinical 
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group. This non-significance may be due to washout effects (Kirschbaum, Tietze, Skoluda, & 
Dettenborn, 2009) and inter-individually varying rates of hair growth (Wennig, 2000) that may 
limit detection of differences in the more distal hair segment, or possibly to insufficient 
statistical power.  
In most previous studies, individuals with threshold mental disorders usually at the 
chronic stage have been investigated, whereas the current sample included help-seeking 
youth in the early stages of mental health problems. Specific patterns of hair cortisol 
alterations were reported in previous studies, e.g. increases in depression (Dettenborn et al., 
2012), and (if diagnosis sustained at least in the medium term) decreases in PTSD (Steudte 
et al., 2013). Concerning associations with clinical, functioning, and lifestyle measures, there 
was only a correlation between first segment cortisol and psychological distress, and a trend 
for depressive symptoms and ruminative style observed. These associations are in line with 
the notion of cortisol being positively correlated with depressive symptoms and psychological 
distress, however, no further associations were observed. Given the relatively small sample 
size, but highly heterogeneous and comorbid sample in terms of clinical symptoms, it is 
conceivable that the results were masked by the interaction of symptoms with each other. 
Furthermore, previous studies included clinical participants with more severe symptoms than 
in this sample – the more narrow range in the current study may have prevented the 
detection of further correlations with cortisol.  
However, the lack of correlations between hair cortisol and perceived stress in this study, 
is not an uncommon finding (Hjortskov, Garde, Orbaek, & Hansen, 2004; Stalder & 
Kirschbaum, 2012; Staufenbiel et al., 2013), considering one is an objective and the other an 
objective measure of stress. Alternative explanations for this lack of association between 
cortisol and the PSS are the mismatch of time frame of one month for the PSS and 3 months 
for the first hair segment, or possibly the lack of validity of perceived stress in increasing hair 
cortisol concentrations (Staufenbiel et al., 2013), e.g. that only certain characteristics of 
stressors might lead to an endocrine response, which may have not been reflected 
(Hjortskov et al., 2004). 
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It has been shown that hair cortisol alterations are implicated in a variety of health 
conditions (Staufenbiel et al., 2013), which is consistent with the finding of elevated cortisol 
in our sample of individuals with a range of mental health symptoms and disorders, e.g. 
depressive, anxiety and sub-threshold psychotic symptoms. Even though there is some 
evidence that cortisol might contribute to the aetiology of psychiatric conditions such as 
depressive symptoms (Johnson, Fournier, & Kalynchuk, 2006), the most plausible 
explanation appears to be a reciprocal relationship between stress promoting the 
development of mental disorders and psychiatric conditions being naturally accompanied by 
distress and a cortisol increase. 
A limitation of this study is that clinical measures were not administered at the same 
time as the hair sample, although it was aimed to collect clinical data as close as possible. A 
possible explanation for the lack of association between cortisol and perceived stress and 
other measures is that they did not entirely correspond with the window of cortisol detection. 
Although the median time from clinical assessment to cortisol measurement was only 63.5 
days, cortisol measurements corresponded approximately with the past 3 and 3 to 6 months, 
whereas some self-reported and interview measures captured information from the previous 
week or month only. This variability constitutes an issue concerning the reliability of 
correlations between cortisol and interview and self-report measures that were conducted for 
this study; however, the main finding of increased hair cortisol in the first segment in the 
clinical group is not affected since clinical participants experienced persistent distress at the 
time of hair sampling. The HC group did not receive clinical assessments, therefore were 
these clinical variables, functioning and lifestyle factors not included as covariates in the 
analyses. HC did not present with any threshold DSM disorder, however, it cannot fully be 
ruled out that sub-threshold distress disorders were present in this group. There was further 
a larger number of male participants in the clinical as compared to control group; however, 
this difference did not reach statistical significance. 
Male sex and mixed-race ethnicity in women constituted a barrier in hair sample 
collection in terms of feasibility and refusal rates of this study, possibly creating a systematic 
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bias towards the findings. The clinical group included significantly more white individuals 
than the control group, whereas controls included more non-white (e.g. Asian and mixed-
race) participants. Wosu et al. (2015) found differences in hair cortisol levels according to 
ethnicity, with lower levels in white participants. However, since our clinical group included 
more white participants, ethnicity is unlikely to account for the main finding of elevated hair 
cortisol. It is further unlikely that increased cortisol levels in the clinical group are due to 
antidepressant intake, as there were no differences in hair cortisol between those clinical 
participants who were taking antidepressant medication and those who were not.    
A relatively small sample size is a further limitation, although as hypothesised, a 
group difference in hair cortisol concentrations in the first segment was discovered. Given 
the clinical heterogeneity of the sample, the sample size was not sufficient to conduct 
subgroup analyses (e.g. comparing different types of anxiety disorders). Differentiation of 
specific mental disorders on the basis of increases or decreases in cortisol (as seen in 
previous studies, e.g. for review, see Staufenbiel et al. (2013)) is more likely to happen 
where there is persistence and progression of symptoms, and therefore more probable to be 
distinguished over the future course of the illnesses in this population. 
Lastly is to mention that it cannot be ruled out that recreational tobacco and alcohol 
consumption, as well as of other psychoactive illegal drugs, exerted effects. However, here 
was neither an association between hair cortisol and alcohol and tobacco use, nor an 
association with tobacco- and alcohol-related problems or behaviours. Parrott et al. (2014) 
found an almost 4-fold increase in hair cortisol levels in regular ecstasy users as compared 
to non-users. However, numbers were too small in the current sample to conduct meaningful 
analyses with any illegal psychoactive drugs. 
The finding of elevated hair cortisol levels in young people with diverse mental health 
problems is consistent with increased HPA axis activity in the early stages of help-seeking 
for mental health problems. Future research should focus on disentangling how actual life 
stressors and subjective stress experience are associated with increases in cortisol and the 
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development and maintenance of mental disorders, and how HPA axis activity develops and 
adapts over the course of illness and with remission of symptoms. 
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CHAPTER FIVE 
BRAIN HYPO-ACTIVATION DURING WORKING MEMORY 
PERFORMANCE 
 
Functional neuroimaging studies on working memory performance tend to segregate 
between a hyper-activation of certain brain areas in individuals with major depression (MD), 
as opposed to a hypo-activation in schizophrenia, most prominently reported in frontal areas 
such as the dorsolateral prefrontal cortex (PFC). Working memory performance was studied 
by means of an n-back (0- and 2-back) task in 34 young people (ages 16 – 26 years) with 
emerging mental health issues (10 males, Mage ± SD: 20.6 ± 2.5 years) and 34 age- and 
gender-matched HC (6 males, Mage ± SD: 20.4 ± 2.7 years). Further information was 
collected on clinical (e.g. depressive, psychotic, anxiety symptoms) and functional outcome, 
as well as longer-term cortisol levels. 2-minus-0-back-condition elicited activation of clusters 
mainly in the superior frontal gyrus (SFG), and in further frontal, parietal and subcortical 
regions in both groups (family-wise error (FWE)-corrected, p < 0.05). HC activated the left 
SFG, putamen, and anterior cingulate cortex (ACC), and right hippocampus and insula more 
strongly than clinical participants. There was no hyper-activation of any brain area in the 
clinical group. There were no differences in reaction times and accuracy between both 
groups, and no association with cortisol levels were detected (all p > 0.05). Adolescents and 
young adults with early mental health problems presented with brain hypo-activation, yet, 
with intact working memory performance. That is, subtle differences in brain activation are 
present during working memory, but do not yet translate into behavioural deficits in the 
clinical group. Longitudinal studies are required to track how these differences translate over 
time with illness progression and/or recovery. 
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5.1 Introduction 
Working memory enables individuals to temporarily store and manipulate information 
that is necessary for understanding language, learning and reasoning (Baddeley, 1992). 
Working memory can be divided in executive control, which refers to encoding and retrieval 
of information, and actively maintaining information on-line. It has been proposed that the 
PFC holds control over executive processes, whereas the parietal cortex is engaged in 
active maintenance (Cohen et al., 1997). The finding of increased activation of the 
dorsolateral prefrontal, inferior and posterior frontal and posterior parietal cortex in early 
studies using a sequential letter memory task in healthy subjects (Cohen et al., 1997), has 
largely been confirmed by a more recent meta-analysis, with further activation being robustly 
identified in the premotor cortex, frontal pole and anterior cingulate (Owen et al., 2005).  
A commonly employed variant to study key processes within working memory is the n-
back task, which demands the monitoring of stimuli series. The participant has to indicate 
whenever a stimulus is presented as the one before n stimuli, where n could be 0, 1, 2, 3 
etc. This involves monitoring, updating, and manipulating information that has previously 
been encoded and remembered, and requires working memory performance (Owen et al., 
2005), with the task demand increasing with n. Likely functional roles during working 
memory, allocated to respective brain regions, are illustrated in Table 5.1. 
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Table 5.1 
Likely functional roles for brain regions implicated in n-back task performance (Owen et al., 
2005) 
Brain region Likely function 
Dorsolateral prefrontal cortex 
 
 
Ventrolateral prefrontal cortex 
 
 
Rostral prefrontal cortex & 
frontal pole 
 
Medial premotor cortex 
 
 
Anterior cingulate cortex 
 
 
Posterior parietal cortex 
Mnemonic strategies: monitor series of stimuli, and compare every 
new stimuli with earlier one 
 
Explicit intention to remember and retrieve information and 
sequencing of responses 
 
Problems comprising multiple cognitive processes (e.g. monitoring, 
adjustment and comparison of information) 
 
Maintenance of attention, e.g. because of delay between stimulus 
and response 
 
Response selection for goal-directed behaviours (Devinsky, Morrell, 
& Vogt, 1995) 
 
Spatial rehearsal 
  
 
One mental disorder that has clearly been associated with working memory 
impairment and altered brain activation during those processes, is schizophrenia. Decreased 
working memory performance (Barch, Sheline, Csernansky, & Snyder, 2003; Lee & Park, 
2005) and decreased activation in the dorsolateral prefrontal cortex (dlPFC) has been 
commonly reported (Barch et al., 2003), and referred to as hypo-frontality (Carter et al., 
1998), and consistently coupled with increased anterior cingulate and left frontal pole 
activation (Barch et al., 2003). This pattern of hypo- and hyperactivation of rather distributed 
brain areas leads to view dlPFC dysfunction within the context of a network perspective, 
rather than focussing on an isolated dlPFC dysfunction, when aspiring to understand 
underlying mechanisms of schizophrenia (Glahn et al., 2005). Even though there are some 
studies that could not replicate decreases in dlPFC activation in schizophrenia patients (e.g. 
Manoach et al., 1999; Walter, Vasic, Höse, Spitzer, & Wolf, 2007), meta-analyses on 
executive functions (Minzenberg, Laird, Thelen, Carter, & Glahn, 2009), and particularly on 
the n-back task (Glahn et al., 2005) in schizophrenia clearly supported the hypo-frontality 
hypothesis.  
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There is, however, inconsistent evidence concerning how brain activation during 
working memory is associated with the clinical presentation of schizophrenia: Whereas some 
studies did not detect correlations between symptom severity and reduced dlPFC brain 
activation in schizophrenia patients (Bleich-Cohen et al., 2014) and the severity of 
psychosis-spectrum symptoms and dlPFC activation in the general population (Wolf et al., 
2015), found another one that decreased activation in frontal and parietal areas during a 
working memory task correlated with greater severity of negative and disorganisation 
symptoms (Sanz et al., 2009). This was further supported when looking at the effects of 
practice: Practising a working memory task reduced brain activation in the left dlPFC in both 
schizophrenia patients and controls, however, smaller effects were discovered in patients. 
This effect of practice on brain activation was – likewise - associated with severity of 
negative and disorganised symptoms (van Veelen, Vink, Ramsey, & Kahn, 2010).  
Even though evidence is comparatively sparse, the literature indicates that affective 
disorders may also comprise abnormalities in fronto-subcortical networks using different 
brain imaging modalities (Soares & Mann, 1997). FMRI studies demonstrated inconsistent 
results with regards to executive function with studies indicating greater (Harvey et al., 2005; 
Matsuo et al., 2006), less, or no differences in activation when comparing depressed 
patients with HC (for review, see Rogers et al., 2004). Greater activation in patients was 
found, e.g. in the dlPFC and ACC in medicated (Harvey et al., 2005) and un-medicated 
patients (Matsuo et al., 2006). In the case of reports for hyper-activation, findings may be 
interpreted that cognitive capacity might be impaired in depressed patients and the same 
neural network needs to recruit more brain resources in those patients as compared to 
healthy individuals, in order to preserve a comparable working memory performance (Harvey 
et al., 2005). Hyper-activation of the cingulate cortex appears to sustain even with remission 
of depressive symptoms. With the dorsal anterior cingulate being crucial for cognitive and 
the ventral anterior cingulate being crucial for emotional processes, alterations in brain 
function are still abnormal even when patients’ mood and other symptoms have improved 
(Schoening et al., 2009). This could reflect persistent changes in neuronal networks after a 
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MD episode or compensatory mechanisms to maintain performance (Schoening et al., 
2009). 
Considering the young age and early stage of mental health problems of the clinical 
participants in this study, as compared to the previously presented studies, it is conceivable 
that the latter present with far more pronounced changes in brain activation. Due to the lack 
of evidence of brain imaging studies in working memory in youth and early stage disorders, 
studies including healthy participants with a family history of schizophrenia and depression 
will be described, compared to which the current clinical participants are assumed to present 
with more pronounced changes in brain activation. Despite no behavioural differences in 
accuracy and reaction time, healthy siblings of schizophrenia patients showed a robust 
increased response of the right dlPFC, and bilateral inferior parietal lobule, and robust hypo-
activation of the left medial frontal gyrus and left precuneus, PCC, thalamus and right 
hippocampus, compared to HC. This quantitative difference in brain activation implies that 
qualitative differences in information processing may exist in certain brain areas, without 
resulting in performance deficits (Callicott et al., 2003a). Similarly, an over-activation of 
diverse brain areas was observed in the offspring of depressed patients during a verbal 
working memory task. However, in that case, increased responses were observed in the 
lateral occipital, superior temporal and superior parietal cortex (Mannie, Harmer, Cowen, & 
Norbury, 2010). The presence of alterations of brain activation during working memory 
processes in healthy relatives of individuals with schizophrenia (Callicott et al., 2003a) and 
depression (Mannie et al., 2010), as well as the observation that deficits persist even after 
remission of depressive disorder for example (Schoening et al., 2009), indicate that these 
deficits might be a vulnerability marker for the respective disorders (Mannie et al., 2010). 
Similarly to studies on healthy individuals with a family history of depression and 
schizophrenia, changes of brain activation in patients with depression did not translate into 
behavioural deficits: Actual working memory performance appears to be mostly intact in 
young to middle-aged depressed patients (Grant, Thase, & Sweeney, 2001; Harvey et al., 
2005; Purcell, Maruff, Kyrios, & Pantelis, 1997), and only more severely impaired in older 
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hospitalised patients with chronic depressive conditions (Barch et al., 2003). Depression and 
age may have additive effects on executive functioning, and therefore leading to more 
distinct deficits (Snyder, 2013). A further factor that might contribute to executive functioning 
deficits is comorbidity. Some evidence suggests that anxiety disorders and trait anxiety are 
associated with executive functioning deficits, in a sense that co-occuring mental disorders 
may have an additive effect on respective impairments (Snyder, 2013). Taken together, 
performance deficits in working memory paradigms appear to be a function of severity of 
overall impairment, instead of being a distinct characteristic for any diagnostic category. 
A variable that might moderate working memory performance and brain activation 
during these processes, is stress. Acute psychosocial stress was found to impair working 
memory performance in healthy males (Luethi, Meier, & Sandi, 2009), especially when 
cognitive load was high (Oei, Everaerd, Elzinga, Van Well, & Bermond, 2006). 
Glucocorticoid receptor agonists given to male rats into the medial PFC, led to an 
impairment of working memory (Barsegyan, Mackenzie, Kurose, McGaugh, & Roozendaal, 
2010). This experimentally induced effect of decreased memory performance after 
glucocorticoid administration has been confirmed by human studies, when administration 
took place before memory retrieval (Het, Ramlow, & Wolf, 2005), and was further found to 
lead to decreases in hippocampal and PFC activation during declarative memory retrieval 
using fMRI (Oei et al., 2007). Experimentally induced psychological stress elicited reduced 
activity in the dlPFC and reduced deactivation of the PCC and orbitofrontal cortex (areas 
constituting the default-mode network) in healthy females during working memory processes 
(Qin, Hermans, van Marle, Luo, & Fernandez, 2009). 
The aim of this study was to compare working memory performance and brain 
activation during a verbal n-back task between clinical participants with early mental health 
issues and HC. Further, brain activation of individuals scoring high on symptom score 
measures for psychotic, depressive and anxiety symptoms and psychological distress were 
compared with low symptom scores, and individuals with low social and role functioning 
were compared to high functioning individuals, and HC. Further covariates such as 
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antidepressant medication, chronic stress and working memory performance (accuracy) 
were considered for the fMRI analyses. Due to the young age and early stage and moderate 
severity of mental illness, no difference in performance between clinical participants and HC 
was hypothesised. Given the inconsistency of findings in terms of activation differences with 
hypo- and hyper-activation in psychotic and depressive patients or relatives of patients, e.g. 
of the dlPFC, and other cortical and subcortical areas, this study looked exploratively at 
potential activation differences as compared to HC in this very heterogeneous sample of 
young help-seeking clinical participants with diverse early mental health problems. Grouping 
into high symptom and low functioning was assumed to exacerbate brain activation when 
comparing to HC. Chronic stress was measured by means of hair samples, and 
hypothesised to correlate with activation of brain areas involved in working memory. 
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5.2 Methods 
5.2.1 Participants 
35 clinical participants who were experiencing psychological distress and 35 HC 
participated in this study. 1 clinical participant was excluded due to image distortion and 1 
HC due to not pressing the correct button for the task. Both groups were recruited the same 
way as described in detail in Chapter 2 and Section 4.2.1. Exclusion criteria for both groups 
were a lack of sufficient English and cognitive ability to provide informed consent and 
adequately complete the assessments, neurological disorder, seizures, or significant head 
injury and any contraindications for MRI. Participants had normal or corrected-to-normal 
vision and hearing. HC were age, gender, occupation and education matched, and required 
to have no personal (assessed using the Structured Clinical Interview for DSM disorders 
screen and report ("SCID", American Psychiatric Association, 2000)) or first-degree family 
history of mental illness. The study was approved by the local ethics committee and 
participants gave their informed consent. 
 
5.2.2 Measures 
Demographic information covered participants’ age, gender, ethnicity, occupation 
and highest qualification. Handedness was enquired via self-report as potential confounder 
for the MRI. Use of psychiatric medication such as antidepressants, neuroleptics, beta-
blockers, anticonvulsants in the past 6 months was gathered. Interview and self-report 
measures from the baseline clinical assessment were used, with median time from the first 
clinical assessment to scanning being 63.5 days (range 5 - 199 days). 
The CAARMS, and SOFAS were employed to determine UHR status, the presence 
of PLE and threshold psychosis (as described in Section 2.5). QIDS, OASIS, K-10, and 
Social and Role scale were further utilised to compare brain activation of clinical participants 
with high and low symptom scores and high and low functioning, with the respective other 
group of clinical participants and HC. Cut-offs and classifications are illustrated in Table 5.2. 
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Table 5.2 
Cut-offs for clinical measures and functioning for brain activation comparisons 
 High scores Low scores 
CAARMS Psychotic (n=3) 
UHR (n=6) 
PLE (n=8) 
 
No significant psychotic symptoms (n=17) 
QIDS 
 
 
OASIS 
 
K-10 
 
 
Social  
Functioning 
 
Role 
Functioning 
Moderate to severe depressive symptoms 
(Score ≥11) (n=19)  
 
Anxiety diagnosis (Score ≥8) (n=24) 
 
Severe mental disorder (Score ≥30) 
(n=20) 
 
Moderate impairment to superior 
functioning (Score 6-10) (n=21) 
 
Moderate impairment to superior 
functioning (Score 6-10) (n=19) 
None to mild depressive symptoms (Score 
<11) (n=15) 
 
No anxiety diagnosis (Score <8) (n=10) 
 
Up to moderate mental disorder (Score 
<30) (n=13) 
 
Serious impairment to extreme dysfunction 
(Score 1-5) (n=13) 
 
Serious impairment to extreme dysfunction 
(Score 1-5) (n=15) 
Notes. CAARMS=Comprehensive Assessment of At-Risk Mental States, QIDS=Quick Inventory of 
Depressive Symptoms, OASIS=Overall Anxiety Severity and Impairment Scale, K10=Kessler 
Psychological Distress Scale, UHR=ultra-high risk, PLE=psychotic-like symptoms. 
 
 
Perceived stress and cortisol levels 
Perceived stress (as measured with the PSS (Cohen et al., 1983) (for the past 
month) and chronic cortisol levels (for the past 3 months) were determined via scalp hair 
samples (for detailed information, see Section 4.2). 
 
5.2.3 Imaging 
5.2.3.1 Task 
Participants underwent one run of a 6 minutes fMRI scan including the 0 and 2-back 
version of a verbal n-back task, being presented with sequences of letters in the centre of 
the screen. In the 0-back condition participants were required to indicate with the index 
finger of their dominant hand, whenever the letter “X” appeared. During the 2-back condition, 
the task was to similarly press the same button, however, when participants saw a letter that 
was the same as the one before last presented. Each of those blocks lasted for 24 seconds, 
and every two blocks were separated by 38 seconds of rest. The block order was the 
following: 0 - 2, rest, 0 - 2, rest, 2 - 0, rest, 2 - 0, rest. During rest conditions a fixation cross 
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was presented in the centre of the screen, followed by two fixation crosses, indicating the 
beginning of the next block/the end of the task. Within each block 12 letters were shown, 
each for 2 seconds, with 3 of each block being targets (see Figure 5.1). The memory 
condition (2-back) was contrasted with the 0-back as sensori-motor and attentional control 
condition (Glahn et al., 2005). In total, 169 whole-brain fMRI volumes were obtained. High- 
and low-performing clinical participants were determined by using a median-split of accuracy 
in the 2-back condition for the whole sample (median = 0.955) and for cortisol covariance 
analyses (median = 10.98pg/mg) and compared with HC. 
 
 
 
 
Figure 5.1. Experimental design of n-back working memory task. 
 
The n-back paradigm was chosen as working memory paradigm as it enables to 
synthesise and compare results across different studies and populations (Owen et al., 2005), 
and a 2-back condition was chosen as memory condition to evoke sufficient activation of 
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resources, but without compromising the validity of results by employing a too difficult task, 
so that the ability to successfully perform would decrease (Callicott et al., 1999). 
5.2.3.2 Data acquisition 
The study was conducted at the Birmingham University Imaging Centre using a 3T 
Philips Achieva MR scanner for obtaining fMRI (169 dynamics, ascending order, TE = 35 
msec, whole-brain coverage, TR = 2.2 seconds, voxel size 2.5 x 2.5 x 3 mm) and high-
resolution 3D T1-weighted MRI data using a 32-channel head coil. T1-weighted images (TR 
= 8.4 msec, TE = 3.8 msec, flip angle = 8°, FOV = 288 x 232 x 175 mm, voxel size 1 x 1 x 1 
mm) were co-registered to the fMRI data for localisation.  
 
5.2.3.3 Data analysis 
Behavioural data was analysed using E-Prime Professional 2.0 (Schneider & 
Zuccoloto, 2007). MRI scans were automatically processed with statistical parametric 
mapping software (SPM8, Friston, The Welcome Department of Cognitive Neurology, 
London, UK; http://www.fil.ion.ucl.ac.uk/spm). 
Functional scans were realigned with the middle scan as a reference. Motion was 
corrected using ArtRepair (http://spnl.stanford.edu/tools/ArtRepair/ArtRepair.htm) in SPM8, if 
rotations were more than 2 degrees or translations more than 2.5 mm. Algorithms of this 
software reduce residual errors by automatically detecting and removing noisy volumes, 
slices, trends, and voxel-wise spikes in the data (Mazaika, Hoeft, Gover, & Reiss, 2009). 
Images were normalised using Montreal Neurological Institute (MNI) templates (Talairach & 
Tournoux, 1988) and smoothed with a 5 × 5 × 6 mm full width at half maximum (FWHM) 
Gaussian kernel. First-level analyses included modelling of blood-oxygenation level-
dependent (BOLD) signal changes of the 2- and 0-back condition individually for all 
participants. Motion parameters were included as regressors in each individual’s first level 
analysis. 
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The statistical parametric maps from each individual from both clinical participants 
and HC were then compared using independent samples t-test at the second level. ANOVA 
were used when splitting clinical participants into high and low symptom, functioning, and 
accuracy scores and comparing the resulting two groups with HC. Additional regression 
analyses were conducted in the clinical group to see if clinical and functioning measures 
positively or negatively correlated with brain activation, in order to determine whether a 
dimensional perspective using total scores, contributes to understanding changes in brain 
activation during working memory.  ANCOVA were employed for determining the potential 
effect of cortisol and perceived stress levels on brain activation when comparing clinical 
participants (n = 26) with HC (n = 26). Individual maps for clinical participant and control 
group and group comparisons were contrasted for 2-minus-0-back condition. Only clusters 
with a size greater than 10 contiguous voxels were reported. Voxel-wise statistical analysis 
was employed with threshold-free cluster enhancement (TFCE) (Smith & Nichols, 2009) and 
FWE-correction for multiple comparisons for all analyses thresholded at p < 0.05. TFCE was 
employed which optimises areas of signal that show spatial contiguity without being reliant 
upon hard threshold-based clustering. An algorithm runs though the image, with the aim to 
better distinguish between signal and noise (Smith & Nichols, 2009).  
Demographic information, and accuracy and reaction time of the n-back task was 
compared for clinical participants and HC, using t-, U- and Χ
 
2-tests. Spearman correlations 
were conducted to investigate the association between n-back task performance and cortisol 
and perceived stress levels. 
 
 
 
 
 
CHAPTER FIVE: BRAIN HYPO-ACTIVATION DURING WORKING MEMORY                        
	  
	  103	  
5.3 Results 
5.3.1 Demographic, behavioural and clinical data 
Clinical participants and HC did not differ in terms of age, gender, handedness, 
occupation and highest qualification, however, the majority of the clinical sample was White-
British, whereas HC were more mixed in terms of ethnicity (see Table 5.3). The time from 
clinical baseline assessment to the scan date ranged from 5-199 days, with a median time of 
63.5 days. 
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Table 5.3 
Demographic information on clinical participants and HC 
 Clinical 
participants 
(n=34) 
HC 
(n=34) 
Test statistic p-
value 
Mean age ± SD (in years) 
Range  
 
Gender (m/f) 
 
Handedness (right/left) 
 
         20.6±2.5 
       16-25 
 
        10/24 
 
         28/6 
20.4±2.7 
16-25 
 
6/28 
 
31/3 
t(66)=0.29 
 
 
Χ
 
2(1)=1.31 
 
Χ
 
2(1)=1.15 
0.78 
 
 
0.25 
 
0.28 
Ethnicity 
      White1 
      Asian2 
      Black3 
      Mixed-race4  
 
Occupation 
      University student5 
      College/A-Levels 
      Unemployed 
      Employed6 
      Homemaker 
 
 
28 
1 
2 
    3 
 
 
10 
11 
5 
6 
2 
 
 
18 
7 
4 
    5 
 
 
17 
6 
2 
9 
0 
 
 
 
Χ
 
2(3)=7.84 
 
 
 
 
 
Χ
 
2(4)=7.17 
 
 
 
0.05* 
 
 
 
 
 
0.13 
Highest qualification 
      University7 
      A-Levels8 
      GSCE9 
      No qualification 
 
Psychiatric medication 
     Antidepressants 
     Neuroleptics 
     Beta-blockers 
     Anticonvulsants 
 
 
4 
16 
13 
1 
 
 
18 
1 
1 
1 
 
9 
19 
6 
0 
 
 
0 
0 
0 
0 
 
 
Χ
 
2(3)=5.76 
 
 
 
 
Χ
 
2(1)=26.25 
Χ
 
2(1)=0.98 
Χ
 
2(1)=0.98 
Χ
 
2(1)=0.98 
 
 
0.12 
 
 
 
 
<0.001*** 
0.32 
0.32 
0.32 
Performance on n-back task 
     0-back (Median % correct; range) 
 
     2-back (Median % correct; range) 
 
     Overall n-back (Median % correct; range) 
 
     0-back RT (Median, in msec; range) 
 
     2-back RT (M±SD, in msec) 
     Overall n-back RT (M±SD, in msec) 
 
100; 0.04 
 
96; 0.22 
 
98; 0.11 
 
473; 370 
 
619±117 
540±86 
 
100; 
0.02 
97; 0.17 
 
99; 0.07 
 
444; 
299 
617±129 
528±82 
 
U=475.5, Z=-
2.25 
U=497, Z=-
1.02 
U=471.5,Z=-
1.34 
U=510,Z=-0.83 
 
t(66)=0.07 
t(66)=0.65 
 
0.02* 
 
0.31 
 
0.18 
 
0.4 
 
0.95 
0.58 
Notes. HC=healthy controls, M=mean, SD=standard deviation, m=male, f=female, RT=reaction time.  
1 White-British & White-Other, 2 Asian-Pakistani, Asian-Bangladeshi & Other Asian, 3 Black-African,    
4 Mixed-Race White-Black-Caribbean, 5 Undergraduate and postgraduate university students,              
6 Working full or part-time, 7 Bachelor or Master degree, 8 A-Levels, National Vocational Qualification 
(NVQ) Level 4, or equivalent, 9 General Certificate of Secondary Education (GCSE, year-10 
equivalent) or NVQ level 1 or 2, * p < 0.05, *** p < 0.001. 
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There were no significant differences in 0- and 2-back reaction time and accuracy 
between clinical participants and HC (all p > 0.05), apart from a not meaningful statistically 
significant difference in median reaction time for the 0-back condition (see Table 5.3). 
Accuracy in the n-back task was significantly worse for the 2-back as compared to 0-back 
condition for the whole sample (Z = -6.11, p < 0.001), and for both clinical participants (Z = -
4.37, p < 0.001) and HC (Z = -4.3, p < 0.001). Across the overall sample, males responded 
faster in the 2-back (t (66) = -2.53. p = 0.01) and overall n-back condition (t (66) = -2.21, p = 
0.03), however there was no group x gender interaction (p > 0.05).  No further measures of 
n-back performance were correlated with gender, age and highest qualification.  
Clinical participants were on average moderately depressed (QIDS), had an anxiety 
diagnosis (OASIS) and were in general classified as having a severe mental disorder (K-10). 
Three individuals were classified as psychotic, 6 as UHR for psychosis, 8 as having PLE and 
17 as having no significant psychotic symptoms according to the CAARMS. Social 
functioning was on average moderately and role functioning on average seriously impaired 
(see Table 5.4). Neither one of the clinical measures was associated with n-back accuracy 
and reaction time (all p > 0.05). 
 
Table 5.4 
Clinical measures (n=34) 
Measure Range M±SD 
CAARMS 0-33 14.4±8.8 
QIDS 3-19 11.1±4.3 
OASIS 0-19 9.7±4.4 
K-10 (n=33) 18-49 31.4±7.3 
Social Functioning 3-9 6.1±1.7 
Role functioning     1-9     5.2±2.6 
Notes. CAARMS=Comprehensive Assessment of At-Risk  
Mental States, QIDS=Quick Inventory of Depressive  
Symptoms, OASIS=Overall Anxiety Severity and Impairment  
Scale, K-10=Kessler Psychological Distress Scale. 
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5.3.2 fMRI data 
5.3.2.1 Working memory activation in clinical participants and HC 
 
2-0 back condition mainly activated a cluster in the SFG in HC and clinical 
participants, and further clusters in the supramarginal gyrus (SMG), ACC, caudate nucleus 
and cerebellum in HC, and in the middle frontal gyrus and orbitofrontal cortex in clinical 
participants (p < 0.05, FWE-corrected) (see Figure 5.2/Table 5.5). 
 
Figure 5.2. Activation pattern of 2-0 back in (A) HC and (B) clinical participants (FWE-
corrected p<0.05). 
 
 
Table 5.5 
Brain areas, coordinates and statistics for 2-0 back activation  
for clinical participants and HC (FWE-corrected p<0.05) 
Brain area MNI coordinates TFCE 
cluster 
P 
HC 
 Superior frontal gyrus 
 Supramarginal gyrus 
 Anterior Cingulate Cortex  
 Caudate nucleus 
 Cerebellum 
 
Clinical participants 
 
3 20 49 
45 -37 43 
-3 8 25 
-15 2 13  
0 -52 -20 
 
5794 
1829 
5740 
1136 
423 
 
 
<0.001*** 
<0.001*** 
0.002** 
0.001** 
0.022* 
 Superior frontal gyrus 
 Middle frontal gyrus 
 
 Orbitofrontal gyrus 
3 20 49 
27 5 55 
-42 23 28 
33 26 -2 
1651 
1491 
1116 
  1024 
<0.001*** 
<0.001*** 
   0.002** 
   0.003** 
Notes. HC=healthy controls, FWE=family-wise error-corrected, MNI= 
Montreal Neurological Institute, TFCE=threshold-free cluster enhancement,                                              
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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The left SFG (k = 545, -12 29 40, p = 0.002 FWE-corrected), hippocampus (k = 314, 
21 -34 13, p = 0.031 FWE-corrected & k = 300, 24 -37 10, p = 0.038 FWE-corrected), 
putamen (k = 307, -30 -16 -8, p = 0.035 FWE-corrected), ACC (k = 302, -9 41 13, p = 0.037 
FWE-corrected) and insula (k = 301, 27 -28 19 FWE-corrected) showed less activation in 
clinical participants with mental health issues as compared to HC (see Figure 5.3). There 
was no pattern of hyper-activation in clinical participants compared to HC during working 
memory (FWE-corrected p < 0.05).
 
Figure 5.3. Hypo-activation pattern in clinical participants (FWE-corrected p<0.05). 
 
5.3.2.2 Working memory activation, clinical measures and other covariates 
In order to observe if changes in brain activation are potentially moderated by 
severity of symptoms or impairment of functioning, clinical participants with high levels of 
clinical symptoms or low levels of functioning (as outlined in Table 5.2) were compared with 
the respective other clinical participant group and also HC using ANOVA with 6 contrasts 
(“HC minus high score”, “HC minus low score”, “high score minus HC”, “low score minus 
HC”, “high score minus low score”, “low score minus high score”). Only the contrasts “HC 
minus high score” and “HC minus low score” yielded significant results (FWE-corrected, p < 
0.05) as follows: Hypo-activation was observed for individuals with high depressive, 
psychotic, and anxiety symptoms and high general distress, low social and role functioning, 
and low psychotic symptoms and high social functioning when respectively compared to HC. 
Coordinates, labels for hypo-activated brain areas, cluster sizes and significance levels of 
the respective groupings of clinical participants as compared to HC, are illustrated in Table 
5.6.  
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Table 5.6 
Brain areas, coordinates and statistics of hypo-activation when comparing high/low 
symptomatic and high/low functioning clinical participants with HC for 2-0 back activation 
(FWE-corrected p<0.05) 
Brain area MNI coordinates Cluster size P 
High depressive symptoms vs HC 
 Superior frontal gyrus 
 Precentral gyrus 
 Orbitofrontal cortex 
 Supramarginal gyrus 
 Thalamus 
 Putamen 
 Caudate nucleus 
 
High psychotic symptoms vs HC 
 
-12 29 40  
51 8 28 
-36 26 -8 
-27 -40 37 
-24 29 -2 
33 -4 -8 
-15 8 19 
 
566 
327 
326 
325 
319 
319 
319 
 
 0.004** 
0.043* 
0.043* 
0.044* 
0.045* 
0.045* 
0.045* 
 Superior frontal gyrus 
 Hippocampus 
 Caudate nucleus 
 
Low psychotic symptoms vs HC 
 Postcentral gyrus 
 Middle temporal gyrus 
 Anterior cingulate cortex 
 
High anxiety symptoms vs HC 
 Superior frontal gyrus 
 Temporal lobe 
 
 Precentral gyrus 
 Insular cortex 
 Posterior cingulate cortex 
 Anterior cingulate cortex 
 
 Premotor cortex 
 Parahippocampal gyrus 
 
High general distress vs HC 
 Superior frontal gyrus 
 Insula 
 Temporal lobe 
 Thalamus 
 Caudate nucleus 
 Precentral gyrus 
 Posterior cingulate cortex 
  
 
Low role functioning vs HC 
 Superior frontal gyrus 
 Insula 
 Caudate nucleus 
 Paracingulate gyrus 
 Insula 
 Posterior cingulate cortex 
 
Low social functioning vs HC 
 Brainstem 
 Anterior cingulate cortex 
 
 
24 -1 40 
36 -10 -14 
-21 23 7 
 
 
39 -22 34 
39 -28 -5 
6 8 25 
 
 
-12 29 43 
42 -40 -8 
21 -34 13 
-24 -22 49 
33 8 -5 
9 -37 43 
-9 41 13 
-12 38 16 
-15 -16 52 
21 -34 -5 
 
 
-12 26 43 
33 8 -5 
42 -40 -8 
18 -22 -2 
15 2 22 
-24 -22 49 
9 -28 34 
-15 -37 34 
 
 
-12 26 40 
-33 5 -11 
9 11 16 
18 44 1 
-36 -4 7 
-12 -13 34 
 
 
-6 -25 -11 
-6 5 28 
-15 29 16 
-15 20 28 
575 
333 
323 
 
 
287 
273 
267 
 
 
623 
335 
305 
299 
378 
293 
292 
290 
285 
285 
 
 
680 
327 
325 
316 
310 
306 
298 
296 
 
 
591 
356 
345 
329 
316 
302 
 
 
386 
371 
305 
301 
0.004** 
0.032* 
0.036* 
 
 
  0.037* 
  0.044* 
  0.047* 
 
 
    0.001** 
  0.027* 
  0.039* 
  0.040* 
  0.023* 
  0.044* 
  0.044* 
  0.046* 
  0.048* 
  0.049* 
 
 
<0.001*** 
        0.03* 
  0.031* 
  0.035* 
  0.037* 
  0.038* 
  0.043* 
  0.044* 
 
 
  0.005** 
 0.030* 
 0.033* 
 0.039* 
 0.044* 
 0.049* 
 
 
  0.019* 
0.021* 
0.047* 
0.05 
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 Superior frontal gyrus 
 Caudate nucleus 
  
 Middle temporal gyrus 
 Putamen 
 Inferior temporal gyrus 
 Insula 
 Posterior cingulate cortex 
 Paracingulate gyrus 
 Occipital cortex 
 
High social functioning vs HC 
 Paracingulate gyrus 
 Precentral gyrus 
 Somatosensory cortex 
 Thalamus 
 
 
 Anterior cingulate cortex 
 Posterior cingulate cortex 
 Insula 
-12 29 40 
-18 5 25 
-12 -4 22 
51 -46 -5 
-33 -16 -8 
39 -52 -2 
-33 -34 4 
9 -31 37 
-12 23 25  
39 -61 -8  
 
 
-12 26 40 
51 8 25 
-39 -7 28 
12 -19 16 
18 -22 -2 
9 -22 -2 
-6 20 19 
6 -34 19 
33 14 -2 
352 
324 
306 
321 
315 
312 
309 
303 
301 
301 
 
 
379 
374 
319 
297 
297 
280 
291 
285 
285 
0.026* 
0.035* 
0.047* 
0.037* 
0.042* 
0.043* 
0.046* 
0.049* 
0.05 
0.05 
 
 
0.013* 
0.015* 
0.027* 
0.036* 
0.037* 
0.045* 
0.039* 
0.042* 
0.043* 
Notes. HC=healthy controls, FWE=family-wise error-corrected, MNI=Montreal Neurological Institute,       
* p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Further regression analyses with total scores of the CAARMS, QIDS, OASIS, social 
and role functioning (n  = 34), and K-10 (n = 33) did not reveal positive or negative 
correlations with brain activation during working memory performance. When clinical 
participants were split into high (n = 17) and low-performing (n = 17) individuals according to 
their accuracy in the working memory (2-back) condition and compared to HC, using an 
ANOVA, only a hypo-activation in the low-performing group as compared to HC was evident 
in the ACC (k = 739, 6 5 25, p = 0.002 FWE-corrected), SFG (k = 368, k = 368, 21 -4 49, p = 
0.034 FWE-corrected), Heschl’s gyrus (k = 334, 45 -19 7, 0.047 FWE-corrected & k = 334, 
48 -22 4, p = 0.047 FWE-corrected), and precentral gyrus (k = 329, 15 -10 55, p = 0.049 
FWE-corrected). Clinical participants who were taking antidepressants demonstrated no 
different brain activation as compared to clinical participants without antidepressant 
medication (FWE-corrected, all p > 0.05).  
 
5.3.2.3 Brain activation, task performance, cortisol, and perceived stress levels 
There was a negative association between accuracy in the 2-back and overall n-back 
condition with cortisol levels and with perceived stress levels (see Table 5.7). Neither a 
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association between 0-back condition and cortisol or with perceived stress levels was 
observed, nor a correlation between reaction time and both of the investigated stress 
parameters.  
 
Table 5.7 
Spearman correlations between task accuracy  
and cortisol and perceived stress levels (n=52) 
Brain area rS P 
Cortisol  
  2-back accuracy 
  overall n-back accuracy 
 
Perceived Stress 
 
-0.301 
-0.309 
 
 
0.030* 
0.026* 
 
  2- back accuracy 
  overall n-back accuracy 
-0.276 
-0.313 
0.048* 
    0.024* 
Notes. * p < 0.05. 
 
 
Figure 5.4. Correlations between (A) hair cortisol and 2-back task accuracy, (B) hair cortisol 
and overall n-back task accuracy, (C) perceived stress score and 2-back task accuracy, and 
(D) perceived stress score and overall n-back task accuracy. 
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No areas in the brain correlated with increased or decreased activation and cortisol 
or perceived stress levels when correlating cortisol and perceived stress with brain activation 
in clinical participants and HC individually, and when comparing clinical participants with HC 
using ANCOVA (all p > 0.05, FWE-corrected). Due to the correlation between accuracy and 
cortisol levels, clinical participants were classified into high- (n =14) vs low- (n = 12) 
performing, and compared with HC using a three-group ANCOVA. However, likewise no 
brain areas correlated with cortisol in this analysis (all p > 0.05, FWE-corrected).  
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5.4 Discussion 
This study looked at differences between young people with early mental health 
problems and HC in brain activation during working memory performance, the association of 
brain activation with clinical symptoms, functioning, hair cortisol levels and indices of task 
performance. The n-back task activated mainly frontal, but also parietal and marginally 
subcortical brain regions in HC and clinical participants in the superior and middle frontal 
gyrus, and SMG, ACC, orbitofrontal cortex and basal ganglia, overlapping or closely 
adjacent to those areas typically detected as relevant for a verbal working-memory task in 
previous literature, such as the dlPFC, and posterior parietal cortex (Owen et al., 2005). 
Clinical participants with mental health issues showed a reduced response in the SFG, ACC, 
insula, putamen and hippocampus, however, no hyper-activation was detected in clinical 
participants. Comparing clinical participants with high symptom and low functioning scores to 
HC replicated the finding of hypo-activation, however of rather distributed brain areas. No 
meaningful behavioural group differences in reaction time and accuracy, and no associations 
with cortisol, and perceived stress levels, and with dimensional scores of the respective 
clinical and functioning measures were detected.  
The finding of intact behavioural working memory performance is in agreement with 
previous literature in young to middle aged depressed patients (Grant et al., 2001; Harvey et 
al., 2005; Purcell et al., 1997). Even though abnormalities in BOLD signal, especially in 
frontal areas such as the dlPFC, were usually identified in studies investigating 
schizophrenia (Barch et al., 2003; Glahn et al., 2005), depression (Harvey et al., 2005; 
Matsuo et al., 2006) and family history of these disorders (Callicott et al., 2003a), it is yet not 
fully clear why some report decreases and other increases (Callicott et al., 2003a). One 
possible explanation is coming from a study dividing schizophrenia patients into high- and 
low-performing individuals. Patients who sustained a comparable performance to HC, 
showed greater prefrontal activation, whereas patients who achieved lower accuracy, 
showed decreased prefrontal activation (Callicott et al., 2003b). The current study found 
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decreases in frontal brain activation when behavioural performance was intact. Alterations of 
brain function during working memory processes appear to emerge during these early 
stages of mental problems, but with the task encompassing moderate cognitive load, these 
differences might not yet translate into behavioural deficits. 
With task difficulty being a factor that has an important effect on the strength and extent 
of the BOLD response, more difficult conditions might have been associated with greater 
brain activation than easy conditions (Fu et al., 2002), and behavioural impairments may 
have therefore only become visible when cognitive load is high (Callicott et al., 1999; Walsh 
et al., 2007), together with further or more pronounced alterations in clinical participants’ 
brain activation. The 2-back condition that was used, may have been too easy to elicit more 
distinct differences between groups, given the young age and comparatively high 
educational level of both clinical participants and HC. This notion is further supported by 
finding a ceiling effect in both groups in accuracy and reaction time. However, the current 
sample consisted of adolescents and young adult outpatients. Only 3 of the clinical 
participants were experiencing a psychotic episode according to the CAARMS at some point 
in the past year, and depressive symptoms existed on a moderate level. This is opposed to 
other studies that often looked into established disorders of inpatients with multiple 
recurrences of episodes, a more extended length and more pronounced severity of illness, 
and it therefore may simply be that working memory performance is still intact in the current 
sample.   
When high-symptomatic and low-functioning clinical participants were compared to low-
symptomatic and high-functioning clinical participants, no difference in brain activation was 
discovered, however, generally high-symptomatic and low-functioning clinical participants 
demonstrated hypo-activation of diverse and distributed frontal, parietal, temporal, insular, 
cingulate and subcortical brain areas as compared to HC. This demonstrates the robustness 
of the finding of hypo-activation during working memory processes, but also that symptom 
severity of some clinical measures might moderate this effect. Clinical participants scoring 
high on depressive, and anxiety symptoms, psychological distress and low on role 
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functioning showed brain hypo-activation as compared to HC, whereas this difference was 
not evident for psychotic symptoms and social functioning, where both clinical participant 
groups displayed deviant brain activation as compared to HC. One possible explanation for 
this finding is that the cut-offs used for these two clinical measures are not relevant for 
differentiating brain activation during working memory processes in this early stage of 
disorder. Regression analyses of clinical and functioning scores of the clinical group did not 
reveal correlations with brain activation. Even though symptom severity is considered to be 
relevant for brain activation as demonstrated when splitting clinical participants into high and 
low symptom and functioning scores, this finding could not be replicated when using a rather 
dimensional approach. This could possibly be due to the reduced power of the latter 
analyses with only including clinical participants instead of the whole sample, or is an 
expression of a problem with approaching this from a dimensional perspective. 
The finding of no differences in brain activation between clinical participants taking 
antidepressants and those who were not, is consistent with the observation that some 
differences persist even with remission of symptoms (Schoening et al., 2009), even though 
this study did not discover activation differences in the cingulate between clinical participants 
and HC. It further confirms that antidepressant treatment may not particularly be affecting 
the neural circuits involved in working memory. 
Cortisol and perceived stress levels were negatively associated with working memory 
accuracy across the whole sample. As opposed to the hypotheses, no correlation between 
chronic stress levels, as measured by hair cortisol and perceived stress, and brain activation 
in the working memory network was confirmed. This may be due to the fact that previous 
studies looked into the acute effects of psychosocial stress (Lueti et al., 2009; Oei et al., 
2006) or glucocorticoid administration (Het et al., 2005) in healthy individuals, whereas the 
current study explored and compared chronic stress of mentally ill patients with HC. Clinical 
participants showed significantly increased cortisol levels as well as perceived stress (see 
Section 4.3), however, this may involve different pathways in the brain than acutely 
increased cortisol levels, and/or only show with persistence of illness or illness progression. 
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There are certain limitations to the study that have to be acknowledged. Firstly, the 
conduction of multiple comparisons has to be acknowledged. Even though stringent FWE-
correction was used for within-analysis comparisons on the voxel-level, multiple 
comparisons were conducted for dividing the clinical group into high vs low scores for clinical 
and functioning measures, performance, and hair cortisol levels, each consisting of six 
contrasts, respectively. However, this distinction of the clinical group replicated the finding of 
brain hypo-activation of the generally more impaired clinical participants as compared to HC. 
Secondly, there is a large number of potential confounders while scanning, e.g. the level of 
experienced anxiety and arousal (Paus et al., 2008) during the fMRI session that may 
influence task performance and brain activation, as well as head motion, whereas motion 
parameters were included as covariate of no interest in the analyses and excessive head 
motion was corrected using specialised software. Albeit mild to moderate claustrophobia 
tendencies were observed for both clinical participants and HC (see Appendix B-18, MRI 
safety screening questionnaire, question “Are you claustrophobic?”), no proper measure was 
used that could give further insight into this issue. Similarly, as outlined in Section 4.4, the 
time elapsed between clinical assessments and brain scan is an issue for the interpretation 
of fMRI data that involves ANOVA and regression analyses with interview and self-report 
data, as both imaging and clinical data contains highly state-specific information which in 
most cases has been collected on different assessment dates. Further, no measure of 
general intelligence or socio-economic status was employed that could help to gain insight 
into pre-existing group differences, however, no differences in highest qualification or 
employment status were detected that indicate that the observed decreased brain activation 
in clinical participants might be due to these covariates. As opposed to other, less controlled 
studies, the current investigation included HC only if they had no family or personal history of 
any mental disorders that may be associated with abnormal brain activation. This is of 
particular relevance since family history, e.g. of schizophrenia (Callicott et al., 2003a) or 
depression (Mannie et al., 2010) was found to be associated with abnormal brain activation 
during working memory.  
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Together, there was a hypo-activation, mainly of frontal areas and the thalamus and 
brainstem in individuals with early mental health issues as compared to HC. Symptom and 
functioning scores moderated this finding, however, no behavioural differences and no 
association with cortisol levels were observed. The current sample was characterised by a 
young age and comparatively short duration of illness, and predominantly mild to moderate 
symptom severity concerning depressive, psychotic and anxiety symptoms. Longitudinal 
investigation of the sample might help to disentangle whether age, recurrence of episodes, 
length and severity of illness, and comorbidity are associated with more pronounced 
disturbances in working memory in mental illnesses such as psychosis and depression. 
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CHAPTER SIX 
SUBTLY REDUCED CONNECTIVITY OF BRAIN NETWORKS 
DURING REST  
 
Resting-state functional magnetic resonance imaging  (rs-fMRI) has revealed 
connectivity alterations in MD, anxiety, and schizophrenia as well as in at-risk individuals, in 
large-scale brain networks such as the default-mode and salience network. The aim of the 
present study was to investigate functional connectivity of brain networks in a group of 
young, help-seeking individuals with mental health problems. 32 young individuals with 
mental health issues and 32 HC underwent a 10-minute rs-fMRI scan. ICA was employed 
with independent components being estimated using a single group ICA with all 64 
individuals. A dual regression method was used to create individual representations of the 
networks. Voxel-wise permutation tests were conducted to compare spatial maps of both 
groups (p < 0.05, FWE-corrected). ICA isolated the default-mode, salience, the dlPFC as 
part of the executive-control network, the primary, medial and lateral visual, auditory, 
sensori-motor, ventral stream and left and right fronto-parietal network. The auditory and 
somatosensory network displayed significantly reduced resting-state connectivity in the 
SMG, and a trend for reduced connectivity in the PCC. Clinical participants with (sub-) 
threshold psychotic symptoms, and with moderate to severe depressive symptoms showed 
significantly reduced connectivity in networks such as the auditory and somatosensory 
network, and ventral stream as compared to HC. The ICA replicated commonly found 
resting-state brain networks in young individuals with early mental health problems and HC. 
Functional resting-state connectivity in the whole clinical group was largely intact, and more 
pronounced network alterations became only apparent when considering symptom severity. 
Longitudinal studies with larger samples are needed to illuminate altered functional 
connectivity in specific networks in the course of illness. 
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6.1 Introduction 
The human brain is a complex organisation of structurally and functionally inter-
connected areas. Large-scale brain networks constitute an integrative model of how 
disturbances of brain connectivity are associated with cognitive and affective dysfunction in 
psychiatric disorders (Menon, 2011). Brain connectivity of various mental disorders has been 
investigated on the grounds of this - on the forefront of these investigations schizophrenia 
has been proposed to involve brain dysconnectivity, especially of frontal areas (Pettersson-
Yeo et al., 2011). Deficits in the maintenance of these neurocognitive networks in other 
disorders such as depression and anxiety has been demonstrated as well (Menon, 2011). 
Depression, e.g. involves various symptoms domains (such as mood, cognition, etc.), and 
these domains can manifest at opposing ends of one and the same symptom category (e.g. 
hyper- vs hyposomnia). Therefore it is rather unlikely that the heterogeneity of depressive 
symptomatology can by explained by alterations of individual brain areas (Veer et al., 2010), 
but instead by dysregulation of multiple areas of brain circuits, amongst others including the 
PFC, ACC, amygdala, and hippocampus (Davidson, Pizzagalli, Nitschke, & Putnam, 2002). 
The large-scale networks of most interest in psychiatric disorders are the salience (SN), 
default-mode (DMN), and executive control network (ECN). The SN is anchored in the dorsal 
anterior cingulate and fronto-insular cortices; the DMN consists of the PCC, medial PFC, 
medial temporal lobe, and angular gyrus; and the ECN is a fronto-parietal system anchored 
in the posterior parietal cortex and dlPFC (Menon, 2011). These large-scale networks 
typically appear to be distinguished on the basis of whether they are up- or down-regulated 
during specific cognitive tasks, and hence described as either task-positive (being activated 
during tasks) or task-negative (being de-activated during tasks, and activated during rest), 
such as in the case of the DMN (Cole, Smith, & Beckmann, 2010; Fox et al., 2005). The SN 
usually switches between the DMN and ECN to guide behaviour, e.g. to enable access to 
attention and working memory resources when needed (Menon & Uddin, 2010). 
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Some functional brain networks are formed before the onset of puberty, but the structure 
and connectivity within these networks may be altered throughout adolescence (Stevens, 
Pearlson, & Calhoun, 2009). Stevens et al. (2009) found fewer significant connections 
between networks and increases of functional integration strength within networks with 
increasing age in healthy individuals aged 12 to 30 years. The DMN was found to be 
sparsely connected in 7-9 year old children, whereas over time these brain areas connected 
to a cohesive network in adulthood (Fair et al., 2008). Furthermore, the fronto-parietal 
network strengthens its connections with age (Fair et al., 2007). A review on functional brain 
networks (Uddin, Supekar, & Menon, 2010) summarised that brain activation during 
cognitive tasks tends to progress from diffuse activation to an increase of the magnitude of 
activation of key frontal brain areas with increasing age, constituting more efficient 
processing. A developmental over-connectivity which is followed by pruning is hypothesised 
to help the reorganisation of (sub-)cortical connectivity. Furthermore, it was reported that 
demands on the PFC decrease, with shifting demands on posterior regions, and that 
connectivity within local functional circuits of one hemisphere preceeds inter-hemispheric 
connectivity. Brain networks associated with higher cognitive functions (such as social and 
emotional processing) show most pronounced developmental effects, than for example 
visual, auditory, and sensori-motor systems, which largely mirror adult brain networks (Uddin 
et al., 2010). 
Therefore, one way to look at neurocognitive networks is to investigate spontaneous 
fluctuations of the BOLD signal when the human brain is at rest. Originally, this resting-state 
literature was model-driven and has focused on a-priori hypotheses concerning functional 
connectivity of a small number of regions of interest (ROIs) and the rest of the brain (seed-
based analyses). However, the focus has more recently shifted to data-driven analyses such 
as ICA, which emphasise connectivity patterns between multiple ROI within spatially 
dispersed networks (Cole et al., 2010). These so-called large-scale or resting-state networks 
have been reliably detected in healthy individuals, and are based on the assumption that 
these low-frequency fluctuations (0.01-0.1 Hz) of the BOLD signal represent the state of the 
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brain when goal-directed behaviour or external input is absent (Damoiseaux et al., 2006b). 
There has been a debate to whether these networks reflect neuronal connectivity or non-
neuronal artifacts (e.g. respiration or heart rate, head motion), concluding that resting-state 
functional connectivity is thought to broadly mirror structural brain connectivity (Greicius, 
Supekar, Menon, & Dougherty, 2009) and are minimally contaminated by physiological 
noise, if data is adequately pre-processed (Van Dijk et al., 2010). Further, ICA analyses 
allow to separate resting-state fluctuations of the brain from these noise-related BOLD signal 
variations (Damoiseaux et al., 2006b). Components identified in past ICA studies 
demonstrate a considerable overlap with task-induced brain connectivity patterns (Smith et 
al., 2009), and correspond to cortical networks that are involved with visual and auditory 
processing, motor and executive functioning, memory, as well as the DMN, and the 
language, dorsal attention, and fronto-parietal system (Damoiseaux et al., 2006b; Van Dijk et 
al., 2010). 
Resting-state functional connectivity is an important indicator for understanding 
abnormal brain function in mental disorders, and has the advantage of not requiring 
complicated experimental designs in clinical settings (Damoiseaux et al., 2006a).  A common 
clinical application is to utilise correlation strength between functionally connected brain 
areas as a marker to how brain systems are integrated (Van Dijk et al., 2010). Decreased 
signal intensity was found in the insula and dorsolateral ACC during an auditory task, as well 
as sustained hyper-activation of the DMN during rest in patients with schizophrenia (Nygård 
et al., 2012). Furthermore, Wotruba et al. (2013) observed functional network alterations in 
individuals at UHR for psychosis, with at-risk individuals presenting with a loss of task-
positive network – task-negative network (TPN-TNN) anti-correlation, and Dandash et al. 
(2014) reported altered cortico-striatal resting-state connectivity in UHR individuals as 
compared to HC. Pettersson-Yeo et al. (2011) reviewed the literature on schizophrenia and 
concluded – despite some inconsistencies - with connectivity reductions across all stages of 
psychotic disorder. 
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A systematic review on MD, mainly including ROI-resting-state studies, concluded with 
altered functional connectivity between areas such as the amygdala, thalamus, and ACC, 
and on the network level, the DMN, involving the medial prefrontal cortex (mPFC), PCC and 
parietal cortex (Wang, Hermens, Hickie, & Lagopoulos, 2012). Greicius et al. (2007) 
confirmed increased functional connectivity within the DMN between the subgenual 
cingulate, thalamus, orbitofrontal cortex and precuneus. Increased connectivity has further 
been demonstrated in MD patients in the TPN, specifically in lateral prefrontal and inferior 
parietal cortices, and in the TNN in the PCC and medial orbitofrontal cortex (Zhou et al., 
2009). On the contrary, decreases in functional connectivity have been revealed in 
medication-free depressed patients using ICA: Thirteen brain networks were identified – 3 of 
which displayed reduced connectivity in the affective network between the amygdala and 
anterior insula, and a network associated with attention and working memory of the left 
frontal pole, and lastly between the lingual gyrus and ventromedial visual areas (Veer et al., 
2010).  Resting-state analyses of first-degree relatives of individuals with MD showed 
decreased regional homogeneity in the insula and cerebellum as compared to HC (Liu et al., 
2010), that is, reduced similarity of time series of voxels in these areas with their nearest 
neighbours. Aberrant intrinsic functional connectivity has furthermore been observed in 
individuals with anxiety disorders, such as social anxiety (Liao et al., 2010) and after 
traumatisation (Lui et al., 2009). 
While important for adaptation to acute stressors, prolonged or excessive exposure to 
glucocorticoids such as cortisol can have damaging neurotoxic effects, such as disruption of 
synaptic plasticity (Herbert, 1998; Sapolsky, 1999). High levels of cortisol are known to be 
associated with the development of mental disorders, e.g. to induce severe mood changes 
(Herbert, 1998). Mondelli et al. (2010) further found that increased cortisol levels at baseline 
significantly predict smaller left hippocampal volume in first episode of psychosis patients 
after a 3-months follow-up scan and concluded that biological changes activated by stress, 
constitute an important factor that influences brain structure. The role of cortisol on brain 
connectivity in mental disorders has, however, been less illuminated and only studies on 
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healthy individuals have been reported so far. Thomason, Hamilton, and Gotlib (2011) 
reported greater cortisol responsivity in healthy adolescents to be associated with higher 
functional connectivity in the SN after acutely inducing social stress. Increased amygdala - 
mPFC connectivity was observed in stress responders in another study using healthy 
volunteers, as well as altered amygdala connectivity with the dlPFC, ACC, anterior 
hippocampal complex, cuneus, and pre-supplementary motor area (Quaedflieg et al., 2015).  
            The aim of this study was to extract functional connectivity networks during a resting-
state with special focus on the DMN, ECN, and SN due to their relative importance in the 
development of mental disorders, such as depression and psychosis (Menon, 2011). 
Furthermore, these networks were tested to whether they show aberrant connectivity in 
young individuals with mental health problems as compared to HC. Since clinical participants 
from this sample were on average moderately depressed, and ruminations being a frequent 
symptom that depressive patients are experiencing, these reoccurring, emotional and self-
reflective thoughts were considered to be reflected in increased resting-state connectivity 
within the DMN in the clinical group (Greicius et al., 2007). Due to the heterogeneity in 
symptomatology of the clinical sample differences between clinical participants and HC were 
assumed for the DMN, ECN, and SN, but no directed hypotheses inferred, and these 3 
networks instead exploratively looked at. Other networks were aimed to be extracted, but 
without network alterations between groups being hypothesised. Given the early disease 
stage and rather mild to moderate clinical symptomatology (as compared to most other 
studies), clinical participants were further divided into high vs low symptomatology in 
depressive, anxiety, and psychotic symptoms, psychological distress, and social and role 
functioning. This was to evaluate whether severity of symptomatology and functional 
impairment matters in terms of resting-state functional connectivity, with clinical participants 
in the high symptom and low functioning groups being hypothesised to have more 
pronounced network alterations as compared to HC (or to be the first to demonstrate 
alterations as compared to HC). A similar approach was adopted for high versus low cortisol 
levels in the clinical group since cortisol levels were found to be associated with resting-state 
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brain function in healthy individuals (Quaedflieg et al., 2015; Thomason et al., 2011), and 
clinical individuals in the high cortisol group being assumed to have more pronounced 
network alterations than the low cortisol group as compared to HC (or to be the first to 
demonstrate alterations as compared to HC).   
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6.2 Methods 
6.2.1 Participants 
35 clinical participants who were experiencing psychological distress and 35 HC 
participated in this study. 1 clinical participant was excluded due to image distortion, and 2 
clinical participants and 3 HC due to head motion being greater than 4mm. Both groups were 
recruited as described in Section 5.2.1 with identical inclusion and exclusion criteria. 
Interview and self-report measures from the baseline clinical assessment were used, with 
median time from the first clinical assessment to scanning being 63.5 days (range 5 - 138 
days). The study was approved by the local ethics committee and participants gave their 
informed consent.  
Similarly to Section 5.2.2, UHR status, the presence of PLE and threshold psychosis, 
as well as QIDS, OASIS, K-10, and social and role functioning total scores were further 
utilised to compare resting-state brain activation of clinical participants by dividing 
participants into high and low symptom and functioning scores, and comparing both groups 
with each other, and with HC. Cut-offs and classifications are illustrated in Table 6.1. Clinical 
participants were further split into high (n = 11) versus low (n = 12) cortisol levels (median = 
13.125 pg/mg), and compared with HC to investigate differences in resting-state brain 
activation. 
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Table 6.1 
Cut-offs for clinical measures and functioning for brain activation comparisons 
 High scores Low scores 
CAARMS Psychotic (n=3) 
UHR (n=6) 
PLE (n=8) 
 
No significant psychotic symptoms (n=15) 
QIDS 
 
 
OASIS 
 
K-10 
 
 
Social  
Functioning 
 
Role 
Functioning 
Moderate to severe depressive symptoms 
(Score ≥11) (n=17)  
 
Anxiety diagnosis (Score ≥8) (n=24) 
 
Severe mental disorder (Score ≥30) 
(n=19) 
 
Moderate impairment to superior 
functioning (Score 6-10) (n=21) 
 
Moderate impairment to superior 
functioning (Score 6-10) (n=17) 
None to mild depressive symptoms (Score 
<11) (n=15) 
 
No anxiety diagnosis (Score <8) (n=8) 
 
Up to moderate mental disorder (Score 
<30) (n=12) 
 
Serious impairment to extreme dysfunction 
(Score 1-5) (n=11) 
 
Serious impairment to extreme dysfunction 
(Score 1-5) (n=15) 
Notes. CAARMS=Comprehensive Assessment of At-Risk Mental States, QIDS=Quick Inventory of 
Depressive Symptoms, OASIS=Overall Anxiety Severity and Impairment Scale, K10=Kessler 
Psychological Distress Scale, UHR=ultra-high risk, PLE=psychotic-like symptoms. 
 
6.2.2 Resting-state analyses 
Resting-state scans lasted for 10 minutes, and participants were instructed to lie still. 
Individuals were asked to close their eyes, whilst letting their mind wander freely without 
thinking about anything specifically. 
 
6.2.2.1 ICA  
Rs-fMRI was chosen as additional indicator for brain function, as it is easy to perform 
(Song et al., 2011) especially for clients with mental health problems and it provided modest 
to high intra- and inter-session and multi-scan reliability (Shehzad et al., 2009). Different 
ways of conducting rs-fMRI analyses have been proposed (Song et al., 2011); in the 
following Multivariate Exploratory Linear Optimised Decomposition into Independent 
Components (MELODIC) (www.fmrib.ox.ac.uk/fsl) (Beckmann & Smith, 2004) will be used 
and described due to its exploratory value for resting-state analyses in a cohort of young 
help-seeking people with mental health problems, that has not been investigated similarly 
before. 
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ICA separates the BOLD signal into spatially independent patterns of brain activity. 
ICA is based on the assumption that the underlying components are spatially independent 
and add up linearly. Multivariate techniques such as ICA decompose the fMRI data into 
spatial maps, which enables the analysis of co-activation in spatially disparate brain regions 
(McKeown et al., 1998). It is investigated if two or more brain areas have a similar phase of 
low-frequency fluctuations (0.01 - 0.1 Hz) (Lowe, Mock, & Sorenson, 1998). This 
decomposition further allows for separation of resting-state networks from physiological 
noise such as respiration and cardiac cycle (Damoiseaux et al., 2006b). 
 
6.2.2.2 Data acquisition, pre-processing and extraction of brain networks 
T2-weighted images were acquired using a 3T Philips Achieva MR scanner (270 
dynamics, ascending order, TE = 35 msec, whole-brain coverage, TR= 2.2 seconds, voxel 
size 2.5 x 2.5 x 3 mm) and high-resolution 3D T1-weighted MRI data was acquired using a 
32-channel head coil. T1-weighted images (TR = 8.4 msec, TE = 3.8 msec, flip angle = 8°, 
FOV = 288 x 232 x 175 mm, voxel size 1 x 1 x 1 mm) were co-registered to the fMRI data for 
localisation.  
Functional scans were analysed using MELODIC software, version 3.14. Default pre-
processing steps were applied to the data sets, including brain extraction, highpass-filtering 
(100s), slice time correction, motion correction (MCFLIRT), normalisation, coregistration with 
T1 image, and spatial smoothing (FHWH = 5mm). After that, data sets from both groups 
were concatenated in time to build a single 4D dataset. The data was then decomposed into 
19 independent components (IC), describing signal variation across time courses and the 
spatial maps. A z-score for every voxel and component was computed, which reflects the 
degree of association between the time series of that voxel and the time series of each 
component. Permutation of the ICA was conducted 500 times with random conditions. To 
enable comparison of spatial maps and time courses between the two groups, GICA 3 back 
reconstruction (Erhardt et al., 2011) was employed, a method that evaluates estimation 
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accuracy to back-construct subject-specific spatial maps and time courses of the 
decomposition (Michael, Anderson, Miller, Adali, & Calhoun, 2014). The number of IC was 
chosen after visual inspection and considered to represent the networks of interest in the 
most informative way. Components were matched with networks of interest, resulting in 11 
networks: DMN, SN, dlPFC as part of the ECN, the primary, medial and lateral visual, 
auditory, sensori-motor, ventral stream, and left and right fronto-parietal network. Group 
differences were hypothesised for the DMN, ECN, and SN based on a recent review on 
aberrant brain networks in psychopathological conditions (Menon, 2011), however, 
hypotheses for none of the other networks could be inferred, and any observed network 
alterations have to be interpreted with caution due to a lack of relevant literature.  
 
6.2.2.3 Statistical analyses  
 
Dual regression generates subject-specific versions of the spatial maps and 
associated time series by using spatial maps from group-average analyses. Firstly, a 
multiple linear regression of the maps of group-average analyses of spatial maps of each 
component is conducted for each subject, resulting in 4D space-time datasets. Secondly, 
these time series are normalised and then regressed as temporal regressors in another 
multiple regression into the same 4D dataset, resulting in a set of subject-specific spatial 
maps, one per group-level spatial map. Component activations across patient and control 
group were then compared for statistically significant differences (p < 0.05, FWE-corrected) 
using FSL's randomise permutation-testing tool with 500 permutations (Beckmann, Mackay, 
Filippini, & Smith, 2009) and TFCE (see Section 5.2.3.3, Smith & Nichols, 2009). 
Demographic information was compared for clinical participants and HC, using t- and Χ
 
2-
tests.  
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6.3 Results 
6.3.1 Demographics & description of clinical sample 
Clinical participants and HC did not differ in terms of age, gender, handedness, 
ethnicity, occupation and highest qualification (see Table 6.2).	  
	  
Table 6.2 
Demographic information on clinical participants and HC 
 CP (n=32) HC (n=32) Test statistic p-value 
Mean age ± SD (in years) 
Range  
 
Gender (m/f) 
 
Handedness (right/left) 
 
20.7±2.5 
16-25 
 
10/22 
 
27/5 
20.6±2.8 
16-25 
 
5/27 
 
29/2 
 
t(62)=0.191 
 
 
Χ2(1)=0.14 
 
Χ2(1)=1.342 
 
0.849 
 
 
0.237 
 
0.426 
Ethnicity 
      White1 
      Asian2 
      Black3 
      Mixed-race4  
 
Occupation 
      University student5 
      College/A-Levels 
      Unemployed 
      Employed6 
      Homemaker 
 
 
26 
1 
2 
    3 
 
 
10 
9 
5 
6 
2 
 
 
18 
6 
4 
    4 
 
 
16 
5 
2 
9 
0 
 
 
 
Χ
 
2(3)=5.835 
 
 
 
 
 
Χ
 
2(4)=6.413 
 
 
 
0.12 
 
 
 
 
 
0.17 
Highest qualification 
      University7 
      A-Levels8 
      GSCE9 
      No qualification 
 
Psychiatric medication 
     Antidepressants 
     Neuroleptics 
     Beta-blockers 
     Anticonvulsants 
 
 
4 
16 
11 
1 
 
 
18 
1 
2 
1 
 
9 
18 
5 
 0 
 
 
0 
0 
0 
0 
 
 
Χ
 
2(3)=5.291 
 
 
 
 
Χ
 
2(1)=24.421 
Χ
 
2(1)=0.984 
Χ
 
2(1)=2.001 
Χ
 
2(1)=0.984 
 
 
0.152 
 
 
 
 
<0.001*** 
0.321 
0.157 
0.312 
Notes. CP=clinical participants, HC=healthy controls, SD=standard deviation, m=male, f=female          
1 White-British & White-Other, 2 Asian-Pakistani, Asian-Bangladeshi & Other Asian, 3 Black-African,       
4 Mixed-Race White-Black-Caribbean, 5 Undergraduate and postgraduate university students,               
6 Working full or part-time, 7 Bachelor or Master degree, 8 A-Levels, National Vocational Qualification 
(NVQ) Level 4, or equivalent, 9 General Certificate of Secondary Education (GCSE, year-10 
equivalent) or NVQ level 1 or 2, *** p < 0.001. 
 
Clinical participants were on average moderately depressed (QIDS), had an anxiety 
diagnosis (OASIS) and were in general classified as having a severe mental disorder (K-10). 
3 individuals were classified as psychotic, 6 as UHR for psychosis, 8 as having PLE and 15 
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as having no significant psychotic symptoms according to the CAARMS. Social functioning 
was on average moderately and role functioning on average seriously impaired (see Table 
6.3).  
 
Table 6.3 
Clinical measures (n=32) 
Measure Range M±SD 
CAARMS 0-33 14.8±8.9 
QIDS 
Ruminative Style 
3-19 
22-40 
10.9±4.3 
30.9±5.1 
OASIS 1-19 10.0±4.2 
K-10 (n=31) 18-49 31.6±7.2 
Social Functioning 3-9 6.1±1.7 
Role functioning     1-9     5.1±2.6 
Notes. CAARMS=Comprehensive Assessment of At-Risk  
Mental States, QIDS=Quick Inventory of Depressive  
Symptoms, OASIS=Overall Anxiety Severity and Impairment  
Scale, K-10=Kessler Psychological Distress Scale 
 
6.3.2 Extraction of resting-state networks from single group ICA 
A single group ICA which included 32 clinical participants and 32 HC and used 19 IC, 
extracted 11 relevant network components comprising of 11 functionally connected networks 
of brain areas associated with the DMN (IC 1 & 2), the SN (IC-3), the dlPFC as part of the 
ECN (IC-4), right (IC-5) and left (IC-6) fronto-parietal network, the medial (IC-7), primary (IC-
8) and lateral (IC-9) visual, auditory (IC-10), somatosensory (IC-10) and ventral stream 
network (IC-11). The extraction of the DMN comprised of a posterior (IC-1) and a frontal 
component (IC-2), and the auditory and somatosensory network both constitute one 
component. Networks are illustrated in Figure 6.1.	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Figure 6.1. Single group independent component analysis extracting functionally relevant 
networks in 32 clinical participants and 32 HC. IC-1 (posterior component of default-mode 
network, DMN), IC-2 (frontal component of DMN), IC-3 (salience network), IC-4 (dlPFC as 
part of the executive control network), IC-5 (right fronto-parietal network, FP), IC-6 (left FP), 
IC-7 (medial visual network), IC-8 (primary visual network), IC-9 (lateral visual network), IC-
10 (auditory network), IC-10 (somatosensory network), and IC-11 (ventral stream). 
 
6.3.3 Group comparison between clinical participants and HC of extracted brain 
networks  
IC-10 representing the auditory and somatosensory network showed significantly 
reduced connectivity in the right SMG (MNI coordinates: 34 -42 32, p = 0.036, FWE-
corrected) and a trend for reduced connectivity in the left posterior cingulate (-26 -66 12, p = 
0.072, FWE-corrected) in clinical participants as compared to HC (see Figure 6.2). No other 
network demonstrated altered functional resting-state connectivity in clinical participants (all 
p > 0.05, FWE-corrected).	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Figure 6.2. Reduced connectivity in clinical participants in IC-10 (auditory and 
somatosensory network). 
 
6.3.4 Three-group comparison of extracted brain networks  
Significant differences in functional resting-state networks are described in the 
following when splitting clinical participants into high vs low symptom and functioning scores 
and cortisol levels as described in Section 6.2.1 and comparing the two respective groups 
with HC. 
	  
6.3.4.1 Classification according to psychotic symptoms 
Reduced connectivity was found in individuals with high psychotic symptoms as 
compared to HC in IC-10 representing the auditory and somato-sensory network in the 
subcallosal cortex (-2 18 -4, p = 0.028, FWE-corrected), STG (10 46 28, p = 0.046, FWE-
corrected), PCC (10 -42 0, p = 0.008), SMG (34 -42 32, p = 0.006, FWE-corrected), ACC (-2 
18 32, p = 0.038, FWE-corrected), lingual gyrus (-18 -54 0, p = 0.01, FWE-corrected), 
angular gyrus (38 -54 48, p = 0.03, FWE-corrected), and frontal pole (-26 46 -4, p = 0.04, 
FWE-corrected), and in IC-11 representing the ventral stream network in the medial frontal 
cortex (-2 46 -12, p = 0.034 & 2 46 -12 p = 0.034, FWE-corrected), orbitofrontal cortex (14 
10-12, p = 0.024 & -18 10 -12, p = 0.03, FWE-corrected), caudate nucleus (6 14 4, p = 
0.034, FWE-corrected), insular cortex (38 10 8, p = 0.034, FWE-corrected), SMG (38 -38 4, 
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p = 0.046, FWE-corrected), middle temporal gyrus (38 -58 12, p = 0.043, FWE-corrected),  
occipital fusiform gyrus (38 -62 -8, p = 0.046, FWE-corrected), and occipital pole (30 -90 -8, 
p = 0.034, FWE-corrected). 
Reduced connectivity was further found in individuals with high psychotic symptoms 
as compared to HC in IC-2 representing the frontal part of the DMN network in the inferior 
temporal gyrus (IFG)  (-38 -58 0, p = 0.04, FWE-corrected). Clinical participants with high 
psychotic symptoms showed increased connectivity in the IFG as compared to clinical 
participants with low psychotic symptoms (-42 -54 -20, p = 0.046, FWE-corrected). 
 
6.3.4.2 Classification according to depressive symptoms 
Similarly to the classification into psychotic symptoms network alterations in the 
auditory/somato-sensory and ventral stream network were discovered when splitting clinical 
participants into high vs low depressive symptoms: Clinical participants with high depressive 
symptoms displayed reduced connectivity in IC-10 in the ACC (10 30 -4, p = 0.048 & -2 18 
32, p = 0.02, FWE-corrected) and IC-11 in the angular gyrus (54 -66 32, p = 0.028 & 38 -62 
12, p = 0.034, FWE-corrected), temporal lobe (38 -34 4, p = 0.034, FWE-corrected), middle 
frontal gyrus (-26 46 -12, p = 0.038, FWE-corrected), and putamen (-26 2 4, p = 0.03 & -26 
46 -12 0.038, FWE-corrected) as compared to HC. Reduced connectivity was furthermore 
found in IC-5 representing the right fronto-parietal network in the insula (47 6 0, p = 0.046, 
FWE-corrected) in clinical participants with high depressive symptoms as compared to 
clinical participants with low depressive symptoms.  
 
6.3.4.3 Classification according to anxiety symptoms, psychological distress and cortisol 
levels 
Reduced connectivity was found in IC-10 representing the auditory/somato-sensory 
network in the ACC (2 18 32, p = 0.016, FWE-corrected), SMG (38 -42 32, p = 0.42, FWE-
corrected), and precuneus (-22 -62 8, p = 0.046, FWE-corrected) in clinical participants with 
high psychological distress as compared HC. No network demonstrated altered functional 
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resting-state connectivity in clinical participants with high vs low anxiety symptoms, and high 
vs low hair cortisol concentrations in the first segment, as compared to HC (all p > 0.05, 
FWE-corrected).	  	  
 
6.3.4.4 Classification according to social and role functioning scores 
Decreased connectivity was found in IC-10 representing the auditory/somato-sensori 
network in the SMG (34 -42 32, p = 0.048, FWE-corrected) in clinical participants with high 
social functioning as compared HC. Reduced connectivity was discovered in IC-7 
representing the medial visual network in the ACC (-2 2 8, p = 0.048, FWE-corrected) in 
clinical participants with low social functioning as compared HC. Reduced connectivity was 
further demonstrated in IC-1 representing the posterior part of the DMN in the IFG (46 38 8, 
p = 0.048, FWE-corrected), in IC-3 representing the SN in the ACC (-14 38 -4, p = 0.048, 
FWE-corrected) and in IC-7 representing the medial visual network in the thalamus (-2 2 -4, 
p = 0.038, FWE-corrected) in clinical participants with low role functioning as compared to 
HC. 
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6.4 Discussion 
The present study aimed to investigate and compare whole brain functional connectivity 
in young, help-seeking individuals with early mental health problems, and age, gender, 
ethnicity, education and highest qualification matched HC during rest. The ICA isolated the 
DMN, SN, part of the ECN with the dlPFC, the primary, medial and lateral visual, auditory, 
sensori-motor, ventral stream, and left and right fronto-parietal network during rest. Contrary 
to the hypothesis, the clinical group did not display increased functional connectivity of the 
DMN during rest as compared to HC. However, the IC representing the auditory and 
somatosensory network displayed significantly reduced resting-state connectivity in the SMG 
and a trend for reduced connectivity in the posterior cingulate. Clinical participants with 
 (sub-)threshold psychotic symptoms showed significantly reduced connectivity in the frontal 
part of the DMN, ventral stream and auditory and somatosensory network as compared to 
HC, and clinical participants with moderate to severe depressive symptoms showed similarly 
decreased connectivity in the auditory and somatosensory and ventral stream network as 
compared to HC, as well as in the right fronto-parietal network as compared to clinical 
participants with none to mild depressive symptoms. 
This study supports the idea that the resting state of the brain is not an inactive, but 
rather a dynamic state with coherent slow fluctuations of the BOLD signal (Damoiseaux et 
al., 2006a), by demonstrating the existence of 11 networks in both young patients with 
mental health issues and HC. The isolation of diverse resting-state networks, such as the 
DMN, SN, visual, auditory, sensori-motor, ventral stream and fronto-parietal networks, is 
mainly consistent with other previous ICA, e.g. in accordance with Veer et al. (2010) who 
identified 13 relevant networks using a 20 component ICA in depressed patients and HC. In 
this study, 11 relevant networks were identified using a 19 component ICA. In contrast to 
Veer et al. (2010), the current study identified the DMN with two components, instead of a 
single one. Achieving one component proved to be difficult with this data set, and therefore 
resulting in posterior and anterior nodes for the DMN. DMN regions are responsible for 
various operations (e.g. autobiographical, self-monitoring, social functions (Menon, 2011)) 
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and so, although coherent on average, components have a degree of independent activity 
as well. 
The current study highlights the relevance of the auditory and somatosensory 
network in young people who are help-seeking for mental health problems, such as the SMG 
and potentially the posterior cingulate, however, resting-state connectivity of no other 
network was altered when comparing clinical participants with HC. In contrast to other 
studies, altered functional connectivity was not discovered, as e.g. decreased connectivity 
within networks relevant for affect regulation, attention and working memory (Veer et al., 
2010), or increased connectivity between cingulate, frontal and parietal regions in depressed 
patients (Greicius et al., 2007; Zhou et al., 2009).  
When splitting the current sample into none to mild, and moderate to severe 
depressive symptoms, and focusing on brain areas instead of networks, decreased 
functional connectivity was discovered for the moderate to severe group in areas such as 
temporal and frontal regions and the insula, similar to areas discovered in Veer et al. (2010), 
yet, as part of different brain networks. The findings are, however, in contrast to increased 
connectivity as shown by Greicius et al. (2007) and Zhou et al. (2009), and in contrast to the 
initial hypothesis of increased connectivity in the DMN due to ruminations.  Zhou et al. 
(2009) included medication-free patients, and Greicius et al. (2007) included severely 
depressed patients. Furthermore, only Veer et al. (2010) included dual regression as method 
to compare groups, whereas Greicius et al. (2007) used ICA but not dual regression, and 
Zhou et al., (2009) used seed-based analyses. The current study included on average 
moderately depressed clinical participants of which more than half were taking 
antidepressants at the time of scanning. Both, less severe depressive symptoms, and the 
effect of antidepressant treatment, as well as the comparatively young age and early stage 
of illness could account for the absence of functional connectivity increases in the DMN and 
similar areas as seen in Greicius et al. (2007) and Zhou et al. (2009), as well as 
methodological differences in the analyses.  
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 Similarly, no group differences were discovered as in other studies on schizophrenia 
(Nygård et al., 2012) and the UHR state of psychosis (Dandash et al., 2014; Wotruba et al., 
2013). This might be due to the fact that brain alterations in threshold schizophrenia are 
more pronounced than in the earlier stages of mixed mental health problems. Furthermore, 
only approximately half of the clinical sample presented with some sort of significant 
psychotic symptoms.  
Nygård et al. (2012) discovered sustained hyper-activation of the DMN during rest 
and decreased connectivity in the insula and dorsolateral ACC in patients with schizophrenia 
as compared to controls, Wotruba et al. (2013) showed that individuals at UHR for psychosis 
showed a loss of TPN-TNN anti-correlation, and Dandash et al. (2014) altered cortico-striatal 
connectivity - no such differences were detected in the current study when comparing clinical 
participants with HC. The current study did not replicate those findings, possibly due to 
methodological differences: Wotruba et al. (2013) and Dandash et al. (2014) used a model-
driven approach by implementing seed-based analyses, whereas the current study and 
Nygård et al. (2012) analysed data-driven by implementing an ICA. However, some of the 
areas that have been identified to be altered in those studies, were found in the current 
study as well, when splitting the clinical sample into (sub-)threshold psychotic symptoms as 
compared to HC, such as the caudate nucleus as striatal structure, the ACC, and DMN 
regions such as the PCC and angular gyrus. Most connectivity alterations were discovered 
to be between clinical participants in the high symptom and low functioning groups, as 
hypothesised to be the first to demonstrate alterations as compared to HC (in contrast to low 
symptomatology and high functioning). The finding of mostly decreased connectivity in 
individuals with (sub-)threshold psychotic symptoms as compared to HC is further consistent 
with a trend for connectivity reductions across all stages of psychotic disorders as reviewed 
by Pettersson-Yeo et al. (2011). 
Whilst prolonged or excessive cortisol excretion has been associated with the 
development of mental disorders (Herbert, 1998) and with changes in brain structure in 
mental disorders such as schizophrenia (Mondelli et al., 2010), no such differences were 
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discovered in the current study with regards to the role of cortisol for brain connectivity 
analyses in early mental health disorders. The scarcity of studies in this field led to 
hypotheses being based on findings from studies of acute stress and cortisol increases in 
healthy individuals (Quaedflieg et al., 2015; Thomason et al., 2011). It is possible that 
longer-term increased cortisol levels in the course of early mental health problems do not 
elicit the same effects on brain connectivity as acutely induced stress in healthy individuals. 
Furthermore, cortisol was only used as a grouping variable instead of a covariate due to 
methodological issues, that is a median split was conducted to classify into clinical 
participants with high and with low cortisol levels as compared to HC.  
There are several limitations to this study. Firstly, the conduction of multiple 
comparisons has to be acknowledged. Similarly to Section 5.4, stringent FWE-correction 
was used for within-analysis comparisons on the voxel-level, but multiple comparisons were 
conducted for dividing the clinical group into high vs low scores for clinical and functioning 
measures, and hair cortisol levels, each consisting of six contrasts, respectively. Even 
though the main finding of reduced connectivity within the auditory and somatosensory 
network was replicated in clinical participants, e.g. when dividing clinical participants into 
high versus low psychotic and depressive symptoms, this network was not one to be a-priori 
hypothesised to show alterations. Network alterations of subgroup analyses which were not 
shown when comparing clinical participants and HC, and which were not a-priori 
hypothesised, such as the medial visual network (when comparing the low social functioning 
with HC group), may constitute this sort of false-positive artefacts and have to be viewed 
with special caution. However, it is noteworthy that differences in the auditory and somato-
sensori network showed up quite consistently in the high symptomatic groups as compared 
to HC, indicating a subtle but robust finding for reduced connectivity. Secondly, due to the 
explorative nature of this study, only one hypothesis was inferred. Studies on resting-state 
functional connectivity in threshold disorders have been conducted (e.g. schizophrenia) but 
often using different methodology, e.g. regional homogeneity or ROI approaches, 
complicating the deduction of clear hypotheses. With ICA being a data-driven approach, 
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relevant differences would have been detected without explicit hypotheses, minimising the 
likelihood of missing relevant network alterations. However, the caveat with the approach 
undertaken lies in balancing the right number of IC when setting the analyses. The aim was 
to obtain networks of interest, e.g. the DMN, ECN and SN, maximising the number of all 
potentially relevant networks, and yet splitting network nodes into as few components as 
possible. This was achieved by using 19 components. Secondly, physiological noise, such 
as head motion, heart rate and breathing was not monitored whilst scanning. Therefore it is 
not clear whether group differences in these variables have accounted in any way for no 
further significant differences in brain networks between clinical participants and HC. 
However, ICA decomposition allows for separation of resting-state networks from 
physiological noise (Damoiseaux et al., 2006b) making it unlikely that group differences in 
network organisation would have been observed if physiological measures were taken. 
Thirdly, medication intake was not controlled for and clinical participants presented with 
unspecific mental health symptoms creating heterogeneity in clinical presentation. However, 
the aim of this study was not to look at diagnostic categories but at how the human brain 
functions at rest in the early stages of mental health problems. This only complicates 
comparison with other studies investigating threshold disorders or clear-cut stages when 
looking at mental health on a continuum, e.g. the UHR state for psychosis (Wotruba et al., 
2013).   
In conclusion, the ICA demonstrated commonly found resting-state brain networks in 
young individuals with early mental health problems and HC. The auditory and 
somatosensory network displayed significantly reduced resting-state connectivity in the SMG 
and a trend for reduced connectivity in the posterior cingulate. Clinical participants with  
(sub-)threshold psychotic symptoms and with moderate to severe depressive symptoms 
showed significantly reduced connectivity in networks such as the auditory and 
somatosensory network, and ventral stream as compared to HC. Functional resting-state 
connectivity in the whole clinical group was largely intact, and more pronounced network 
alterations became only apparent when considering symptom severity. Longitudinal studies 
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with larger samples are needed to address how certain diagnostic groups of mental 
disorders are related with altered functional connectivity in specific networks and when in the 
course of illness these alterations become apparent. 
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CHAPTER SEVEN 
GENERAL DISCUSSION 
7.1 Overview 
Even though having proven useful in medical (e.g. cancer) research, clinical staging has 
only recently been introduced into psychiatric disciplines. Psychiatric staging models have 
been proposed, yet only limited and preliminary validation has taken place so far. This thesis 
aimed to integrate neurobiological parameters into the early stages of a clinical staging 
approach: Youths with mental health problems shared their perceptions, feelings and 
thoughts that helped to assess the level of depressive, anxiety and psychotic symptoms and 
functioning at the first clinical study contact and after 3 and 6 months, which were reported in 
the first and main study. The following studies were built on the clinical data of the first study, 
and extended it with neurobiological assessments. The second study investigated hair 
cortisol concentrations and the third and fourth study looked at brain activation during 
working memory processes and during rest. Both hormonal levels and brain maturation 
undergo extensive changes during the period of adolescence until young adulthood, and 
both have been found to be associated with the onset of mental disorders. These 
neurobiological parameters shall be integrated into the concept of clinical staging, focusing 
on the early stages of mental ill health. Clinical variables and functioning will be used as 
dimensional (e.g. total scores of individual interview and self-report data) and categorical 
(e.g. classification into UHR for psychosis) information, in order to discern associations 
amongst these variables and with neurobiological factors in the pathogenesis of early mental 
health problems. 
 
7.2.1 Summary of neurobiological findings into clinical staging 
Findings from Chapter 4 suggested elevated hair cortisol concentrations representing 
the past three months of exposure in adolescents and young adults with early mental health 
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problems compared to healthy participants. Perceived stress was also elevated in clinical 
participants, yet there was no association between cortisol and perceived stress experience, 
and cortisol was only significantly correlated with psychological distress. This may be 
explained by perceived stress scales inquiring information about subjective stress 
experiences, whereas psychological distress rather relates to depressive and anxiety 
symptoms that may be experienced by the individual, and therefore possibly being a more 
objective measure, as is cortisol itself. 
The n-back task, as described in Chapter 5, activated mainly frontal, but also parietal 
and marginally subcortical brain regions in HC and clinical participants such as the superior, 
middle, and orbito-frontal areas, SMG, ACC, and basal ganglia, which overlapped with those 
areas typically detected as relevant for a verbal working-memory task in previous literature, 
such as the dlPFC, and PCC (Owen et al., 2005). Clinical participants with mental health 
issues showed a reduced response in the SFG, ACC, insula, putamen and hippocampus, 
however, no hyper-activation was detected in clinical participants. Comparing clinical 
participants with high symptom and low functioning scores to HC replicated the finding of 
hypo-activation, however, of more distributed brain areas. No behavioural group differences 
in reaction time and accuracy, and no associations with cortisol levels, were detected.  
Chapter 6 aimed to investigate and compare whole brain functional connectivity during 
rest. The ICA isolated the DMN, SN, part of the ECN with the dlPFC, the primary, medial and 
lateral visual, auditory, sensori-motor, ventral stream, and left and right fronto-parietal 
network during rest. The IC representing the auditory and somatosensory network displayed 
significantly reduced resting-state connectivity in the SMG and a trend for reduced 
connectivity in the posterior cingulate. Clinical participants with (sub-)threshold psychotic 
symptoms showed significantly reduced connectivity in the frontal part of the DMN, ventral 
stream and auditory and somatosensory network as compared to HC, and clinical 
participants with moderate to severe depressive symptoms showed similarly decreased 
connectivity in the auditory and somatosensory and ventral stream network as compared to 
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HC, possibly indicating that symptom severity of depressive and psychotic symptoms 
influences the magnitude of resting-state connectivity alterations. No association with cortisol 
levels was detected.  
Considering the different nature of the composition of the current sample with youths 
with early and unspecific mental health problems who have not been assigned a clinical 
diagnosis for the analyses, these findings are in agreement with some other studies using 
diagnostic classification systems. Previous studies have mostly included individuals with 
clear diagnoses such as depression and schizophrenia, or classified individuals as UHR for 
psychosis. However, the hair cortisol findings of the current studies are consistent with 
elevations found in clinically depressed individuals (Dettenborn et al., 2012), as opposed to 
anxiety disorders which have been found to manifest in both hyper- and hypocortisolism  
(potentially due to time elapsed between onset of anxiety disorder and/or trauma, with higher 
cortisol levels soon after onset, and a decline below normal as time passes) using hair 
analyses (Steudte et al., 2011a; Steudte et al., 2011b). Almost all clinical participants of the 
current study were somehow, and on average moderately depressed, which is in agreement 
with Dettenborn et al. (2012). The majority of the current sample was assigned to have the 
severity of anxiety symptoms as seen when an anxiety diagnosis is given, however, 
comparison with other findings is complicated since no differentiation into anxiety disorders 
took place and the presence of (recent) traumatic events was not controlled for, whose 
timing majorly impacts on HPA axis functioning, e.g. in terms of hyper- and hypo-cortisolism. 
Despite inconsistent results concerning brain activation during working memory 
processes with activation increases and decreases in schizophrenia and depressed patients, 
and their healthy siblings, the current findings of hypo-activation of diverse frontal, parietal 
and subcortical areas, are e.g. consistent with less activation (e.g. in the thalamus, 
precentral gyrus and parietal cortex) (Barch et al., 2003) and of the medial frontal gyrus, 
precuneus, PCC, thalamus and hippocampus in healthy siblings of schizophrenia patients 
(Callicott et al., 2003a). Even though the current findings of e.g. hypo-activated superior, 
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middle, and orbito-frontal areas in youths with mental health problems as compared to HC, 
are consistent with the general idea of hypo-frontality in schizophrenia (Pettersson-Yeo et 
al., 2011), since about half of the clinical sample displayed (sub-)threshold psychotic 
symptoms, no differences in brain activation were found when splitting the clinical sample 
and comparing those with (sub-)threshold psychotic symptoms with clinical participants with 
no significant psychotic symptoms. However, reduced brain activation during working 
memory processes was apparent when comparing clinical participants with high psychotic 
symptoms with HC in the SFG, hippocampus and caudate nucleus, and clinical participants 
with low psychotic symptoms with HC in the post-central and middle temporal gyrus and 
ACC. Differences in brain connectivity during rest were likewise apparent, e.g. in the auditory 
and somatosensory and ventral stream network between clinical participants with high 
psychotic symptoms and HC. The general finding of subtle hypo-connectivity of the SMG 
and potentially posterior cingulate, further supports the functional dysconnectivity hypothesis 
in schizophrenia (Stephan et al., 2006) which, however, clearly involves more pronounced 
alterations in threshold disorder as compared to the current sample of assumably sub-
threshold distress disorders.  
Hair cortisol levels of the first segment representing the past 3 months prior to MRI scan 
were hypothesised to moderate brain activation during working memory and undirected 
mental activity, since acute psychosocial stress was found to impair working memory 
performance in healthy participants (Luethi et al., 2009) and elicited reduced activity in the 
dlPFC and reduced deactivation of the PCC and orbitofrontal cortex (areas constituting the 
DMN) during working memory processes (Qin et al., 2009). Thomason et al. (2011) reported 
greater cortisol responsivity in healthy adolescents to be associated with higher functional 
connectivity in the SN after acutely inducing social stress, and altered connectivity between 
the amygdala and PFC and other cortical regions was observed (Quaedflieg et al., 2015). 
Therefore, chronic stress, as measured by means of hair samples, was hypothesised to 
correlate with activation of brain areas involved in working memory (such as the dlPFC) and 
clinical individuals with high cortisol levels being assumed to have more pronounced network 
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alterations than the low cortisol group as compared to HC. Neither hypothesis held true, 
possibly due to the fact that hypotheses were based on studies including healthy participants 
as compared to clinical samples and psychological stress was acutely induced instead of 
naturally occurring during an extended period of time, as measured with the hair analyses. 
	  
 7.2.2 Relevance of functioning for UHR and clinical staging 
As demonstrated in Chapter 3, psychotic-(like) symptoms in help-seeking young 
people appear to be associated with more severe depressive symptoms and poorer 
functioning. However, UHR status for psychosis did not differentiate severity of depressive 
and anxiety symptoms and functioning: No differences were found between UHR clinical 
participants and those with only PLE and no significant psychotic symptoms for the severity 
of depressive or anxiety symptoms, and functioning. This indicates it is the overall severity 
and frequency of psychotic(-like) symptoms exerting the effect on depressive and anxiety 
symptoms and functioning, and not the classification as UHR for psychosis per se that 
matters, which gives indirect evidence against including the functioning criterion for UHR 
classification and clinical staging in general. However, this conclusion should be considered 
with great caution due to the for this research question comparatively small sample sizes 
and the preliminary nature of the of the study design. 
	  
7.2.3 Summary of relevance of approaches to youth mental health 
	  
Issues that are associated with categorical approaches (Section 1.3.1) to mental 
health have proven to exist in the current sample, such as co-occurrence of symptoms: 
About two fifths presented with both depressive and psychotic(-like) symptoms and about 
three fifths experienced depressive symptoms whilst classified as having an anxiety 
diagnosis and one forth was diagnosed with an anxiety disorder whilst experiencing 
psychotic(-like) symptoms at baseline. Despite the fact that the current sample did not 
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present with threshold disorders, such as schizophrenia, it can be said that these symptom 
sets co-occur instead of isolatedly occurring in individuals.  
The description of the current sample is in accordance with McGorry (2013) who 
summarises that mental disorders are considered to be dynamic syndromes that overlap and 
share aetiologies and courses. Major psychiatric disorders are in this regard often said to be 
preceded by prodromes, consisting of non-specific symptoms, such as anxiety and 
depression, frequently being associated with persistent stress and disability. Depending on 
whether clinical participants of this sample go on to develop threshold disorder, the term 
prodrome will hold true, whereas for the remainder the term sub-threshold distress disorder 
may be more accurate.   
Even though the current studies did not provide any evidence to evaluate the bifactor 
model (Brodbeck et al., 2011, see Section 1.3.3) and the idea of ideographic and nomothetic 
parameters (that is, individual-specific profiles and group-based classifications, Wigman et 
al., 2012, see Section 1.3.4) of mental health, the idea of a general distress factor underlying 
depression and anxiety (and psychotic) symptoms relates to the overlap of depressive and 
anxiety (and psychotic) symptoms of the current sample (Sections 3.3.5 and 3.3.6).  
To conclude, both dimensional and categorical approaches are needed to observe 
the overlap in biosignatures and risk factors across psychiatric disorders (Keshavan et al., 
2014). Despite sharp criticism of categorical approaches in the recent past, neither the merit 
of categorical approaches is disputable, nor is clinical staging inherently different, e.g. from 
the DSM, especially with including the consideration of symptom severity in the DSM-V 
(American Psychiatric Association, 2013). Dimensional approaches, such as clinical staging 
(e.g. McGorry et al., 2007) or the notion of a general construct underlying psychopathology 
(Brodbeck et al., 2011; Wigman et al., 2012) add to the knowledge about the development of 
mental disorders and are meant to refine diagnosis and treatment selection, and not entirely 
replace existing systems. 
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8.3 Methodological considerations 
This thesis used data from a cohort of young individuals with early mental health 
problems, who were followed up after 3 and 6 months. Those individuals who had a family 
history with a first-degree relative with mental health problems and/or whose problems did 
not improve within 6 weeks after the baseline assessment according to self-report, were 
included in the neurobiological assessments. These youths underwent fMRI scans and/or 
donated hair samples within 7 months after the clinical baseline assessment and were 
compared to a group of mentally healthy youths without a family history of mental problems. 
Strengths and weaknesses of this thesis and studies that were included, are discussed in 
the following.  
8.3.1 Strengths 
This thesis combined different methodological modalities that complemented each 
other: Self-report and interview data from the first study were included as correlates and 
covariates in the neurobiological chapters. Depressive, psychotic, and anxiety symptoms, 
psychological distress, and functioning were correlated with cortisol concentrations to 
discern whether increased cortisol levels in clinical participants were driven by or otherwise 
related to these individual factors rather than the underlying component of unspecific 
symptoms during the early stages of mental health problems. Furthermore, the objective 
nature of cortisol levels and fMRI data added to the rather subjective, and bias-prone self-
report information. A relatively large sample size is another strength of this thesis (clinical 
assessments: nBaseline = 73, n6 months = 55) when considering the longitudinal nature and 
detailed information that has been gathered in the course of clinical assessments, as well as 
for a neuroimaging study (n = 70). 
Large cohort studies on youth mental health and clinical staging have been published 
in the past years, however, to date this thesis is amongst the first attempts to integrate 
neurobiological markers into the early stages of the clinical staging model of mental 
disorders (e.g. McGorry et al., 2007). Furthermore, findings from this thesis existing literature 
supplement on rather chronic mental health conditions in comparatively older individuals, 
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often with repeated episodes of mental health disorders (e.g. Barch et al., 2003; Staufenbiel 
et al., 2013; Wang et al., 2012), genetic risk studies (e.g.  Callicott et al., 2003a; Liu et al., 
2010; Mannie et al., 2010),  and UHR for psychosis (e.g. Goghari et al., 2014; Wotruba et 
al., 2013). 
 
8.3.2 Weaknesses 
A major issue of the neurobiological part of this thesis is the absence of clinical 
information for the control group. Even though HC were screened for present and past 
mental disorders, sub-threshold distress - which does not yet meet diagnostic criteria – may 
have existed. This lack of clinical data for controls restricted correlational analyses and 
ANCOVA to the clinical group only, resulting in low power of the analyses and relocating the 
analyses to the more pronounced end of the continuum of mental health symptoms. 
However, the clinical group experienced self-reported distress at a level significant enough 
to reach secondary care, indicating that clear-cut differences between the two groups 
existed. Despite some potential symptomatology in the control group, are the groups in fact 
very different. 
The time window of follow up assessments was comparatively short with 6 months 
for the clinical chapter, and only a cross-sectional design was used for the neurobiological 
chapters. Slow recruitment rates for these studies were, among other factors, down to 
limited access to health services amongst individuals with mental health problems (McGorry 
et al., 2014), which in turn, impeded opting for a more extensive follow-up period and a 
prospective design for the neurobiological chapters. Youth mental health, however, is a fairly 
new discipline and evidence for better health outcomes and economical benefits with this 
new mental health approach are required, but difficult to achieve given the long-term nature 
of validating mental health outcomes. Longitudinal studies are therefore needed to replicate 
current findings within a larger scope and time frame. The implementation of such studies is 
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encouraged by pioneering work of evidence-based staging and early intervention in 
psychosis (McGorry et al., 2014). 
  The neurobiological assessments took place up to 7 months after the first clinical 
assessment. Therefore, clinical and functioning variables that were used for the analyses, 
were extracted from the clinical baseline assessment. This option was chosen - despite 
producing a comparatively large gap - as compared to using the closest clinical assessment 
(e.g. 3 or 6 months follow-up) - because the interest lay in clinical stage classification which 
usually happens at the first clinical contact, and further, because little is known about 
dynamic staging over time. Considering the improvement of the current sample regarding 
clinical symptomatology, if individuals were staged later in the course of the study, it is likely 
that earlier stages would have been assigned. 
The measures which were selected in accordance with similar cohort studies 
conducted in Australia, to yield consistency and comparability, constitute a further limitation. 
First of all, the measures capture symptoms for varying time periods from 2 days to 12 
months, which complicates to compare the impact of different symptom sets with each other. 
Secondly and related to this, issues exist with individual measures such as the QIDS: Even 
though depressive symptoms may have been present for which the individual sought help, 
these symptoms have not necessarily been covered, since the QIDS refers to the past week 
only. This fact is especially of interest because of a likely gap of days up to weeks between 
recruitment and actual clinical assessment.  
Measures that related to mania, eating and substance use symptoms were excluded 
from this thesis (despite being included as branches in the Trunk and Branches model), for 
example, due to methodological reasons, e.g. the Young Mania Rating Scale (Young, Biggs, 
Ziegler, & Meyer, 1978) covered manic symptoms for the past 2 days only, and the SCOFF 
(acronym for the items, Luck et al., 2002) was supposed to cover eating disorders with a 
rather minimalistic number of 5 items. Substance use disorders were excluded due to small 
numbers of stage classifications according to the ASSIST (Humeniuk et al., 2008) in the 
current sample. This constitutes another simplification of the underlying heuristic 
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representation of the clinical staging model (despite being a necessary exclusion), and takes 
potential explanatory value from the respective analyses. 
Finally, as a minor limitation to mention is that 4 clinical participants who were originally 
classified as experiencing a FEP (in the main study and for consequent sub-analyses in the 
neurobiological chapters), were submerged with UHR for psychosis and PLE for practical 
and statistical reasons, depending on the existence of functional impairment. Therefore there 
are two options possible: these individuals were either actually experiencing a psychotic 
episode and therefore correctly detected as FEP, but incorrectly included in the current 
analyses, or correctly included in the analyses but constituting type 1 classification errors 
when using the CAARMS. Nevertheless, this concerned a comparatively small number of 
participants only, and was a necessary adjustment for the respective analyses. 
 
8.4 Implications for future research 
Research on individuals at UHR for psychosis has shown that there is a need to start 
looking at cohorts of young people without focusing on diagnostic categories in the first 
instance. Psychological distress and the need for clinical care often exist long before a 
threshold diagnosis has been assigned – not only for those at risk for developing psychotic 
disorders. Therefore, studies have started to emerge on practicing clinical staging in young 
people for a variety of mental disorders, however, these are only yet in the fledging stage 
and need further refinement and replication. 
This thesis can be seen as a first step with the superior goal of establishing 
neurobiological markers and looking at boundaries of clinical measures in order to refine and 
validate the clinical staging model for mental disorders. A second step would explicitly test 
cut-offs of clinical measures, e.g. by using latent class analyses in recognising meaningful 
and definable sub-populations (Jung & Wickrama, 2008) in the larger and heterogeneous 
group of individuals with mental disorders. In simple terms, this means creating algorithms to 
use clinical variables in order to assign clinical stages to individuals. These sub-populations 
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are thought to focus on progression of illness, and only in a second instance, when illness 
has progressed beyond a significant threshold (stage 2), on classifying into rather common 
categories of mental disorders (psychosis, depression, mania, anxiety, substance use, and 
eating disorders). Whereas this thesis included individuals considered to be in the early 
stages (e.g. stage 1a and 1b) and focused on neurobiological correlates in these early 
stages, more work needs to be done on whether preliminary cut-offs are valid boundaries 
between stages, e.g. which clinical measure scores are valid cut-offs to differentiate between 
sub-threshold distress (stage 1b) and threshold disorder (stage 2) and whether receipt of 
evidence-based treatment (e.g. cognitive-behavioural therapy or psychiatric medication) is a 
necessary condition for assignment to stage 2. This modelling of developmental trajectories 
with latent class analyses requires extensive datasets with longitudinal variables, aiming to 
investigate variation between individuals in intra-individual transition over time (Jung & 
Wickrama, 2008).  
Continuous longitudinal follow-up is needed to not only follow transition to stage 2, but 
also to validate landmarks for remission and incomplete remission (stage 3a), relapses after 
remission (stage 3b & 3c), non-response for treatment and persistent disorder (stage 4). 
Other neurobiological markers such as sex hormones (e.g. testosterone, progesterone, 
estradiol), structural grey and white matter connectivity, and performance and brain 
activation during other cognitive functions (e.g. social cognition, attention, decision making) 
are further related to the development and phenotype of mental disorders. 
Lastly, one important factor that has been neglected in this thesis, and which should be 
considered for future research in similar psychiatric populations, is sleep: abnormal sleep 
duration has repeatedly been shown to severely affect individuals’ health, cognition and 
mood (Waters & Bucks, 2011). Sleep disturbance frequently accompanies psychiatric 
disorders and likely affects their course (Krystal, Thakur, & Roth, 2008). Further, sleep 
deprivation in healthy individuals has been reported to increase evening cortisol levels 
(McEwen, 2006), and negatively affect cognitive processes as demonstrated in fMRI studies 
(Chee & Chua, 2008). 
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8.5 Implications for clinical practice 
This thesis, which is embedded in a larger clinical staging model for mental disorders, 
has also implications for “diagnosis” and treatment in clinical practice. However, the term 
diagnosis appears in this context not entirely appropriate, especially when looking at young 
people in the early stages, presenting with psychological distress and unspecific psychiatric 
symptoms and/ or UHR features. In these cases, focusing on symptoms (rather than 
syndromes or diagnoses), impairment and actual help-seeking behaviour might be indicated, 
to conclude about treatment options. Whereas need for care has usually been based on 
threshold diagnosis, this clinical staging model suggests that need for care exists before 
threshold disorder. This idea is supported by the fact that most clinical participants from the 
current cohort were considered to be stages 1a and 1b, due to their young age and seeking 
professional help for their mental health problems. Furthermore, individuals were not 
recruited from UHR clinics, but a considerate proportion displayed UHR features or PLE (1/4 
were classified as UHR for psychosis and an additional 1/5 as experiencing PLE in the main 
study). This suggests that even though psychotic(-like) experiences were generally not the 
reason why clinical participants sought help, they need additional consideration from mental 
health professionals, as they have the potential to cause significant distress and impairment. 
The findings of increased perceived stress and cortisol levels and subtle alterations in brain 
activation during working memory processes and rest add to the notion of need for care on 
the grounds of emerging neurobiological abnormalities. 
According to the clinical staging model neurobiological parameters are considered to 
have potential for the refinement of treatment selection. This thesis has given an impetus for 
using cortisol levels and brain activation during working memory and rest, to refine treatment 
selection. Even though no data is available to compare the early and later stages of mental 
health problems, it appears that individuals with early mental health problems are distinct on 
average by increased cortisol levels and subtle alterations of brain activity during working 
memory and rest from HC (see Chapters 4 to 6). Early intervention, e.g. during the UHR 
state for psychosis, has amongst others, the purpose to delay or prevent transition to 
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threshold disorder (Fusar-Poli et al., 2012). It is especially relevant in this regard, to 
distinguish those individuals who will go on to transition from those who will not, considering 
the burden and impairment of threshold disorder. Interview measures such as the CAARMS 
have good (Yung, Phillips, Yuen, & McGorry, 2004) - but not perfect -  sensitivity and 
specificity.  Therefore identification based on more objective neurobiological correlates, 
offers improvement in sensitivity to detect prodromal cases and prevent or delay transition, 
and specificity to prevent overtreatment for those individuals who may only need treatment 
based on actual symptom presentation. This thesis offered some preliminary evidence that 
more severe clinical symptomatology and functional impairment is associated with, e.g. more 
pronounced changes in brain activation. It has, however, been beyond the scope to 
longitudinally assess whether those who are more impaired are more likely to have a worse 
clinical and functional outcome later on. Further research is needed to make use of 
neurobiological correlates in addition to already established measures, to support guiding 
treatment and employing a sequential approach. Ultimately, risk-benefit considerations (e.g. 
in case of uncertainty when using self-report and interview data) could potentially be 
supported by neurobiological correlates to guide treatment selection. 
 
8.6 Conclusion 
Clinical participants from this study were recruited from general early intervention 
services, however, one fourth were classified at UHR for psychosis and another fifth 
presented with (sub)threshold psychotic symptoms without functional decline. UHR 
classification did not appear to be crucial in predicting need for clinical care among these 
youths seeking help for mental health problems. Intensity and frequency of psychotic 
symptoms, however, partly predicted clinical symptoms in the short-term. This period of early 
and rather unspecific mental health problems was associated with significantly increased 
perceived stress, and increased cortisol levels over the past three months. Despite no 
behavioural differences, clinical participants showed a subtle hypo-activation of the SFG, 
CHAPTER SEVEN: GENERAL DISCUSSION                        
	  
	  153	  
anterior cingulate, insula, putamen and hippocampus and reduced resting-state connectivity 
in the auditory and somato-sensori network in the SMG. Grouping clinical participants into 
high vs low symptoms and functioning replicated findings for brain activation for the working 
memory paradigm with more dispersed hypo-activated brain areas and led to additional 
resting-state network alterations, especially when comparing the high symptom and low 
functioning groups with HC.  
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Snapshot	  of	  the	  study	  The	  purpose	  of	  the	  Transitions	  Study	  is	  to	  track	  the	  development	  of	  mental	  illnesses	  in	  young	  people	  through	  their	  natural	  course	  from	  first	  emergence,	  with	  the	  aim	  of	  identifying	  underlying	  vulnerability	  markers	  and	  modifiable	  risk	  factors.	  	  In	  the	  long	  run,	  the	  superior	  objective	  is	  to	  develop	  and	  test	  a	  clinical	  staging	  model	  of	  mental	  
health	  disorders	  by	  means	  of	  clinical,	  psychological,	  social	  and	  genetic	  markers	  which	  could	  be	  implemented	  reliably	  in	  clinical	  services.	  We	  aim	  to	  recruit	  500	  participants	  from	  in	  the	  South	  Birmingham	  area,	  and	  follow	  them	  up	  periodically	  for	  at	  least	  2	  years.	  	  
	  
Who	  is	  eligible	  and	  what	  would	  be	  involved?	  
We	  are	  looking	  for	  any	  young	  person	  aged	  14	  to	  25	  years	  who	  is	  seeking	  help	  at	  
	  for	  mental	  health	  issues.	  Participation	  will	  involve	  an	  interview	  and	  questionnaires	  about	  symptoms,	  personal	  history,	  life	  events	  and	  functioning.	  These	  would	  take	  place	  at	  the	  University	  of	  Birmingham	  or	  the	  participant’s	  home	  at	  baseline	  and	  after	  3,	  6,	  12,	  18,	  and	  24	  months.	  We	  will	  reimburse	  young	  people	  £20	  for	  each	  assessment	  in	  recognition	  of	  their	  time.	  	  	  
The	  only	  exclusion	  is	  an	  inability	  to	  consent	  because	  of	  lack	  of	  capacity	  or	  poor	  
English	  language	  skills.	  	  
Your	  part	  We	  ask	  your	  support	  in	  recruiting	  young	  people	  into	  the	  study.	  We	  appreciate	  that	  your	  time	  is	  very	  limited,	  but	  we	  ask	  that	  if	  you	  see	  a	  young	  person	  who	  fits	  our	  criteria,	  you	  refer	  them	  to	  us.	  	  We	  hope	  to	  attend	  clinics.	  In	  this	  case,	  we	  will	  be	  available	  for	  you	  to	  introduce	  us	  to	  young	  people	  who	  are	  interested	  in	  participating	  at	  the	  end	  of	  their	  appointment.	  	  If	  we	  are	  not	  at	  the	  clinic,	  young	  people	  can	  fill	  out	  the	  attached	  form	  to	  give	  us	  consent	  to	  contact	  them.	  If	  you	  could	  keep	  these	  forms,	  we	  will	  organise	  to	  collect	  them	  from	  you.	  	  Young	  people	  can	  contact	  us	  directly	  using	  any	  of	  the	  contact	  details	  on	  the	  ‘Letter	  to	  Participants’	  or	  information	  pamphlet.	  	  We	  are	  very	  grateful	  for	  your	  support	  in	  recruitment,	  which	  is	  essential	  to	  the	  success	  of	  this	  study.	  If	  you	  have	  any	  questions,	  please	  contact	  Dr	  Ashleigh	  Lin	  on	  0121	  414	  6241	  or	  a.lin@bham.ac.uk.	  	  	  	  	  Many	  thanks,	  	  The	  Transtitions	  Team	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More	  information	  about	  the	  study	  and	  clinical	  staging…	  	  	  	  The	  planned	  research	  program	  (the	  Transitions	  Study)	  will	  test	  a	  theoretical	  framework	  known	  as	  the	  ‘clinical	  staging	  model’,	  which	  defines	  the	  extent	  of	  a	  young	  person’s	  mental	  illness	  along	  a	  continuum:	  	  starting	  with	  those	  who	  are	  at	  increased	  risk	  of	  a	  mental	  illness	  but	  are	  not	  yet	  showing	  symptoms	  then	  moving	  through	  to	  mild	  and	  then	  increasingly	  severe	  symptoms.	  	  	  Clinical	  staging	  is	  a	  tool	  used	  to	  better	  individualise	  and	  tailor	  each	  young	  person’s	  services	  and	  care.	  It	  allows	  interventions	  to	  be	  matched	  to	  the	  young	  person’s	  illness	  course,	  characterising	  and	  monitoring:	  	  
• Vulnerability	  
• Early	  symptoms	  
• Established	  illness	  trajectory	  
• Recovery	  phase	  	  To	  our	  knowledge,	  this	  concept	  has	  never	  been	  tested	  before	  on	  a	  large	  scale.	  	  	  To	  better	  allow	  us	  to	  define	  the	  progression	  of	  any	  mental	  illness	  over	  time,	  we	  have	  proposed	  a	  clinical	  staging	  model	  for	  psychiatry,	  similar	  to	  that	  used	  in	  physical	  medicine.	  This	  type	  of	  staging	  framework	  is	  particularly	  useful	  since	  it	  organises	  clinical,	  psychosocial	  and	  biological	  data	  in	  a	  coherent	  fashion,	  and	  allows	  clinicians	  to	  determine	  where	  an	  individual	  lies	  on	  the	  continuum	  of	  the	  course	  of	  their	  illness.	  This	  can	  be	  used	  to	  guide	  the	  selection	  of	  treatments	  that	  are	  most	  appropriate	  to	  the	  specific	  stage	  of	  illness.	  Thus,	  more	  benign	  interventions	  can	  be	  chosen	  for	  those	  in	  the	  earlier	  stages	  of	  illness,	  leaving	  treatments	  that	  carry	  greater	  risk	  for	  those	  whose	  illness	  is	  long-­‐standing	  and	  pervasive.	  	  We	  will	  test	  the	  validity	  of	  a	  range	  of	  clinical,	  psychological,	  biological,	  genetic	  and	  social	  markers	  for	  their	  ability	  to	  define	  the	  individual’s	  stage	  of	  illness	  and	  predict	  their	  risk	  of	  transition	  to	  a	  more	  advanced	  stage	  of	  illness.	  We	  are	  particularly	  interested	  in	  determining	  which	  of	  these	  markers	  represent	  modifiable	  risk	  factors	  and	  which	  represent	  the	  consequence	  of	  illness.	  We	  aim	  to	  use	  these	  data	  to	  further	  develop	  clinical	  staging	  criteria,	  so	  that	  staging	  of	  mental	  disorders	  can	  be	  implemented	  with	  reliability	  and	  validity,	  and	  finally,	  to	  use	  this	  cohort	  as	  a	  backbone	  for	  more	  specific	  studies	  of	  clinical	  staging,	  including	  testing	  stage-­‐based	  interventions	  and	  more	  specialised	  neurobiological	  investigations	  of	  stage	  transitions.
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  We	  are	  currently	  carrying	  out	  some	  research	  at	  the	  University	  of	  Birmingham	  and	  working	  with	  the	  Birmingham	  and	  Solihull	  Mental	  Health	  Foundation	  Trust	  to	  find	  people	  interested	  in	  participating.	  The	  aim	  of	  this	  research	  is	  to	  better	  understand	  the	  development	  of	  mental	  health	  disorders	  in	  adolescents	  and	  young	  adults.	  We	  would	  like	  to	  invite	  you	  to	  take	  part	  in	  this	  study,	  which	  will	  include	  questions	  about	  different	  kinds	  of	  thoughts	  and	  feelings	  (that	  might	  or	  might	  not	  relate	  to	  you),	  your	  personal	  history	  and	  other	  aspects	  of	  your	  life.	  We	  will	  also	  ask	  you	  for	  a	  saliva	  sample	  for	  genetic	  analysis,	  although	  you	  don’t	  have	  to	  do	  this	  part	  if	  you	  don’t	  want	  to.	  	  The	  first	  assessment	  will	  take	  around	  two	  hours,	  and	  we	  will	  pay	  you	  £20	  for	  your	  time	  and	  travel	  expenses.	  After	  three,	  six,	  twelve,	  18	  and	  24	  months	  we	  will	  ask	  you	  again	  to	  take	  part	  in	  a	  shorter	  version	  of	  the	  assessment	  (taking	  around	  one	  hour)	  for	  which	  you	  will	  receive	  £20	  each	  time.	  	  If	  you	  would	  like	  to	  take	  part	  in	  this	  study,	  or	  if	  you	  would	  like	  more	  information	  about	  it	  before	  you	  decide,	  please	  contact	  us	  in	  one	  of	  these	  ways:	  	  Call	  or	  text:	   	  Email:	   	  Facebook	  message:	   	  	  Another	  option	  is	  to	  fill	  out	  the	  form	  on	  the	  next	  page	  and	  leave	  it	  with	  your	  clinician	  and	  we	  will	  contact	  you.	  	  We	  look	  forward	  to	  hearing	  from	  you!	  	  	  Best	  wishes,	  
	  
	  
The	  Transition	  Team	  (Research	  team	  at	  the	  University	  of	  Birmingham)	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  I,	  ______________________________________,	  agree	  to	  being	  contacted	  by	  the	  research	  team	  to	  discuss	  participation	  in	  the	  Transitions	  Study.	  	  The	  best	  way	  to	  contact	  me	  is	  by:	  
	  Email:	  ___________________________________________________	  	  Telephone:	  ________________________________________________	  
	  
	  Today’s	  Date:	  _____________________________________________	  	  Your	  signature:	  ____________________________________________	  
	  	  That’s	  it–	  now	  just	  leave	  your	  form	  with	  your	  clinician	  and	  you’ll	  hear	  from	  us	  soon!	  
Put	  your	  name	  here	  
Add	  your	  contact	  details	  here!	  
Put	  your	  signature	  here	  
A-5: PARTICIPANT INFORMATION SHEET                                  
 A-­‐8	  
PARTICIPANT	  INFORMATION	  
	  
Study	  Title:	   	  The	  Transitions	  Study	  	  You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  whether	  or	  not	  you	  wish	  to	  take	  part,	  it	  is	  important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  will	  involve.	  	  Please	  take	  time	  to	  read	  the	  following	  information	  carefully	  and	  discuss	  it	  with	  others	  if	  you	  wish.	  	  Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  	  	  	  
The	  purpose	  of	  the	  study:	  This	  study	  aims	  to	  better	  understand	  the	  development	  of	  mental	  health	  disorders	  in	  adolescents	  and	  young	  people.	  We	  hope	  to	  assess	  young	  people	  presenting	  with	  mental	  health	  concerns	  over	  an	  extended	  period.	  This	  will	  hopefully	  tell	  us	  more	  about	  the	  relationships	  between	  mental	  health	  and	  other	  personal	  and	  lifestyle	  factors.	  We	  want	  to	  find	  out	  whether	  it	  helps	  people’s	  treatment	  and	  recovery	  if	  we	  can	  classify	  the	  problems	  into	  recognisable	  stages.	  	  
Why	  have	  I	  been	  chosen?	  We	  are	  inviting	  young	  people	  who	  are	  experiencing	  mental	  health	  issues	  to	  take	  part	  in	  this	  study.	  You	  have	  been	  asked	  because	  you	  sought	  help	  for	  these	  problems.	  	  	  
Do	  I	  have	  to	  take	  part?	  No	  –	  involvement	  in	  this	  study	  is	  voluntary.	  If	  you	  decide	  to	  take	  part,	  you	  are	  still	  free	  to	  withdraw	  at	  any	  time	  without	  giving	  a	  reason.	  	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  health	  care	  you	  receive	  now	  or	  in	  the	  future.	  	  	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  The	  researcher	  will	  meet	  with	  you	  at	  the	  University	  of	  Birmingham,	  your	  home	  or	  at	  a	  health	  centre	  to	  carry	  out	  some	  assessments	  with	  you.	  These	  will	  consist	  of	  an	  interview	  and	  some	  questionnaires	  asking	  about	  different	  symptoms	  and	  feelings	  (that	  might	  or	  might	  not	  relate	  to	  you)	  and	  other	  aspects	  of	  your	  life	  and	  personal	  history.	  We	  will	  also	  ask	  you	  to	  give	  a	  saliva	  sample	  for	  genetic	  analysis,	  although	  you	  don’t	  have	  to	  do	  this	  if	  you	  don’t	  want	  to.	  	  The	  first	  assessment	  will	  take	  approximately	  two	  hours	  to	  complete	  and	  you	  will	  receive	  
£20	  in	  recognition	  of	  your	  time	  and	  expenses,	  upon	  completion	  of	  assessments.	  We	  will	  also	  make	  contact	  with	  you	  in	  three,	  six,	  twelve,	  18	  and	  24	  months	  time	  to	  complete	  a	  shorter	  assessment	  of	  about	  60	  minutes	  each.	  You	  will	  receive	  £20	  each	  time.	  	  	  We	  may	  invite	  you	  to	  take	  part	  in	  further	  related	  studies,	  such	  as	  the	  investigation	  of	  biological	  factors	  that	  may	  underlie	  mental	  health	  issues,	  for	  example	  brain	  imaging.	  You	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will	  be	  paid	  for	  your	  time	  if	  deciding	  to	  participate	  in	  these	  add-­‐on	  studies,	  which	  you	  don’t	  have	  to	  do	  if	  you	  don’t	  want	  to.	  
	  
What	  are	  the	  possible	  side	  effects	  of	  taking	  part?	  We	  do	  not	  expect	  that	  any	  part	  of	  this	  study	  will	  cause	  harm	  to	  anyone	  taking	  part	  in	  it.	  Some	  people	  might	  find	  it	  difficult	  discussing	  their	  symptoms,	  life	  events	  or	  other	  personal	  information.	  You	  don’t	  have	  to	  answer	  anything	  that	  you	  are	  not	  comfortable	  with	  and	  you	  can	  stop	  at	  any	  time.	  If	  you	  experience	  distress	  and	  would	  like	  to	  discuss	  it	  with	  someone,	  we	  will	  organise	  this	  for	  you.	  	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  On	  a	  personal	  level,	  participants	  from	  previous	  studies	  have	  found	  that	  talking	  to	  a	  study	  researcher	  and	  sharing	  issues	  that	  might	  contribute	  to	  the	  mental	  health	  issues	  they	  are	  experiencing	  to	  be	  helpful.	  Although	  we	  cannot	  promise	  the	  study	  will	  help	  you,	  the	  information	  we	  get	  from	  this	  study	  may	  help	  other	  young	  people	  dealing	  with	  similar	  kinds	  of	  problems.	  	  
	  
What	  will	  happen	  when	  the	  research	  study	  stops?	  The	  data	  will	  be	  put	  into	  a	  database	  and	  analysed	  together	  with	  data	  from	  other	  participants	  who	  took	  part	  in	  the	  study.	  The	  results	  will	  be	  published	  in	  journal	  articles	  -­‐	  your	  identity	  will	  never	  be	  revealed.	  We	  will	  ask	  you	  at	  your	  appointment	  if	  you	  would	  like	  to	  see	  the	  results	  of	  the	  study	  when	  it	  is	  finished.	  	  	  	  	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  All	  information	  collected	  as	  part	  of	  this	  research	  will	  be	  kept	  in	  a	  locked	  filing	  cabinet	  and	  stored	  securely	  on	  a	  computer	  at	  University	  of	  Birmingham.	  We	  will	  give	  you	  an	  individual	  code,	  and	  all	  data	  from	  your	  interview	  will	  be	  stored	  using	  this	  code,	  not	  your	  name.	  Your	  GP	  or	  clinician	  may	  be	  informed	  of	  your	  participation,	  but	  only	  the	  research	  team	  will	  have	  access	  to	  your	  personal	  information.	  In	  the	  future,	  we	  may	  also	  send	  some	  of	  your	  data	  to	  colleagues	  in	  other	  universities,	  but	  we	  will	  never	  send	  information	  that	  could	  identify	  you.	  The	  data	  will	  be	  stored	  for	  a	  minimum	  of	  five	  year.	  All	  your	  information	  will	  be	  kept	  confidential,	  unless	  you	  tell	  us	  something	  that	  gives	  us	  reason	  to	  believe	  that	  you	  or	  others	  are	  in	  danger	  (e.g.	  having	  strong	  suicidal	  thoughts).	  In	  this	  event,	  we	  will	  talk	  with	  you	  about	  it	  before	  we	  share	  the	  information	  (e.g.	  telling	  your	  clinician).	  	  	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  The	  results	  of	  the	  study	  will	  be	  written	  up	  for	  publication	  in	  health	  professional	  journals	  and	  will	  be	  presented	  at	  conferences	  in	  the	  UK	  and	  abroad.	  Your	  identity	  will	  never	  be	  revealed.	  	  
Who	  is	  organising	  and	  funding	  the	  research?	  The	  research	  is	  sponsored	  by	  The	  University	  of	  Birmingham	  and	  is	  a	  PhD	  student	  project.	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What	  if	  there	  is	  a	  problem?	  If	  you	  are	  worried	  or	  concerned	  about	  any	  aspect	  of	  the	  study	  you	  should	  talk	  to	  the	  researcher.	  If	  they	  are	  unable	  to	  address	  your	  concerns	  or	  wish	  to	  make	  a	  complaint	  about	  the	  study,	  you	  can	  contact	  your	  local	  Patient	  Advice	  and	  Liaison	  Service	  -­‐	  call	  0800	  953	  0045;	  text	  07985	  883	  509;	  email	  pals@bsmhft.nhs.uk	  	  	  
Who	  has	  reviewed	  the	  study?	  All	  research	  in	  the	  NHS	  is	  examined	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  Ethics	  Committee.	  Their	  job	  is	  to	  protect	  your	  safety,	  rights,	  wellbeing	  and	  dignity.	  This	  study	  has	  been	  reviewed	  by	  the	  NRES	  Committee	  West	  Midlands	  -­‐	  Edgbaston.	  	  	  
Contact	  for	  Further	  Information	  Please	  contact	  Dr	  Ashleigh	  Lin	  (Project	  Coordinator)	  or	  Kareen	  Heinze	  (PhD	  Researcher)	  on	  07774	  274	  268	  or	  transitions@contacts.bham.ac.uk.	  We	  are	  situated	  at	  School	  of	  Psychology,	  University	  of	  Birmingham.	  
	  
If	  you	  agree	  to	  participate,	  you	  will	  be	  given	  a	  copy	  of	  this	  Information	  Sheet	  and	  a	  copy	  of	  
the	  signed	  consent	  form	  to	  keep.	  	  
	  
Thank	  you	  for	  reading	  this!
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PARTICIPANT CONSENT FORM (16 years of age or older) 
	  
	  
Study	  Title:	  The	  Transitions	  Study	  	  
	  
Name	  of	  Researcher:	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	   	  	  	  	  	  	  	  	  	  No	  
	  	  	  	  	  	   	   	   	   	   	   	  	  	  	  	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  dated	  	  
May	  2012	  (version	  2)	  for	  the	  above	  study	  and	  have	  had	  the	  opportunity	  
to	  ask	  questions.	  
	  
I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  to	  	  
withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  my	  medical	  	  
care	  or	  legal	  rights	  being	  affected.	  
	  
I	  give	  permission	  for	  researchers	  on	  this	  study	  to	  access	  to	  my	  medical	  	  
records	  from	  my	  GP	  and	  the	   	  	  
	  
	  
I	  give	  permission	  for	  researchers	  to	  inform	  my	  GP/clinician	  of	  my	  	  
participation	  in	  the	  study.	  
	  
I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  	  
collected	  during	  the	  study,	  may	  be	  looked	  at	  by	  individuals	  from	  the	  	  
University	  of	  Birmingham,	  from	  regular	  authorities	  or	  from	  the	  NHS	  
Trust,	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  
	  
I	  give	  permission	  for	  researchers	  to	  provide	  my	  treating	  	  
clinician/GP	  with	  a	  written	  summary	  of	  my	  scores	  from	  this	  	  
assessment,	  where	  it	  is	  relevant	  to	  my	  treatment	  and	  care.	  
	  
I	  agree:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  	  
study.	  
	  
To	  provide	  a	  saliva	  sample	  for	  genetic	  analyses.	  
	  
A-6: CONSENT FORM (≥	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To	  being	  contacted	  for	  follow-­‐up	  assessments	  as	  part	  of	  the	  	  
ongoing	  study.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  	  
to	  this	  one.	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Participant	   	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	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PARTICIPANT CONSENT FORM (younger than 16 years of age) 
	  
	  
Study	  Title:	  The	  Transitions	  Study	  	  
	  
Name	  of	  Researcher:	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  dated	  	  
May	  2012	  (version	  2)	  for	  the	  above	  study	  and	  have	  had	  the	  opportunity	  	  
to	  ask	  questions.	  
	  
I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  to	  	  
withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  my	  	  
medical	  care	  or	  legal	  rights	  being	  affected.	  
	  
I	  give	  permission	  for	  researchers	  on	  this	  study	  to	  access	  to	  my	  	  
medical	  records	  from	  my	  GP	  and	  the	   	  	  
.	  
	  
I	  give	  permission	  for	  researchers	  to	  inform	  my	  GP/clinician	  of	  	  
my	  participation	  in	  the	  study.	  
	  
I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  	  
collected	  during	  the	  study,	  may	  be	  looked	  at	  by	  individuals	  from	  	  
the	  University	  of	  Birmingham,	  from	  regular	  authorities	  or	  from	  the	  	  
NHS	  Trust,	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  
	  
I	  give	  permission	  for	  researchers	  to	  provide	  my	  treating	  clinician/GP	  	  
with	  a	  written	  summary	  of	  my	  scores	  from	  this	  assessment,	  where	  it	  is	  	  
relevant	  to	  my	  treatment	  and	  care.	  
	  
	  I	  agree:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  provide	  a	  saliva	  sample	  for	  genetic	  analyses.	  
	  
To	  being	  contacted	  for	  follow-­‐up	  assessments	  as	  part	  of	  the	  ongoing	  study.	  
A-7: CONSENT FORM (<	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To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	   	   	  
	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Participant	   	   	   Date	   	   	   	   Signature	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Parent/Guardian	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	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PARENT/GUARDIAN CONSENT FORM (for participants under 16 years) 
	  
	  
Study	  Title:	  The	  Transitions	  Study	  	  
	  
Name	  of	  Researcher:	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  	  
dated	  May	  2012	  (version	  2)	  for	  the	  above	  study	  and	  have	  had	  	  
the	  opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  the	  participation	  of	  the	  child	  under	  my	  	  
guardianship	  is	  voluntary	  and	  that	  he/she	  is	  free	  to	  withdraw	  	  
at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  his/her	  medical	  	  
care	  or	  legal	  rights	  being	  affected.	  
	  
I	  give	  permission	  for	  researchers	  on	  this	  study	  to	  access	  to	  the	  	  
medical	  records	  of	  the	  child	  under	  my	  guardianship	  from	  his/her	  	  
GP	  and	  the 	  	  
	  
	  
I	  give	  permission	  for	  researchers	  to	  inform	  the	  GP/clinician	  of	  the	  	  
child	  under	  my	  guardianship	  of	  his/her	  participation	  in	  the	  study.	  
	  
I	  understand	  that	  relevant	  sections	  of	  medical	  notes	  and	  data	  	  
collected	  during	  the	  study	  may	  be	  looked	  at	  by	  individuals	  from	  	  
the	  University	  of	  Birmingham,	  from	  regular	  authorities	  or	  from	  	  
the	  NHS	  Trust,	  where	  it	  is	  relevant	  to	  his/her	  taking	  part	  in	  this	  	  
research.	  	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  his/her	  	  
records.	  
	  
I	  give	  permission	  for	  researchers	  to	  provide	  the	  treating	  clinician/GP	  
	  of	  the	  child	  under	  my	  guardianship	  with	  a	  written	  summary	  of	  their	  	  
scores	  from	  this	  assessment,	  where	  it	  is	  relevant	  to	  his/her	  treatment	  	  
and	  care.	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  I	  agree	  for	  the	  child	  under	  my	  guardianship:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  provide	  a	  saliva	  sample	  for	  genetic	  analyses.	  
	  
To	  being	  contacted	  for	  follow-­‐up	  assessments	  as	  part	  of	  the	  ongoing	  study.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	   	   	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Parent/Guardian	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	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Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  
Transitions	  Study)	  	  We	  are	  writing	  to	  invite	  you	  to	  take	  part	  in	  an	  extra	  study	  that	  is	  related	  to	  your	  participation	  in	  the	  Transitions	  Study.	  The	  aim	  of	  this	  research	  is	  to	  investigate	  the	  role	  of	  neurobiological	  factors	  that	  underlie	  mental	  health	  issues	  in	  adolescents	  and	  young	  people.	  Taking	  part	  in	  this	  research	  will	  involve	  brain	  imaging	  (Magnetic	  Resonance	  Imaging,	  MRI)	  and	  hormone	  analysis,	  which	  we	  do	  by	  taking	  hair	  samples	  (please	  find	  a	  detailed	  description	  in	  the	  enclosed	  Participant	  Information	  Sheet).	  	  	  The	  assessment	  will	  take	  around	  one	  and	  a	  half	  hours,	  and	  we	  will	  pay	  you	  £20	  for	  your	  time	  and	  travel	  expenses.	  After	  six	  months	  we	  will	  ask	  you	  again	  to	  take	  part	  in	  the	  same	  assessment,	  and	  after	  12	  months	  we	  will	  ask	  you	  for	  a	  hair	  sample	  and	  to	  answer	  some	  questions.	  We	  will	  give	  you	  additional	  £20	  for	  completing	  the	  assessment	  after	  six	  months	  and	  another	  £5	  after	  completing	  the	  assessment	  after	  12	  months.	  If	  you	  only	  want	  to	  take	  part	  in	  either	  the	  MRI	  study	  or	  the	  hair	  hormone	  study,	  we	  would	  reimburse	  you	  separately	  with	  £15	  for	  the	  MRI	  study	  and	  £5	  for	  the	  hair	  hormone	  study	  at	  the	  first	  and	  second	  assessment.	  	  If	  you	  would	  like	  to	  take	  part	  in	  this	  study,	  or	  if	  you	  would	  like	  more	  information	  about	  it	  before	  you	  decide,	  please	  contact	  us	  in	  one	  of	  these	  ways:	  	  Call	  or	  text	  us:	  07774	  274268	  Email	  us:	  transitions@contacts.bham.ac.uk	  Facebook	  message	  us:	  Transitions	  Birmingham	  	  We	  look	  forward	  to	  hearing	  from	  you!	  	  Best	  wishes,	  
	  
Kareen	  &	  the	  Transition	  Team
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Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  –	  First	  
follow-­‐up	  study	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (The	  Transitions	  Study)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  We	  are	  writing	  to	  invite	  you	  to	  a	  follow-­‐up	  study	  that	  is	  related	  to	  your	  participation	  in	  the	  brain	  imaging	  (Magnetic	  Resonance	  Imaging,	  MRI)	  and	  hair	  hormone	  study.	  The	  aim	  of	  this	  research	  is	  to	  investigate	  the	  role	  of	  neurobiological	  factors	  that	  underlie	  mental	  health	  issues	  in	  adolescents	  and	  young	  people	  over	  an	  extended	  period	  of	  time.	  Taking	  part	  in	  this	  research	  will	  involve	  the	  same	  assessment	  that	  you	  did	  six	  months	  ago,	  in	  which	  you	  had	  a	  brain	  scan	  and	  gave	  a	  sample	  of	  hair.	  	  	  The	  assessment	  will	  take	  around	  one	  and	  a	  half	  hours,	  and	  we	  will	  pay	  you	  £20	  for	  your	  time	  and	  travel	  expenses.	  If	  you	  only	  want	  to	  take	  part	  in	  either	  the	  MRI	  study	  or	  the	  hair	  hormone	  study,	  we	  would	  reimburse	  you	  separately	  with	  £15	  for	  the	  MRI	  study	  and	  £5	  for	  the	  hair	  hormone	  study.	  	  If	  you	  would	  like	  to	  take	  part	  in	  this	  study,	  or	  if	  you	  would	  like	  more	  information	  about	  it	  before	  you	  decide,	  please	  contact	  us	  in	  one	  of	  these	  ways:	  	  Call	  or	  text	  us:	  07774	  274268	  Email	  us:	  transitions@contacts.bham.ac.uk	  Facebook	  message	  us:	  Transitions	  Birmingham	  	  	  We	  look	  forward	  to	  hearing	  from	  you!	  	  	  Best	  wishes,	  
	  
	  
	  
Kareen	  &	  the	  Transition	  Team	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PARTICIPANT INFORMATION 
	  
	  
Study	  Title:	   Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  
Study)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  whether	  or	  not	  you	  
wish	  to	  take	  part,	  it	  is	  important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  
what	  it	  will	  involve.	  	  Please	  take	  time	  to	  read	  the	  following	  information	  carefully	  and	  discuss	  
it	  with	  others	  if	  you	  wish.	  	  Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  
more	  information.	  	  	  
	  
The	  purpose	  of	  the	  study	  
This	  study	  will	  investigate	  the	  role	  of	  different	  hormones	  (such	  as	  cortisol,	  cortisone,	  
testosterone)	  and	  the	  structure	  and	  function	  of	  the	  brain	  in	  the	  development	  of	  mental	  
health	  issues.	  We	  want	  to	  find	  out	  whether	  there	  are	  any	  identifiable	  brain	  or	  hormonal	  
factors	  that	  contribute	  to	  mental	  health	  issues	  and	  if	  they	  help	  to	  classify	  mental	  problems	  
into	  recognisable	  stages.	  
	  
Why	  have	  I	  been	  chosen?	  
We	  are	  inviting	  young	  people	  who	  are	  taking	  part	  in	  the	  Transitions	  Study	  and	  who	  are	  
experiencing	  mental	  health	  issues	  which	  persist	  for	  more	  than	  6	  weeks	  and/or	  have	  a	  family	  
member	  with	  mental	  health	  issues,	  to	  participate	  in	  this	  study.	  	  
	  
Do	  I	  have	  to	  take	  part?	  
No	  –	  involvement	  in	  this	  study	  is	  voluntary.	  If	  you	  decide	  to	  take	  part,	  you	  are	  still	  free	  to	  
withdraw	  at	  any	  time	  without	  giving	  a	  reason.	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  
decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  health	  care	  you	  receive	  now	  or	  in	  
the	  future.	  	  
	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
You	  will	  undergo	  an	  Magnetic	  Resonance	  Imaging	  scan	  (please	  find	  information	  below)	  and	  
you	  will	  be	  asked	  to	  give	  a	  small	  hair	  sample	  from	  the	  back	  of	  your	  head	  and	  answer	  some	  
questions	  that	  are	  relevant	  for	  the	  hair	  hormone	  analysis.	  	  
	  
Magnetic	  resonance	  imaging	  (MRI)	  is	  a	  way	  to	  take	  pictures	  of	  the	  inside	  of	  the	  body,	  and	  for	  
this	  study,	  specifically	  of	  your	  brain.	  The	  process	  uses	  intense	  magnetic	  fields	  and	  radio	  
waves	  to	  create	  these	  images.	  We	  will	  get	  information	  about	  both	  the	  structure	  and	  function	  
of	  your	  brain.	  You	  will	  be	  asked	  to	  go	  through	  a	  safety	  questionnaire	  with	  a	  scan	  operator	  
before	  being	  allowed	  into	  the	  scanner	  itself.	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You	  will	  be	  asked	  to	  lie	  completely	  still	  on	  your	  back	  while	  the	  machine	  will	  surround	  the	  
upper	  part	  of	  your	  body.	  The	  scanning	  session	  will	  last	  around	  45	  minutes	  during	  which	  
there	  will	  be	  times	  when	  you	  have	  to	  do	  some	  tasks	  while	  looking	  at	  a	  screen,	  and	  times	  
when	  you	  will	  be	  asked	  to	  let	  your	  mind	  wander	  freely.	  
	  
The	  full	  assessment	  will	  take	  around	  one	  and	  a	  half	  hours,	  and	  we	  will	  pay	  you	  £20	  for	  your	  
time	  and	  travel	  expenses	  for	  both	  parts	  of	  the	  study.	  If	  you	  only	  feel	  happy	  to	  take	  part	  in	  
one	  assessment,	  we	  will	  offer	  you	  £15	  for	  the	  scanning	  session	  and	  £5	  for	  the	  hair	  hormone	  
analysis.	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
It	  is	  unlikely	  that	  there	  will	  be	  any	  direct	  benefits	  to	  you	  from	  taking	  part.	  However,	  we	  hope	  
that	  this	  study	  will	  help	  us	  understand	  the	  development	  of	  mental	  health	  issues,	  and	  give	  us	  
some	  idea	  of	  whether	  there	  are	  ‘stages’	  to	  these	  illness	  that	  can	  be	  separated	  by	  looking	  at	  
brain	  scans	  or	  hormone	  measures.	  If	  we	  can	  do	  this,	  it	  may	  help	  us	  to	  select	  the	  best	  
treatment	  for	  a	  person’s	  stage	  of	  illness.	  	  	  
	  
What	  are	  the	  possible	  side	  effects	  of	  taking	  part?	  
The	  MRI	  procedure	  is	  considered	  to	  be	  extremely	  safe	  and	  non-­‐invasive.	  However,	  the	  
scanner	  is	  noisy	  so	  all	  participants	  will	  wear	  earplugs	  and	  headphones.	  The	  MRI	  is	  a	  small	  
space	  and	  can	  cause	  distress	  for	  people	  who	  are	  afraid	  of	  small	  places.	  If	  you	  think	  you	  may	  
feel	  claustrophobic,	  please	  discuss	  this	  with	  us	  and	  we	  can	  do	  a	  practice	  run	  in	  a	  mock	  
scanner.	  If	  this	  is	  uncomfortable	  for	  you,	  we	  don’t	  need	  to	  proceed.	  
	  
The	  main	  risks	  of	  MRI	  are	  because	  of	  people	  taking	  metal	  objects	  into	  the	  scanning	  room.	  
This	  is	  particularly	  dangerous	  if	  you	  have	  metal	  in	  your	  body	  from	  surgery	  (for	  example	  a	  
pacemaker),	  or	  from	  an	  accident	  (such	  as	  having	  metal	  filings	  in	  your	  eye	  from	  welding	  or	  
grinding	  metal).	  We	  will	  ask	  you	  questions	  about	  this,	  and	  it	  is	  important	  for	  you	  to	  tell	  us	  if	  
there	  is	  a	  chance	  you	  have	  metal	  in	  you.	  
	  
You	  will	  be	  carefully	  introduced	  to	  the	  scanner	  and	  you	  are	  allowed	  to	  leave	  at	  any	  stage.	  	  
While	  lying	  motionless	  on	  the	  scanner	  bed,	  you	  may	  experience	  back	  and	  neck	  pain.	  This	  will	  
be	  minimized	  by	  the	  use	  of	  comfortable	  padding	  and	  positioning.	  
	  
There	  is	  no	  known	  extra	  risk	  in	  conducting	  MRI	  scans	  on	  women	  who	  are	  pregnant.	  
However,	  it	  is	  conventional	  to	  exclude	  women	  who	  are	  pregnant	  from	  research	  using	  MRI	  
scans.	  A	  pregnancy	  test	  kit	  will	  be	  available,	  should	  women	  wish	  to	  use	  it	  before	  undergoing	  
a	  scan.	  
	  
Whilst	  in	  the	  scanner,	  you	  can	  talk	  to	  the	  operator	  at	  any	  time	  and	  will	  be	  holding	  an	  
emergency	  button	  which	  you	  can	  squeeze	  during	  a	  scan	  in	  the	  event	  of	  distress.	  This	  will	  
activate	  an	  alarm	  and	  cause	  the	  operator	  to	  immediately	  stop	  the	  scan.	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What	  will	  happen	  when	  the	  research	  study	  stops?	  
The	  results	  will	  be	  written	  up	  for	  scientific	  publication.	  All	  data	  will	  be	  reported	  
anonymously.	  	  
	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  
All	  information	  collected	  as	  part	  of	  this	  research	  will	  be	  kept	  in	  a	  locked	  filing	  cabinet	  and	  
stored	  securely	  on	  a	  computer	  at	  University	  of	  Birmingham.	  We	  will	  give	  you	  an	  individual	  
code,	  and	  all	  data	  from	  your	  interview	  will	  be	  stored	  using	  this	  code,	  not	  your	  name.	  Your	  GP	  
or	  clinician	  may	  be	  informed	  of	  your	  participation,	  but	  only	  the	  research	  team	  have	  access	  to	  
your	  personal	  information.	  The	  data	  will	  be	  stored	  for	  a	  minimum	  of	  five	  years.	  All	  your	  
information	  will	  be	  kept	  confidential,	  unless	  you	  tell	  us	  something	  that	  gives	  us	  reason	  to	  
believe	  that	  you	  or	  others	  are	  in	  danger	  (e.g.	  having	  strong	  suicidal	  thoughts).	  In	  this	  event,	  
we	  will	  talk	  with	  you	  about	  it	  before	  we	  share	  the	  information	  (e.g.	  telling	  your	  clinician).	  	  
	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  
The	  results	  of	  the	  study	  will	  be	  written	  up	  for	  publication	  in	  health	  professional	  journals	  and	  
will	  be	  presented	  at	  conferences	  in	  the	  UK	  and	  abroad.	  Your	  identity	  will	  never	  be	  revealed.	  
	  
Who	  is	  organising	  and	  funding	  the	  research?	  
The	  research	  is	  being	  undertaken	  as	  part	  of	  a	  PhD	  at	  the	  University	  of	  Birmingham.	  
	  
What	  if	  there	  is	  a	  problem?	  
If	  you	  are	  worried	  or	  concerned	  about	  any	  aspect	  of	  the	  study	  you	  should	  talk	  to	  the	  
researcher.	  If	  they	  are	  unable	  to	  address	  your	  concerns	  or	  wish	  to	  make	  a	  complaint	  about	  
the	  study,	  you	  can	  contact	  your	  local	  Patient	  Advice	  and	  Liaison	  Service	  -­‐	   ;	  
text	   ;	  email	   	  
	  
Who	  has	  reviewed	  the	  study?	  
All	  research	  in	  the	  NHS	  is	  examined	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  
Ethics	  Committee.	  Their	  job	  is	  to	  protect	  your	  safety,	  rights,	  wellbeing	  and	  dignity.	  This	  study	  
has	  been	  reviewed	  by	  the	  NRES	  Committee	   .	  	  
	  
Contact	  for	  Further	  Information	  
Please	  contact	  Kareen	  Heinze	  (PhD	  Researcher)	  on 	  or	  
	  We	  are	  situated	  at	  School	  of	  Psychology,	  University	  of	  
Birmingham.	  
	  
If	  you	  agree	  to	  participate,	  you	  will	  be	  given	  a	  copy	  of	  this	  Information	  Sheet	  and	  a	  copy	  of	  
the	  signed	  consent	  form	  to	  keep.	  	  
	  
Thank	  you	  for	  reading	  this.	  
	  
	  
A-13: PATIENT CONSENT FORM (≥ 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 A-­‐23	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
PARTICIPANT CONSENT FORM (16 years of age or older) 
	  
	  
Study	  Title:	  Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  Study)	  	  
	  
Name	  of	  Researcher:	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  	  
dated	  June	  2012	  (version	  1)	  for	  the	  above	  study	  and	  have	  had	  the	  	  
opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  	  
to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  	  
my	  medical	  care	  or	  legal	  rights	  being	  affected.	  
	  
I	  give	  permission	  for	  researchers	  on	  this	  study	  to	  access	  to	  my	  	  
medical	  records	  from	  my	  GP	  and	  the	   	  	  
	  
	  
I	  give	  permission	  for	  researchers	  to	  inform	  my	  GP/clinician	  of	  	  
my	  participation	  in	  the	  study.	  
	  
I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  
collected	  during	  the	  study,	  may	  be	  looked	  at	  by	  individuals	  from	  	  
the	  University	  of	  Birmingham,	  from	  regular	  authorities	  or	  from	  
the	  NHS	  Trust,	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  
	  
	  
I	  agree:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  do	  the	  magnetic	  resonance	  imaging	  session.	  
	  
To	  give	  a	  hair	  sample	  for	  hormone	  analysis.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
A-13: PATIENT CONSENT FORM (≥ 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 A-­‐24	  
	   	   	   	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Participant	   	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
A-14: PATIENT CONSENT FORM (< 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 A-25 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
PARTICIPANT CONSENT FORM (younger than 16 years) 
	  
	  
Study	  Title:	  Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  Study)	  	  
	  
Name	  of	  Researcher:	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  	  
dated	  June	  2012	  (version	  1)	  for	  the	  above	  study	  and	  have	  had	  	  
the	  opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  	  
free	  to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  and	  	  
without	  my	  medical	  care	  or	  legal	  rights	  being	  affected.	  
	  
I	  give	  permission	  for	  researchers	  on	  this	  study	  to	  access	  to	  my	  	  
medical	  records	  from	  my	  GP	  and	  the	   	  	  
	  
	  
I	  give	  permission	  for	  researchers	  to	  inform	  my	  GP/clinician	  of	  	  
my	  participation	  in	  the	  study.	  
	  
I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  	  
collected	  during	  the	  study,may	  be	  looked	  at	  by	  individuals	  from	  	  
the	  University	  of	  Birmingham,	  from	  regular	  authorities	  or	  from	  	  
the	  NHS	  Trust,	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  
	  
	  
I	  agree:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  give	  a	  hair	  sample	  for	  hormone	  analysis.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	   	   	  
A-14: PATIENT CONSENT FORM (< 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 A-26 
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Parent/Guardian	   	   Date	   	   	   	   Signature	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Participant	   	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
A-15: PATIENT PARENT CONSENT FORM, NEUROBIOLOGICAL STUDY 
A-­‐27	  
 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
PARENT/GUARDIAN CONSENT FORM  
	  
	  
Study	  Title:	  Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  Study)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Name	  of	  Researcher:	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  	  
dated	  June	  2012	  (version	  1)	  for	  the	  above	  study	  and	  have	  had	  	  
the	  opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  the	  participation	  of	  the	  child	  under	  my	  	  
guardianship	  is	  voluntary	  and	  that	  he/she	  is	  free	  to	  withdraw	  	  
at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  his/her	  	  
medical	  care	  or	  legal	  rights	  being	  affected.	  
	  
I	  give	  permission	  for	  researchers	  on	  this	  study	  to	  access	  to	  the	  
	  medical	  records	  of	  the	  child	  under	  my	  guardianship	  from	  his/her	  	  
GP	  and	  the 	  	  
	  
	  
I	  give	  permission	  for	  researchers	  to	  inform	  the	  GP/clinician	  of	  	  
the	  child	  under	  my	  guardianship	  of	  his/her	  participation	  in	  the	  study.	  
	  
I	  understand	  that	  relevant	  sections	  of	  medical	  notes	  and	  data	  	  
collected	  during	  the	  study	  may	  be	  looked	  at	  by	  individuals	  from	  
	  the	  University	  of	  Birmingham,	  from	  regular	  authorities	  or	  from	  	  
the	  NHS	  Trust,	  where	  it	  is	  relevant	  to	  his/her	  taking	  part	  in	  this	  	  
research.	  	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  his/her	  	  
records.	  
	  
	  
I	  agree	  for	  the	  child	  under	  my	  guardianship:	  
	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  do	  the	  magnetic	  resonance	  imaging	  session	  (only	  if	  child	  is	  over	  	  
16	  years	  of	  age).	  
A-15: PATIENT PARENT CONSENT FORM, NEUROBIOLOGICAL STUDY 
A-­‐28	  
 
	  
To	  give	  a	  hair	  sample	  for	  hormone	  analysis.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	   	   	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Parent/Guardian	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
A-16: CONTROL INFORMATION, NEUROBIOLOGICAL STUDY 
A-­‐29	  
 
	  
	  
PARTICIPANT INFORMATION  
	  
	  
Study	  Title:	   Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  
Study)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  whether	  or	  not	  you	  
wish	  to	  take	  part,	  it	  is	  important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  
what	  it	  will	  involve.	  	  Please	  take	  time	  to	  read	  the	  following	  information	  carefully	  and	  discuss	  
it	  with	  others	  if	  you	  wish.	  	  Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  
more	  information.	  	  	  
	  
The	  purpose	  of	  the	  study	  
This	  study	  will	  investigate	  the	  role	  of	  different	  hormones	  (such	  as	  cortisol,	  cortisone,	  
testosterone)	  and	  the	  structure	  and	  function	  of	  the	  brain	  in	  the	  development	  of	  mental	  
health	  issues.	  We	  want	  to	  find	  out	  whether	  there	  are	  any	  identifiable	  brain	  or	  hormonal	  
factors	  that	  contribute	  to	  mental	  health	  issues	  and	  if	  they	  help	  to	  classify	  mental	  problems	  
into	  recognisable	  stages.	  
	  
Why	  have	  I	  been	  chosen?	  
We	  are	  inviting	  healthy,	  young	  people	  to	  take	  part	  in	  this	  study.	  Your	  data,	  as	  a	  control	  
participant,	  will	  be	  compared	  to	  young	  people	  who	  sought	  help	  for	  mental	  health	  issues.	  	  
	  
Do	  I	  have	  to	  take	  part?	  
No	  –	  involvement	  in	  this	  study	  is	  voluntary.	  If	  you	  decide	  to	  take	  part,	  you	  are	  still	  free	  to	  
withdraw	  at	  any	  time	  without	  giving	  a	  reason.	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  
decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  health	  care	  you	  receive	  now	  or	  in	  
the	  future.	  	  
	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
You	  will	  undergo	  a	  Magnetic	  Resonance	  Imaging	  scan	  (please	  find	  information	  below)	  and	  
you	  will	  be	  asked	  to	  give	  a	  small	  hair	  sample	  from	  the	  back	  of	  your	  head	  and	  answer	  some	  
questions	  that	  are	  relevant	  for	  the	  hair	  hormone	  analysis.	  	  
	  
Magnetic	  resonance	  imaging	  (MRI)	  is	  a	  way	  to	  take	  pictures	  of	  the	  inside	  of	  the	  body,	  and	  for	  
this	  study,	  specifically	  of	  your	  brain.	  The	  process	  uses	  intense	  magnetic	  fields	  and	  radio	  
waves	  to	  create	  these	  images.	  We	  will	  get	  information	  about	  both	  the	  structure	  and	  function	  
of	  your	  brain.	  You	  will	  be	  asked	  to	  go	  through	  a	  safety	  questionnaire	  with	  a	  scan	  operator	  
before	  being	  allowed	  into	  the	  scanner	  itself.	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You	  will	  be	  asked	  to	  lie	  completely	  still	  on	  your	  back	  while	  the	  machine	  will	  surround	  the	  
upper	  part	  of	  your	  body.	  The	  scanning	  session	  will	  last	  around	  45	  minutes	  during	  which	  
there	  will	  be	  times	  when	  you	  have	  to	  do	  some	  tasks	  while	  looking	  at	  a	  screen,	  and	  times	  
when	  you	  will	  be	  asked	  to	  let	  your	  mind	  wander	  freely.	  
	  
The	  full	  assessment	  will	  take	  around	  one	  and	  a	  half	  hours,	  and	  we	  will	  pay	  you	  £20	  for	  your	  
time	  and	  travel	  expenses	  for	  both	  parts	  of	  the	  study.	  If	  you	  only	  feel	  happy	  to	  take	  part	  in	  
one	  assessment,	  we	  will	  offer	  you	  £15	  for	  the	  scanning	  session	  and	  £5	  for	  the	  hair	  hormone	  
analysis.	  
	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
It	  is	  very	  unlikely	  that	  there	  will	  be	  any	  direct	  benefits	  to	  you	  from	  taking	  part.	  However,	  we	  
hope	  that	  this	  study	  will	  help	  us	  understand	  the	  development	  of	  mental	  health	  issues,	  and	  
give	  us	  some	  idea	  of	  whether	  there	  are	  ‘stages’	  to	  these	  illness	  that	  can	  be	  separated	  by	  
looking	  at	  brain	  scans	  or	  hormone	  measures.	  If	  we	  can	  do	  this,	  it	  may	  help	  us	  to	  select	  the	  
best	  treatment	  for	  a	  person’s	  stage	  of	  illness.	  
	  
What	  are	  the	  possible	  side	  effects	  of	  taking	  part?	  
The	  MRI	  procedure	  is	  considered	  to	  be	  extremely	  safe	  and	  non-­‐invasive.	  However,	  the	  
scanner	  is	  noisy	  so	  all	  participants	  will	  wear	  earplugs	  and	  headphones.	  The	  MRI	  is	  a	  small	  
space	  and	  can	  cause	  distress	  for	  people	  who	  are	  afraid	  of	  small	  places.	  If	  you	  think	  you	  may	  
feel	  claustrophobic,	  please	  discuss	  this	  with	  us	  and	  we	  can	  do	  a	  practice	  run	  in	  a	  mock	  
scanner.	  If	  this	  is	  uncomfortable	  for	  you,	  we	  don’t	  need	  to	  proceed.	  	  
	  
The	  main	  risks	  of	  MRI	  are	  because	  of	  people	  taking	  metal	  objects	  into	  the	  scanning	  room.	  
This	  is	  particularly	  dangerous	  if	  you	  have	  metal	  in	  your	  body	  from	  surgery	  (for	  example	  a	  
pacemaker),	  or	  from	  an	  accident	  (such	  as	  having	  metal	  filings	  in	  your	  eye	  from	  welding	  or	  
grinding	  metal).	  We	  will	  ask	  you	  questions	  about	  this,	  and	  it	  is	  important	  for	  you	  to	  tell	  us	  if	  
there	  is	  a	  chance	  you	  have	  metal	  in	  you.	  
	  
You	  will	  be	  carefully	  introduced	  to	  the	  scanner	  and	  you	  are	  allowed	  to	  leave	  at	  any	  stage.	  	  
While	  lying	  motionless	  on	  the	  scanner	  bed,	  you	  may	  experience	  back	  and	  neck	  pain.	  This	  will	  
be	  minimized	  by	  the	  use	  of	  comfortable	  padding	  and	  positioning.	  
	  
There	  is	  no	  known	  extra	  risk	  in	  conducting	  MRI	  scans	  on	  women	  who	  are	  pregnant.	  
However,	  it	  is	  conventional	  to	  exclude	  women	  who	  are	  pregnant	  from	  research	  using	  MRI	  
scans.	  A	  pregnancy	  test	  kit	  will	  be	  available,	  should	  women	  wish	  to	  use	  it	  before	  undergoing	  
a	  scan.	  
	  
Whilst	  in	  the	  scanner,	  you	  can	  talk	  to	  the	  operator	  at	  any	  time	  and	  will	  be	  holding	  an	  
emergency	  button	  which	  you	  can	  squeeze	  during	  a	  scan	  in	  the	  event	  of	  distress.	  This	  will	  
activate	  an	  alarm	  and	  cause	  the	  operator	  to	  immediately	  stop	  the	  scan.	  
	  
What	  will	  happen	  when	  the	  research	  study	  stops?	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The	  results	  will	  be	  written	  up	  for	  scientific	  publication.	  All	  data	  will	  be	  reported	  
anonymously.	  	  
	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  
All	  information	  collected	  as	  part	  of	  this	  research	  will	  be	  kept	  in	  a	  locked	  filing	  cabinet	  and	  
stored	  securely	  on	  a	  computer	  at	  University	  of	  Birmingham.	  We	  will	  give	  you	  an	  individual	  
code,	  and	  all	  data	  from	  your	  interview	  will	  be	  stored	  using	  this	  code,	  not	  your	  name.	  The	  
data	  will	  be	  stored	  for	  a	  minimum	  of	  five	  years.	  All	  your	  information	  will	  be	  kept	  
confidential,	  unless	  you	  tell	  us	  something	  that	  gives	  us	  reason	  to	  believe	  that	  you	  or	  others	  
are	  in	  danger	  (e.g.	  having	  strong	  suicidal	  thoughts).	  In	  this	  event,	  we	  will	  talk	  with	  you	  about	  
it	  before	  we	  share	  the	  information.	  	  
	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  
The	  results	  of	  the	  study	  will	  be	  written	  up	  for	  publication	  in	  health	  professional	  journals	  and	  
will	  be	  presented	  at	  conferences	  in	  the	  UK	  and	  abroad.	  Your	  identity	  will	  never	  be	  revealed.	  
	  
Who	  is	  organising	  and	  funding	  the	  research?	  
The	  research	  is	  being	  undertaken	  as	  part	  of	  a	  PhD	  at	  the	  University	  of	  Birmingham.	  
	  
	  
What	  if	  there	  is	  a	  problem?	  
If	  you	  are	  worried	  or	  concerned	  about	  any	  aspect	  of	  the	  study	  you	  should	  talk	  to	  the	  
researcher.	  If	  they	  are	  unable	  to	  address	  your	  concerns	  or	  wish	  to	  make	  a	  complaint	  about	  
the	  study,	  you	  can	  contact	  your	  local	  Patient	  Advice	  and	  Liaison	  Service	  -­‐	  call	   ;	  
text	   ;	  email	   	  
	  
Who	  has	  reviewed	  the	  study?	  
All	  research	  in	  the	  NHS	  is	  examined	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  
Ethics	  Committee.	  Their	  job	  is	  to	  protect	  your	  safety,	  rights,	  wellbeing	  and	  dignity.	  This	  study	  
has	  been	  reviewed	  by	  the	  NRES	  Committee	   .	  
	  
Contact	  for	  Further	  Information	  
Please	  contact	  Kareen	  Heinze	  (PhD	  Researcher)	  on 	  or	  
.	  We	  are	  situated	  at	  School	  of	  Psychology,	  University	  of	  
Birmingham.	  
	  
If	  you	  agree	  to	  participate,	  you	  will	  be	  given	  a	  copy	  of	  this	  Information	  Sheet	  and	  a	  copy	  of	  
the	  signed	  consent	  form	  to	  keep.	  	  
	  
Thank	  you	  for	  reading	  this.	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PARTICIPANT CONSENT FORM (16 years of age or older) 
	  
Study	  Title:	  Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  Study)	  	  
	  
Name	  of	  Researcher:	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  
dated	  June	  2012	  (version	  1)	  for	  the	  above	  study	  and	  have	  had	  	  
the	  opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  	  
free	  to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  and	  	  
without	  my	  legal	  rights	  being	  affected.	  
	  
I	  understand	  that	  relevant	  sections	  of	  data	  collected	  during	  the	  	  
study,	  may	  be	  looked	  at	  by	  individuals	  from	  the	  University	  of	  	  
Birmingham,	  from	  regular	  authorities	  or	  from	  the	  NHS	  Trust,	  	  
where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  I	  give	  	  
permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  
	  
	  
I	  agree:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  do	  the	  magnetic	  resonance	  imaging	  session.	  
	  
To	  give	  a	  hair	  sample	  for	  hormone	  analysis.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	   	   	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Participant	   	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
A-17: CONTROL CONSENT FORM (≥	 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 A-33 
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature
A-18: CONTROL CONSENT FORM (<	 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 
A-34 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
PARTICIPANT CONSENT FORM (younger than 16 years) 
	  
	  
Study	  Title:	  Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  	  	  	  
Study)	  	  
	  
Name	  of	  Researcher:	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  	  
dated	  June	  2012	  (version	  1)	  for	  the	  above	  study	  and	  have	  had	  	  
the	  opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  	  
to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  	  
my	  legal	  rights	  being	  affected.	  
	  
I	  understand	  that	  relevant	  sections	  of	  data	  collected	  during	  the	  	  
study,	  may	  be	  looked	  at	  by	  individuals	  from	  the	  University	  of	  	  
Birmingham,	  from	  regular	  authorities	  or	  from	  the	  NHS	  Trust,	  	  
where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  
	  
	  
I	  agree:	  
To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
To	  give	  a	  hair	  sample	  for	  hormone	  analysis.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	   	   	  
	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Parent/Guardian	   	   Date	   	   	   	   Signature	  
	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Participant	   	   	   Date	   	   	   	   Signature	  
A-18: CONTROL CONSENT FORM (<	 16 YEARS), NEUROBIOLOGICAL STUDY 
                                 
 
A-35 
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
A-19: CONTROL PARENT CONSENT, NEUROBIOLOGICAL STUDY 
 
 
A-­‐36	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  
	  
PARENT/GUARDIAN CONSENT FORM  
	  
Study	  Title:	  Neurobiological	  Markers	  of	  Risk	  for	  Mental	  Health	  Issues	  (The	  Transitions	  Study)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Name	  of	  Researcher:	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  	  
dated	  June	  2012	  (version	  1)	  for	  the	  above	  study	  and	  have	  had	  	  
the	  opportunity	  to	  ask	  questions.	  
	  
I	  understand	  that	  the	  participation	  of	  the	  child	  under	  my	  	  
guardianship	  is	  voluntary	  and	  that	  he/she	  is	  free	  to	  withdraw	  	  
at	  any	  time,	  without	  giving	  any	  reason,	  and	  without	  his/her	  	  
legal	  rights	  being	  affected.	  
	  
I	  understand	  that	  relevant	  sections	  data	  collected	  during	  the	  	  
study	  may	  be	  looked	  at	  by	  individuals	  from	  the	  University	  of	  	  
Birmingham,	  from	  regular	  authorities	  or	  from	  the	  NHS	  Trust,	  	  
where	  it	  is	  relevant	  to	  his/her	  taking	  part	  in	  this	  research.	  	  
I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  his/her	  	  
records.	  
	  
	  
	  I	  agree	  for	  the	  child	  under	  my	  guardianship:	  
	   To	  participate	  in	  the	  interview	  and	  questionnaire	  part	  of	  this	  study.	  
	  
	   To	  do	  the	  magnetic	  resonance	  imaging	  session	  (only	  if	  child	  is	  	  
over	  16	  years	  of	  age).	  
	  
To	  give	  a	  hair	  sample	  for	  hormone	  analysis.	  
	  
To	  being	  contacted	  for	  participation	  in	  other	  studies	  related	  to	  this	  one.	  
	   	   	  
	   	   	  
____________________	  	  	  	   	   ________________	   	   _______________	  
Name	  of	  Parent/Guardian	   	   Date	   	   	   	   Signature	  
	  
____________________	   	   ________________	   	   _______________	  
Name	  of	  Person	  taking	  consent	   Date	   	   	   	   Signature	  
(if	  different	  from	  researcher)	  
	  
______________________	   	   _________________	   	   ________________	  
Researcher	   	   	   	   Date	   	   	   	   Signature	  
B-1: TRACKING INFORMATION 
 
B-1 
	  
	  
Tracking	  Information	  
	   	  
Full	  name	  (include	  middle)	   	  
Mobile	  number	   	  
Home	  number	   	  
Home	  address	  (include	  
postcode)	  
	  
	  
Email	  address	   	  
Facebook	  	  	  	  	  	   	  	  Yes	  	  	  	  No	  	  	  	  	  	  	  	  	  	  	  	  	  	  username:	  
Name	  and	  contact	  of	  
GP/health	  professional	  
	  
	  
	  
	  
	  
	  
Full	  name	  of	  Mother	  
(include	  middle)	  
	  
Full	  name	  of	  Father	  
(include	  middle)	  
	  
	  
	  
Name	  and	  contact	  details	  of	  a	  person	  who	  may	  know	  how	  to	  get	  in	  contact	  with	  you.	  
	   	   	   	   	  
	  Full	  name	  
(include	  middle)	  
	   Mobile	  #	   	  
Relationship	  to	  
young	  person	  
	   Home	  #	   	  
Home	  address	   	  
	  
Email	  address	   	  
	  
	  
	  
B-2: HEALTH SERVICE USE 
 
B-2 
	  
	  
What	  is/are	  the	  main	  mental	  health	  problem(s)	  for	  which	  you	  went	  to 	  
	  see	  your	  GP?	  Have	  you	  been	  given	  a	  diagnosis?	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
Depression	  
Generalised	  Anxiety	  
Panic	  Disorder	  
PTSD	   	  
Psychosis	  
Eating	  Disorder	  
Drug	  and	  alcohol	  
ADHD	  
	  
Are	  there	  any	  other	  mental	  health	  issues	  you	  are	  struggling	  with	  at	  the	  moment	  or	  in	  the	  past?	  
(diagnoses,	  when	  did	  it	  start/end,	  medication	  or	  other	  treatments,	  etc.)	  	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
When	  did	  your	  current	  problem(s)	  start?	  (How	  old	  were	  you?)	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
When	  and	  where	  did	  you	  start	  seeking	  treatment	  for	  the	  current	  issues?	  (overview	  of	  treatment	  
history	  for	  current	  issues;	  details	  of	  prior	  treatment)	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
What	  treatment	  are	  you	  receiving	  at	  the	  moment?	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
Health	  services	  use	  
B-2: HEALTH SERVICE USE 
 
B-3 
	  
	  Medication	  
	  Psychotherapy,	  if	  known,	  type	  (e.g.CBT):	  ___________________________	  
	  Counselling	  
	  Other	  (e.g.	  priest):	  _________________	  
   
 B-2: HEALTH SERVICE USE 
 
   
 
B-4 
Are	  you	  receiving	  any	  other	  kind	  of	  help	  or	  support	  (e.g.	  information	  about	  mental	  illness,	  its	  
treatment,	  and	  available	  services;	  help	  to	  sort	  out	  housing/money	  problems,	  to	  improve	  ability	  to	  
work/use	  time	  in	  other	  ways	  or	  to	  look	  after	  yourself	  or	  home,	  or	  to	  meet	  other	  people	  for	  support	  and	  
company)	  
	  	  	  	  	  	  	  	  	  Yes	  	   	   No	  
If	  yes,	  details:	  
___________________________________________________________________________________
___________________________________________________________________________________	  
___________________________________________________________________________________	  	  	  	  	  	  	  	  
	  
If	  receiving	  medication	  at	  the	  moment	  (e.g.	  antidepressants,	  neuroleptics,	  fish	  oil,	  vitamins	  etc.):	  	  
Name:	  ___________________________________________________________________________	  
Type	  (if	  other	  than	  tablets):	  ___________________	  
Dose:	  _________________	  
Date	  commenced:	  _____________	  
Duration	  classification:	  
Less	  than	  1	  month	  
1	  to	  3	  months	  
3	  to	  6	  months	  
More	  than	  6	  months	  
	  
If	  more	  than	  one,	  take	  notes	  here:	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
If	  applicable:	  prior	  medication,	  dose	  and	  when	  commenced/ended	  or	  if	  changes	  in	  dose	  of	  present	  
medication:	  
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
Do	  you	  usually	  take	  your	  medication	  according	  to	  the	  recommended	  dose?	  
	  	  	  	  	  Yes	  
	  	  	  	  	  	  No	  
Comments:__________________________________________________________________________	  
	  
Did	  you	  see	  the	  following	  professionals	  for	  mental	  health	  in	  the	  past	  12	  months?	  
	   GP	  	  	  	   	   	   	   	   	   	   	   ___	  times	  
	   Counsellor	   	   	   	   	   	   	   ___	  times	  
	   Psychiatrist	   	   	   	   	   	   	   ___	  times	  	  
	   Psychologist	   	   	   	   	   	   	   ___	  times	  
	   Care	  coordinator/CPN	  	   	   	   	   	   ___	  times	  
	   Other	  mental	  health	  professional:	  _________	   	   ___	  times	  
	   Other	  non-­‐mental	  health	  professional:	  _______	   	   ___	  times	  
	  
	  
	  
	  
   
 B-2: HEALTH SERVICE USE 
 
   
 
B-5 
In	  the	  past	  12	  months,	  were	  you	  /	  did	  you:	  
	  
admitted	  overnight	  or	  longer	  to	  any	  hospital	  for	  problems	  with	  your	  mental	  health	  (such	  as	  
stress,	  anxiety,	  depression,	  self	  harm	  	  or	  dependence	  on	  alcohol	  or	  drugs)?____	  times	  
	   had	  a	  consultation	  with	  a	  professional	  for	  physical	  health?	  ____	  times	  
	   use	  the	  internet	  for	  mental	  health	  concerns?	  ____	  times	  
	   use	  a	  self-­‐help	  group	  for	  problems	  with	  your	  mental	  health?	  ____	  times	  
	   use	  a	  telephone	  counselling	  service	  for	  problems	  with	  your	  mental	  health?____	  times	  
	  
	  
	  
What	  self	  management	  strategies	  have	  you	  used	  in	  the	  past	  year	  to	  cope	  with	  mental	  health	  
problems?	  
___________________________________________________________________________________
___________________________________________________________________________________	  
	  
	   Increased	  level	  of	  exercise	  or	  physical	  activity	  
	   Did	  more	  of	  the	  things	  enjoyed	  
	   Sought	  support	  from	  family	  or	  friends	  
	   Used	  alcohol	  or	  drugs	  
	   Cut	  out	  alcohol	  or	  drugs	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
   
 B-3: FAMILY HISTORY 
 
   
 
B-6 
	  
	  
Has	  your	  biological	  mother,	  father,	  brother(s)	  or	  sister(s)	  had	  a	  serious	  psychological	  or	  emotional	  
problem?	  (This	  refers	  to	  conditions	  such	  as	  depression,	  severe	  anxiety,	  nervous	  breakdown	  and	  
schizophrenia)	  
	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  
	  
	   Problem	   Diagnosed?	   Treatment/	  
Hospitalisation?	  
Suicide?	  
Mother	  	  
	  
	  
	  
	  
	   	   	  
Father	  
	  
	  
	  
	  
	   	   	  
Brother(s)	  
	  
	  
	  
	  
	   	   	  
Sister(s)	  
	  
	  
	  
	  
	   	   	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Family	  history	  of	  Psychological	  Disorders	  
   
 B-4: QIDS 
   
 
B-7 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
QUICK	  INVENTORY	  OF	  DEPRESSIVE	  SYMPTOMATOLOGY	  (CLINICIAN-­‐RATED)	  
   
 B-4: QIDS 
 
B-8 
   
 B-4: QIDS 
 
B-9 
	  
   
 B-4: QIDS 
 
B-10 
   
 B-5: ASSIST 
   
 
B-11 
	  
ASSIST	  
   
 B-5: ASSIST 
 
   
 B-5: ASSIST 
 
 
B-13 
   
 B-5: ASSIST 
 
 
B-14 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
   
 B-6: CAARMS 
   
 
B-15 
	  
	  
CAARMS	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
   
 B-6: CAARMS 
   
 
B-16 
	  
   
 B-6: CAARMS 
   
 
B-17 
	   	   	   	   	   	   	   	   	   	   	  	  	  	   	   	   	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
   
 B-6: CAARMS 
   
 
B-18 
   
 B-6: CAARMS 
 
B-19 
B-6: CAARMS 
	   B-20 
B-6: CAARMS 
	   B-21 
	  
	  
	  
	  
	  
	  
	  
	  
	  
B-6: CAARMS 
	   B-22 
	  
	  
B-7: SOFAS 
	   B-23 
B-8: SOCIAL FUNCTIONING 
	   B-24 
B-8: SOCIAL FUNCTIONING 
	   B-25 
B-8: SOCIAL FUNCTIONING 
	   B-26 
	  
	  
B-9: ROLE FUNCTIONING 
	   B-27 
B-9: ROLE FUNCTIONING 
	   B-28 
	  
B-9: ROLE FUNCTIONING 
	   B-29 
B-9: ROLE FUNCTIONING 
	   B-30 
B-10: PHYSICAL MEASUREMENTS 
	   B-31 
	  
	  
	  
Height:	  ___________________________cm	  
	  
Weight:	  ___________________________kg	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Physical	  measurements	  
B-11: DEMOGRAPHICS, EDUCATION, WORK 
	   B-32 
B-11: DEMOGRAPHICS, EDUCATION, WORK 
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B-11: DEMOGRAPHICS, EDUCATION, WORK 
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B-11: DEMOGRAPHICS, EDUCATION, WORK 
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B-12: RUMINATIVE STYLE 
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B-13: CTQ 
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CTQ	  
B-13: CTQ 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   B-38 
	  
	  
	  
	  
	  
B-14: K-10 
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B-15: OASIS 
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   B-40 
 
 
	  
OVERALL	  ANXIETY	  SEVERITY	  AND	  IMPAIRMENT	  SCALE	  (OASIS)	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
B-15: OASIS 
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B-16: SCID-I 
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B-16: SCID-I 
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B-16: SCID-I 
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B-17: SCREENING FOR HAIR ANALYSES & MRI	  
	  B-148 
B-18: MRI SAFETY SCREENING QUESTIONNAIRE	  
	  B-149 
B-19: MRI DOCUMENTATION 
	  B-150 
Name:	  _____________________________	  
ID:	  _____	  
DOB:	  ___/___/______	  
Registration	  number:	  ________________	  
Exam	  card:	  ____________________	  
Time	  in:	  _________	  
Time	  out:	  _________	  
Handedness:	  	  	  	  	  	  	  	  	  left	  	  	  	  	  	  	  	  	  right	  	  	   	  
	  	  	  	  	  	  	  ambidexterity	  
Scan	  order	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
	  
Comments	  
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
________________	  
	  
Slices:	  ___	  
Voxels:	  ____	  x	  _____	  x	  ____	  mm	  
TE:	  ____	  ms	  
TR:	  ____	  sec	  
Dummy	  scans:	  __	  
n-­‐back	  dynamics:	  ____	  
faces	  dynamics:	  _
B-20: PSS	  
	  B-151 
	  
